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Efficacy and safety of adalimumab treatment in psoriasis with psoriatic arthritis: Result from 
post-marketing surveillance in Japan
A Asahina,1 H Torii,2 M Ohtsuki,3 J Sawa,4 Y Yamaguchi4 and H Nakagawa5 1 Sagamihara 
National Hospital, Kanagawa, Japan, 2 Social Insurance Central General Hospital, Tokyo, 
Japan, 3 Jichi Medical University, Tochigi, Japan, 4 AbbVie G.K., Tokyo, Japan and 5 The 
Jikei University School of Medicine, Tokyo, Japan
The TNF-α antagonist adalimumab (ADA) has been used to treat patients (pts) with moderate to 
severe plaque psoriasis (Ps) and psoriatic arthritis (PsA) in Japan. This analysis assessed efficacy 
and safety of ADA treatment in pts with PsA from post-marketing surveillance. This 24-week (wk), 
open-label, post-marketing, observational trial was conducted at 634 sites in Japan (NCT01155570) 
in pts with Ps and with or without PsA. In PsA pts, efficacy evaluations included the proportion of 
pts achieving ≥75% reduction in Psoriasis Area Severity Index (PASI) from baseline (PASI75; LOCF), 
Disease Activity Score 28 (DAS28; observed cases), and European League Against Rheumatism 
(EULAR; LOCF) response (moderate, good); safety was also assessed. Of registered Ps pts (n=749; 
excluding 3 from 1 site), 217 and 213 pts with PsA were evaluated for safety and efficacy, respec-
tively, of which 146 (67.3%) were men. Pts mean age was 47.9±12.0 years and mean disease (Ps 
or PsA) duration 13.3±9.8 years; 97.2% had previous Ps or PsA treatment. PASI75, evaluated in 156 
PsA pts, was achieved by 45.2% and 51.3% at wks16 and 24, respectively. Mean DAS28-erythrocyte 
sedimentation rate, evaluated in 94 pts, improved from 4.4±1.7 at baseline to 2.4±1.3 (n=60) at 
wk16 and 2.3±1.3 (n=62) at wk24 (p<0.0001, both). Mean DAS28-C-reactive protein, evaluated 
in 131 pts, improved from 3.5±1.3 at baseline to 2.0±1.0 (n=81) at wk16 and 1.8±0.9 (n=85) at 
wk24 (p<0.0001, both). EULAR response (good/moderate), evaluated in 113 pts, was 7.1%/65.5% 
at wk16 and 8.9%/68.1% at wk24. Adverse events (AEs) were reported by 82 (37.8%) pts; serious 
AEs by 9 (4.1%). Following ADA treatment in Japanese pts with PsA, no new AEs or new incidences 
of AEs were observed; PASI, DAS28 and EULAR response improved significantly from baseline to 
wks 16 and 24.    
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Similarity in survival in stage 4 basosquamous carcinoma and stage 4 squamous cell carci-
noma: Results of a single-site retrospective cohort study
GA Zhu, C Danial, A Liu, S Li and AL Chang Dermatology, Stanford University School of 
Medicine, Redwood City, CA
Basosquamous carcinoma (BSC) is a rare histological subtype of basal cell carcinoma (BCC) thought 
to have a clinical course more similar to squamous cell carcinoma (SCC). However, no estimates 
of overall survival (OS) or progression-free survival (PFS) are currently available for BSC of any 
stage, making direct comparison impossible. The objective of this single-institution retrospective 
cohort study was to estimate and compare OS and PFS of Stage 4 BSC and Stage 4 SCC, as well as 
to relate these values to published estimates of OS and PFS of Stage 4 BCC. Biopsy-proven cases 
were identified by querying an institutional cancer registry, yielding 18 Stage 4 BSC and 36 Stage 
4 SCC cases. The median OS (95% confidence interval (CI)) was 6.5 (3.9-∞) years for BSC and 3.5 
(1.8-5.7) years for SCC. The five-year OS rate (95% CI) was 53% (19-79%) for BSC and 30% (14-
49%) for SCC. The median PFS (95% CI) was 1.2 (0.5-3.0) years for BSC and 0.7 (0.5-1.0) years for 
SCC. Cox models adjusting for age at Stage 4 diagnosis and nodal status revealed a hazard ratio 
(95% CI) of 0.77 (0.32-1.85) for OS and 0.86 (0.43-1.73) for PFS of BSC compared to SCC. Log-rank 
tests for differences in OS (p=0.15) and PFS (p=0.53) between BSC and SCC were not statistically 
significant. Our study is the first to report survival data for BSC. While the OS and PFS of BSC and 
SCC are not significantly different in this study, the survival curves do show that BSC carries an 
intermediate prognosis compared to BCC and SCC. This suggests that larger studies may reveal 
statistically significant differences in OS and PFS between BSC and SCC.    
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Free dermatoplasty combining with vacuum sealing drainage with or without Pelnac used 
for the treatment of extensive follicular occulusion triad in the gluteal and perianal regions
D Ben, T Li and Z Xia Department of Burn and Trauma Surgery, Changhai Hospital, 
Shanghai, China
INTRODUCTION: Follicular occulusion triad is a chronic suppurative disease having a great impact 
on quality of life. In this study, we present extensive follicular occulusion triad cases with their 
respective treatment and outcomes. METHODS: A retrospective review of the medical records from 
January 1998 to December 2012 of 21 patients was performed. RESULTS: Twenty-one patients with 
extensive follicular occulusion triad in the gluteal and perianal regions underwent total surgical 
excision. All patients were male and had a total number of 57 operations. The median operation 
time was 2.7 times. The wound was left open for secondary healing in 16 cases, and the mean 
time for fully healing was 4.3 weeks (range: 2.7-9.4 weeks). 12 patients with large-area skin defects 
ranged from 8×12 to 25×37 cm2 were treated by free mesh dermatoplasty combining with Vacuum 
sealing drainaging (VSD) after surgical excision. Pelnac was placed onto the skin defect after removal 
of the lesion in 4 patients. Two weeks postoperatively, the silicone film was peeled off and a thin 
split-thickness skin graft was placed on the regenerated dermis-like connective tissues. In this group, 
it took 2 months in total to heal the wound completely. In addition, three patients achieved primary 
wound closure by using mesh skin grafting, the other two by rotation flaps. Successful treatment 
without recurrence was accomplished in 17 (80.9%) of the patients. CONCLUSION: Conservative 
treatment methods have little or no effect on extensive perineal/perianal follicular occulusion triad. 
The only successful treatment was wide surgical excision. Management of the wound after wide 
excision should be tailored to the individual patient. Free dermatoplasty combining with VSD with 
or without Pelnac used for the treatment of large-area soft tissue defects maybe a simple, fast and 
effective treatment method.    
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The effect of conditioned media of adipose-derived stem cells on wound healing after ablative 
fractional carbon dioxide laser resurfacing
D Luo, J Zhang and B Zhou Department of Dermatology, the First Affiliated Hospital of 
Nanjing Medical University, Nanjing, China
To evaluate the benefits of conditioned medium of Adipose-derived stem cells (ADSC-CM) on 
wound healing after Fractional carbon dioxide laser resurfacing (FxCR) on human skin. Nineteen 
subjects were treated with FxCR on the bilateral inner arms. ADSC-CM was applied on FxCR site 
of one randomly selected arm. Transepidermal water loss (TEWL), skin color, and gross-elasticity 
of FxCR site on both arms were measured. Skin samples were taken by biopsy from three subjects 
3 weeks after treatment for histopathological manifestations and mRNA expressions of procollagen 
types I and III, elastin genes were noted. The index of erythema, melanin, and TEWL of the ADSC-
CM-treated skin were significantly lower than those of the control side. The mRNA expression of 
type III procollagen in ADSC-CM-treated group at 3 weeks post-treatment was 2.6 times of that 
of control group. Application of allograft ADSC-CM is an effective method for enhancing wound 
healing after FxCR, by reducing transient adverse effects such as erythema, hyperpigmentation, 
and increased TEWL.    
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Leukemia cutis patients with AML demonstrate comparable survival to the general AML 
population and long-term survival when treated with stem cell transplantation
SJ Divito,1 C Joyce2 and A Saavedra1 1 Dermatology, Brigham and Women’s Hospital, 
Boston, MA and 2 Biostatistics, Tulane University, New Orleans, LA
Leukemia cutis refers to skin infiltration by lymphoid or myeloid malignant cells, and is considered a 
poor prognostic factor in patients with hematologic malignancy. However, studies of the disease are 
limited, especially over the past decade despite major advancements in chemotherapeutics and stem 
cell transplantation. We hypothesized that leukemia cutis is not a poor prognostic factor in AML. 
To study this, we performed a retrospective study of patients ≥ 18 years old with histopathologic 
diagnosis of leukemia cutis over 12 years at Brigham and Women’s Hospital/Dana Farber Cancer 
Institute. We identified 51 patients with acute myelogenous leukemia (AML) with leukemia cutis. 
Duration of survival for all AML patients with leukemia cutis was 22 months, with absolute survival 
rate of 36% and 24% at 1- and 5-years, respectively, comparable to the current national 5-year 
survival rate in AML of 24.9%. Survival in leukemia cutis patients varied with type of AML. Further, 
leukemia cutis patients who were treated with stem cell transplantation had significantly prolonged 
survival of mean duration 44 months, with absolute 1- and 5-year survival rates of 69 and 46%, 
respectively, compared to only 7 months mean survival, and 1- and 5-year survival rates of 10 and 
0%, respectively, in non-transplanted patients with leukemia cutis. In conclusion, our data suggests 
that leukemia cutis may not be the poor prognostic factor that it was previously thought to be and 
stem cell transplantation can lead to improved survival in this patient population.    
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Cyclosporine A treatment in atopic dermatitis results in suppression of Th2/Th22 inflamma-
tion and epidermal pathology
S Khattri,1 A Shemer,2 M Rozenblit,1,3,4 M Suarez-Farinas,1,4 N Dhingra,1,5 JG Krueger1,4 and 
E Guttman-Yassky1,3,4 1 The Laboratory for Investigative Dermatology, Rockefeller University, 
New York, NY, 2 Department of Dermatology, Tel-Hashomer, Tel-Aviv, Israel, 3 Department 
of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 4 Center for 
Clinical and Translational Science, Rockefeller University, New York, NY and 5 Columbia 
University College of Physicians and Surgeons, New York, NY
Atopic dermatitis (AD) is the most common inflammatory skin disease. Evolving disease models 
link changes in epidermal differentiation to Th2/Th22 cytokine activation. However, these models 
have not been tested by in-vivo suppression of T-cell cytokines. Cyclosporine A (CsA) is an effective 
treatment for severe disease, but its mechanism in AD lesions has not been studied. We aimed 
to establish the ability of a systemic immune-suppressant to modulate immune and epidermal 
alterations that form the pathogenic disease phenotype and to correlate changes with clinical 
improvement. The effects of CsA on AD skin pathology were evaluated using gene-expression and 
immunohistochemistry studies in baseline, week 2 and 12 lesional and non-lesional biopsies from 
19 patients treated with 5 mg/kg/d CsA. After 2 and 12 weeks of treatment, reductions of 50.89% 
and 73.44% in Scoring of AD/SCORAD were seen. Clinical improvements were associated with 
significant genomic changes in lesional but also non-lesional skin, particularly reductions of Th2, 
Th22, and some Th17-related molecules (i.e IL-13, IL-22, CCL17, CCL18, S100A7-9, PI3), and 
modulation of epidermal hyperplasia and differentiation markers (K16, LOR, FLG, PPL). This is the 
first study that establishes a link between Th2/Th22 cytokines and molecular epidermal alterations as 
well as correlations between clinical improvement and skin biomarkers. The reversal of the molec-
ular phenotype with CsA and the associated disease response biomarkers can serve as a reference 
for the successful modulation of tissue inflammation with specific immune-antagonists in future 
studies, contributing to the understanding of the specific cytokines involved in epidermal pathology.   
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Impact of ixekizumab on blood neutrophil levels and the incidence of infections caused by 
candida albicans or staphylococcus aureus
A Blauvelt,1 DK Braun,2 GS Cameron,2 D Shrom2 and MP Heffernan2 1 Oregon Medical 
Research Center, Portland, OR and 2 Lilly, Indianapolis, IN
IL-17A homodimers and IL-17A/F heterodimers play important roles in neutrophil recruitment and 
protection against extracellular pathogens such as C. albicans and S. aureus. Ixekizumab, a mono-
clonal antibody directed against IL-17A, is currently in development for treating plaque psoriasis. 
In this analysis, using data from an open-label extension of a previously reported phase 2 study 
(1), the impact of ixekizumab treatment on blood neutrophil levels and the incidence of candidal 
and staphylococcal infections were assessed. In an open-label manner, 120 patients received 120 
mg of ixekizumab subcutaneously every 4 weeks. Safety data were available through Week 52 
for all patients; additional data for some patients were available through Week 100. Incidence of 
neutropenia was graded according to CTCAE criteria. Candidal and staphylococcal infections were 
as reported by the investigator and microbiologic confirmation was not required. Among all 120 
patients, 4 patients experienced transient grade 1 neutropenia that were not clinically significant; 
no grade 2 or grade 3 neutropenia occurred. Overall, 49 patients experienced a treatment-emergent 
infection of any kind. Five of these 49 had a reported candidal (4 oral and 1 vulvovaginal), 1 patient 
had a vulvovaginal infection due to an unspecified yeast and 2 had a reported staphylococcal 
infection (ear infection and impetigo), all of which resolved with proper treatment and did not 
interfere with ixekizumab dosing. None of these patients had concurrent neutropenia. In this study 
there was a low incidence of neutropenia, which was transient and not severe in psoriasis patients 
treated for 1 year with ixekizumab. Unlike what may have been expected based upon mechanism 
of action, ixekizumab treatment was associated with a low frequency of candidal or staphylococ-
cal infections. Further study is needed to fully understand the impact of ixekizumab treatment on 
circulating neutrophil levels and host defense.    
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A single application of acyclovir mucoadhesive buccal tablet reduces recurrence of herpes 
labialis in a randomized double-blind phase 3 study: Exploratory results
SK Tyring,1 TO Bieber,2 O Chosidow,3 M Bloch,4 M Lewis,5 M Davis6 and P Attali7 1 
Dermatology, University of Texas Health Science Center, Houston, TX, 2 Dermatology 
and Allergy, University of Bonn, Bonn, Germany, Germany, 3 Dermatology, Hospital 
Henri Mondor, Creteil, France, 4 Holdsworth House Medical Practice, Darlinghurst, NSW, 
Australia, 5 School of Dentistry, Cardiff University, Cardiff, United Kingdom, 6 Rochester 
Clinical Research, Rochester, NY and 7 BioAlliance Pharma, Paris, France
Objectives: Acyclovir mucoadhesive buccal tablet (ABT), is an innovative drug delivery system that 
provides high sustained-release local exposure to acyclovir in oral mucosa. ABT 50mg was reported 
in the LIP study to significantly reduce the time to healing (TTH) of vesicular lesions and increase 
the incidence of aborted episodes of herpes labialis (HL) . A secondary endpoint was to examine 
incidence and time to next recurrence of HL. Methods: In a randomized, multicenter, phase 3, 
double-blind, placebo-controlled study, 775 patients, (378 in the ABT group and 397 in the placebo 
group), with at least 4 recurrent HL lesions per year were treated. Participants self-applied a single 
ABT 50mg or placebo tablet as soon as prodromal symptoms occurred. 537 patients, 267 patients 
ABT and 270 placebo, agreed to participate in a 9-month follow-up for the evaluation for assessing 
whether one single dose administration of ABT could have an impact on incidence and time to 
the next recurrence of HL (TTR). Results: Following a single application of ABT 50mg or placebo 
during the HL episode, a HL episode recurred during the 9-month follow up period in 64.2% of 
patients treated with ABT50mg vs 73.6% in the placebo group (p=0.027). The mean TTR in the 
ABT 50mg group (304±19.4 days) was significantly longer than that of the placebo group (199±9.3 
days, Δ=105 days, Logrank test p=0.042). Good safety and tolerability were found in both ABT 
50mg and placebo groups. Conclusions: A single application of ABT 50 mg during the prodromal 
symptoms of HL reduces the incidence of the next recurrence and delays the recurrence of next 
herpes episodes. Thus ABT 50mg may modify the clinical course of labial herpes.    
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Off-target effects of BRAF inhibitors: Roles in SCC induction and the relationship to para-
doxical ERK signaling
L Du,2 CH Adelmann,2 G Ching,2 V Chitsazzadeh,2,3 SS Ojeda,2 H Vin,2 T Kaoud,4 
SB Ferguson,4 KN Dalby4 and K Tsai1,2,3 1 Dermatology, UT MD Anderson Cancer Center, 
Houston, TX, 2 Immunology, UT MD Anderson Cancer Center, Houston, TX, 3 Graduate 
School of Biomedical Sciences, UT MD Anderson Cancer Center, Houston, TX and 4 
Medicinal Chemistry, UT Austin, Austin, TX
B/RAF inhibitors are known to induce cutaneous squamous cell carcinomas (cSCC) in patients, an 
effect ascribed to paradoxical ERK activation. We recently reported that the RAF inhibitors vemu-
rafenib and sorafenib potently suppress JNK-mediated apoptosis through the off-target inhibition of 
ZAK (PMID: 24192036, 24170769), demonstrating this as an independent mechanism accounting 
for 20-40% of the total tumor-promoting effect of these drugs. However, it is not known why B/
RAF inhibitors differ substantially in their ability to induce cSCC. Sorafenib and vemurafenib, but 
not dabrafenib or LGX818, bind and inhibit ZAK at clinically relevant doses, leading to inhibition 
of JNK activation. We show that ZAK primarily activates JNK1 to initiate apoptosis using a chemical 
genetic approach with covalent small molecule inhibitors of JNK. Surprisingly, ZAK is also required 
for apoptosis following MEK or BRAF inhibition in BRAF-mutant melanoma cells. Our results show 
that RAF inhibitors should be counterscreened against activators of JNK1, including ZAK, to avoid 
countervailing off-target effects. There are also major differences in the ability of B/RAF inhibitors 
(sorafenib, dabrafenib, LGX818, PLX4720, paradox breakers) to activate ERK signaling in BRAF 
wild-type cells. Using a novel fluorescent kinase activity probe, we show that all of these inhibitors 
exhibit paradoxical ERK activation, but not always at clinically relevant doses, with widely varying 
magnitudes and lengths of activation, from a few hours to over 72 hours. Taken together, our results 
show that the paradoxical and off-target effects of B/RAF inhibitors have potent biologic effects that 
can account for differences in the frequency of adverse events such as cSCC, suggesting that the 
design of kinase inhibitors must incorporate a detailed understanding of these effects.    
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Risk of rash associated with panitumumab in cancer patients: A systematic review of the 
literature and meta-analysis
B Nardone,1 S Wu,2,3 A Picker,1 DP West1 and ME Lacouture4 1 Department of Dermatology, 
Northwestern University, Feinberg School of Medicine, Chicago, IL, 2 Division of Medical 
Oncology, Department of Medicine, Stony Brook University School of Medicine, Stony 
Brook, NY, 3 Northport VA Medical Center, Northport, NY and 4 Dermatology Service, 
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
Panitumumab (Pan) is indicated as a single agent for the treatment of epidermal growth factor 
receptor (EGFR)-expressing, metastatic colorectal carcinoma (mCRC). The incidence and risk of 
rash have been reported, however they have been inconsistent in published trials. We conducted 
a systematic review and meta-analysis of the literature to determine the incidence and risk of 
developing rash. We searched PubMed (1998-2013), ASCO Conferences (2004-2013) and Web 
of Science (1998-2013) databases. Eligible studies were limited to randomized controlled trials in 
which patients received Pan doses of 6 mg/kg every 14 days (Q2W). Incidence, relative risk (RR), 
and 95% confidence intervals (CI) were calculated using random-effects and fixed-effects models 
based on heterogeneity of included studies. Data from 6 randomized controlled trials with a total of 
2,053 patients treated with Pan were available for analysis. The overall incidence of all-grade rash 
for Pan was 71.3% (95%CI: 42.3% - 35.5%) while for controls was 5.6% (95%CI: 1.7%- 17.1%). 
The overall incidence of high-grade (grade ≥3) skin rash for Pan was 28.2% (95%CI: 21.5%-36%) 
compared to 1.4% (95% CI: 0.8%-2.3%) for controls group. Pan was associated with increased 
risk of all-grade rash (RR=10.5, 95%CI: 4.7%-23.5%; P<0.001) when compared to controls. The 
risk of high-grade rash was also increased (RR=22.4, 95%CI: 14.8%-33.9%; P<0.001). Patients 
with mCRC who are treated with panitumumab are at significantly greater risk for developing rash, 
especially high-grade rash. Further studies for prevention and treatment of this toxicity are needed 
in order to maintain patient’s quality of life and minimize the need for dose modification, all of 
which may impact clinical outcome.    
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Interventions for management of Stevens-Johnson syndrome (SJS) and toxic epidermal 
necrolysis (TEN) in the human immunodeficiency virus (HIV) population: A systematic lit-
erature review
KC Webb,1 B Nardone,2 DP West,2 T Maurer3 and M Rani2 1 University of Illinois at Chicago, 
Chicago, IL, 2 Department of Dermatology, Feinberg School of Medicine, Northwestern 
University, Chicago, IL and 3 Department of Dermatology, UCSF Medical Center, San 
Francisco, CA
Although SJS and TEN are rare and potentially life-threatening, anti-HIV drugs pose a higher risk of 
these reactions, and there exists no evidence-based assessment of treatments for these reactions in 
the HIV-positive population. We conducted a systematic review of literature for intervention and 
outcome of SJS and TEN in the HIV-positive population. We searched Ovid Medline, Cochrane 
Central Register of Controlled Trials, Scopus, and EMBASE databases (1980-June 2013). Search 
criteria included HIV-positive individuals, a diagnosis of drug-induced SJS or TEN and a stated 
intervention with outcome (living or deceased). The search generated 908 total reports, 89 of which 
were evaluable and which represented 565 patients. Only case reports, case series and observa-
tional studies constituted the evaluable reports, for which there were 7 categories of interventions. 
Despite insufficient data to provide high-level evidence-based recommendations for interventions 
in HIV-positive individuals with SJS or TEN, our findings are consistent with those of the general 
population: immediate discontinuation of the inciting drug(s) is an advisable intervention in all 
cases. Furthermore, the available evidence supports discontinuation of inciting drug(s) plus med-
icated skin-directed therapies and supportive care as additional categories of intervention in the 
management and successful outcome for HIV-positive patients with SJS/TEN. Moreover, our findings 
suggest that systemic corticosteroid use, alone or in combination with other interventions, did not 
significantly change survival. Further investigations are needed to determine optimal management 
of SJS and TEN in the HIV-positive population.    
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Cutaneous ATLL is a diagnostic challenge and has heterogenous clinical and histologic features
MA Marchetti,1 M Pulitzer,1 P Myskowski,1 S Dusza,1 M Lunning,2 S Horwitz,1 A Moskowitz1 
and C Querfeld1 1 Memorial Sloan-Kettering Cancer Center, New York, NY and 2 University 
of Nebraska Medical Center, Omaha, NE
Adult T-cell leukemia/lymphoma (ATLL) patients with skin involvement are not well studied in the 
United States. The objective was to characterize clinical and histologic features of ATLL patients with 
cutaneous disease. 53 patients [17 skin-first (SF), 8 skin-second (SS), and 29 skin-uninvolved (SU)] 
seen at MSKCC from 1998 to 2013 were identified, of which 46% (n=25) had skin involvement. 
SF were primarily of Caribbean origin (94%) and had a median symptom duration of 11.9 months 
(vs. 1.9 months for SS+SU, P < 0.001). Median overall survival in SF appeared significantly longer 
compared to SS+SU (26.7 vs. 10.0 months, P <0.001), but no difference remained when stratified 
by Shimoyama subtype. In SF, 11 died, 4 were lost to f/u, and 2 were alive at last f/u. Fifteen patients 
(88%) were evaluated by a dermatologist before ATLL diagnosis, with 5 (33%) correctly diagnosed. 
32 clinical diagnoses were considered, with mycosis fungoides (MF) (n=9), Sézary syndrome (n=3), 
and dermatophytoses, psoriasis, drug rash, and eczema (each n=2) most common. After skin biopsy, 
14/17 (82%) received an initial clinicopathologic diagnosis other than ATLL, most commonly MF 
(n=8). Caribbean origin (35%) and an unusual clinical presentation (29%) were the most common 
clues for clinicians to suspect ATLL. Predominant lesion morphology at diagnosis was nodules 
(35%), followed by plaques (24%), papules (24%), patches (12%), and erythroderma (6%). 43 skin 
biopsies from 22 patients revealed notable findings, including large cell morphology (70%), epider-
motropism (67%) with large collections of atypical lymphocytes (55%), >20:1 CD4:CD8 ratio (79%), 
CD30 positivity (68%), angiocentricism (78%), folliculotropism (65%), granulomatous inflammation 
(14%), and follicular mucin (10%). A more refined understanding of clinical and histologic features 
in cutaneous ATLL may help clinicians and pathologists to more accurately diagnose patients with 
this uncommon disease, particularly in non-endemic areas.    
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A selective defect in IFNγ production possibly explains viral skin infections in atopic dermatitis
T Czarnowicki,1 J Krueger,1 J Gonzalez3 and E Guttman1,2 1 Investigative Dermatology, 
Rockefeller University, New-York, NY, 2 Department of Dermatology, Icahn School of 
Medicine at Mount Sinai, New York, NY and 3 Translational Technology Core Laboratory ( 
CCTS), Rockefeller University, New York, NY
Atopic Dermatitis (AD) patients are highly susceptible to recurrent skin viral infections, particularly 
Eczema Herpeticum (EH). We hypothesized that abnormal differentiation of CLA+ (skin homing) 
T-cells might create a selective defect in cutaneous immunity to viral pathogens. We studied 16 
adults with severe AD (mean SCORAD 68), and 16 age-matched healthy individuals. Blood from 
patients and controls was activated by PMA/Ionomycin and stained by a 12-color antibody panel 
for flow cytometry analyses. INFγ+, IL22+ and IL13+ producing cells were compared in CLA- and 
CLA+ skin homing T-cells between the two groups. We measured increased Th2/IL-13 and Th22/
IL-22 populations in CLA+ lymphocytes of AD patients vs. controls (p=0.05, and 0.1, respectively). 
Overall, a lower frequency of INFγ-producing cells was observed in AD patients vs. controls. The 
difference was largest in the CLA+ T-cell population (12.6% vs. 22.5%; p<0.05). In addition, the 
Th1/Th2 ratio was highly imbalanced in AD (1.4 vs. 3.9, p<0.05) and aberrant Th1 differentiation 
was detected since we found a Th1 population co-producing INFγ&L-13. Negative correlations 
(r=-0.5) were also found between the IFNγ/CLA+ population, INFγ/IL-13 cytokines ratio and dis-
ease severity (measured by SCORAD). We demonstrated that although there is no global cytokine 
production defect, severe AD patients harbor a selective defect in INFγ+ expression in skin homing 
CLA+ T-cells with a relative predominance of IL-13 and IL-22 CLA+ skin homing cells. These data 
may provide a fundamental immunologic explanation for skin-specific viral dissemination in AD 
despite lack of other visceral involvement.    
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“Iceberg” hemangioma: A segmental scalp lesion marking extensive multifocal extracuta-
neous involvement
MB Chu,1 EC Siegfried,2 A Wild,3 M Reis,4 I Frieden5 and BA Drolet6 1 Dermatology, Saint 
Louis University, St. Louis, MO, 2 Pediatrics and Dermatology, Saint Louis University/
Cardinal Glennon Children’s Hospital, St. Louis, MO, 3 Otolaryngology, Saint Louis 
University, St. Louis, MO, 4 Radiology, Saint Louis University, St. Louis, MO, 5 Dermatology, 
UCSF, San Francisco, CA and 6 Dermatology, Medical College of Wisconsin, Milwaukee, WI
We describe 3 infants with similarly distributed deep hemangiomas on the posterior scalp and nuchal 
area marking extensive extracutaneous involvement including the paralaryngotracheal area and 
mediastinum. We dubbed this configuration “iceberg” hemangioma because the cutaneous compo-
nent only hinted at the vast somatic involvement. The tumors were multifocal and almost exclusively 
localized to deep connective tissue, suggesting trophism for this type of matrix. One patient had 
caudal extension associated with spinal cord deviation,1 had orbital involvement and 1 had arterial 
tortuosity. No other signs of PHACE syndrome were seen. All 3 cases had airway compromise with 
circumferential paratracheal compression, distinct from the laryngeal involvement described with 
“beard” distribution hemangiomas. In 2 cases, stridor associated with the hemangiomas was initially 
misdiagnosed as croup after plain neck radiographs demonstrated symmetric airway narrowing 
(croup “steeple sign”). However, subsequent cross-sectional imaging including MRI/MRA was able 
to reveal the true somatic extent of the cutaneous lesions, supporting the diagnosis of hemangioma 
(although the radiographic differential diagnosis included plexiform neurofibromas and soft tissue 
neoplasms such as sarcoma). In summary, the “iceberg” hemangioma represents a constellation 
of findings that includes more extensive extracutaneous hemangioma involving the spine, fascial 
spaces of the neck and mediastinum, and paralaryngeal tissues with airway compromise. Early 
recognition of this entity and timely evaluation and treatment can prevent serious sequelae.    
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A unique presentation of necrobiotic xanthogranuloma associated with a peripheral T-cell 
lymphoma treated with lenalidomide
J Cappel and R el-Azhary Mayo Clinic, Rochester, MN
A 71 year old gentleman presented to the dermatology clinic for a progressive skin rash over the last 
6 months. This started over his knees and progressed to involve much of his body. Additionally he 
gradually became weak, fatigued, had weight loss and developed significant cervical lymphadenop-
athy. A right cervical node biopsy revealed only follicular lymphoid hyperplasia. His skin findings 
on presentation to our institution revealed numerous large red to brown thick granulomatous lesions 
involving the lower legs and overlying the elbows and dorsum of the forearms and hands. Biopsies 
were obtained and revealed diffuse dermal palisading granulomatous inflammation with numerous 
giant cells. This was thought to be most consistent with necrobiotic xanthogranuloma. He did not 
have any abnormalities on serum protein electrophoresis and immunofixation. Additionally, clonal 
T-cell receptor gene rearrangement was detected both in the tissue and peripheral blood. Peripheral 
blood flow cytometric analysis revealed a phenotypically abnormal CD4-positive T-cell population. 
Lymph node biopsy and bone marrow biopsy were both unrevealing. The skin and marrow showed 
no involvement by the malignant T cells and this was thought to represent a peripheral T cell lym-
phoma as opposed to T cell leukemia. He thus was felt to have both peripheral T cell lymphoma 
and necrobiotic xanthogranuloma. For his peripheral T cell lymphoma he was treated with six 
cycles of CHOEP chemotherapy. During and following treatment of this, his skin lesions persisted 
and actually progressed. He then was started on lenalidomide and dexamethasone for necrobiotic 
xanthogranuloma. Several months after treatment, he had complete remission of lymphoma and 
resolution of skin lesions with no subsequent treatment. This appears to be quite a unique case for 
two reasons. First, it appears that possibly peripheral T cell lymphoma may have been the driving 
force for his necrobiotic xanthogranuloma. Second, he had complete remission of both lymphoma 
and necrobiotic xanthogranuloma treated with CHOEP and lenalidomide.    
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Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment 
with response to anti-PD-1 therapy
JM Taube,1,2 A Klein,2,3,5 JR Brahmer,3 H Xu,1 X Pan,3 J Kim,1 L Chen,6 DM Pardoll,3 
SL Topalian4 and RA Anders2 1 Dermatology, Johns Hopkins University (JHU), Baltimore, 
MD, 2 Pathology, JHU, Baltimore, MD, 3 Oncology, JHU, Baltimore, MD, 4 Surgery, JHU, 
Baltimore, MD, 5 Epidemiology, JHU, Baltimore, MD and 6 Immunobiology, Yale University, 
New Haven, CT
Immunomodulatory drugs differ in mechanism-of-action from directly cytotoxic cancer therapies. 
Identifying factors predicting clinical response could guide patient selection and therapeutic opti-
mization. Patients (N=41) with melanoma and other solid tumor types were treated on an early 
phase trial of anti-PD-1 at one institution and had evaluable pre-treatment tumor specimens. Immu-
noarchitectural features including PD-1, PD-L1, and PD-L2 expression, patterns of immune cell 
infiltration, and lymphocyte subpopulations, were assessed for interrelationships and potential 
correlations with clinical outcomes. Membranous (cell surface) PD-L1 expression by tumor cells 
and immune infiltrates varied significantly by tumor type and was most abundant in melanoma, 
non-small cell lung carcinoma, and renal cell carcinoma. PD-L1 expression was geographically 
associated with infiltrating immune cells (p<0.001), although lymphocyte-rich regions were not 
always associated with PD-L1 expression. Expression of PD-L1 by tumor cells and immune infiltrates 
was significantly associated with expression of PD-1 on lymphocytes. PD-L2, the second ligand for 
PD-1, was associated with PD-L1 expression. Tumor cell PD-L1 expression correlated with objective 
response to anti-PD-1 therapy, when analyzing either the specimen closest to therapy or the highest 
scoring sample among multiple biopsies from individual patients. This correlation was stronger than 
borderline associations of PD-1 expression or the presence of intratumoral immune cell infiltrates 
with response. Tumor PD-L1 expression reflects an immune-active microenvironment and, while 
associated with other immunosuppressive molecules including PD-1 and PD-L2, is the single factor 
most closely correlated with response to anti-PD-1 blockade.    
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Decreased expression of caveolin-1 contributes to the pathogenesis of psoriasis
Y Yamaguchi, Y Watanabe, N Koumitsu, T Watanabe and M Aihara Department of 
Environmental Immuno-Dermatology, Yokohama City University Graduate School of 
Medicine, Yokohama, Japan
Introduction: Psoriasis is a chronic inflammatory skin disease characterized by excessive prolifer-
ation and abnormal development of keratinocytes. T helper-17 cells and activation of signal trans-
ducer and activator of transcription 3 (STAT3) play a pivotal role in the pathogenesis of psoriasis. 
Caveolin-1 (Cav-1) serves as a platform for membrane trafficking and signal transduction pathways 
in cell proliferation and differentiation. Aberrant Cav-1 expression is involved in a variety of diseases. 
In this study, we investigate the association of Cav-1 in the pathogenesis of psoriasis. Methods: Cav-1 
expressions in the skin obtained from psoriasis patients and imiquimod (IMQ)-induced psoriasis 
model mice were determined by immunohistochemistry, polymerase chain reaction, and western 
blot. Co-localization and binding of Cav-1 and phospho-STAT3 (pSTAT3) in human keratinocytes 
was also assessed by immunocytochemistry and immunoprecipitation-western blot analysis. In 
addition, the level of STAT3 phosphorylation was examined in human keratinocytes silenced with 
Cav-1 stimulated with IL-22 or epidermal growth factor (EGF). Finally, Cav-1 function was restored 
in IMQ-induced psoriasis model in mice using Cav-1 scaffolding peptide (CSD). Results: Cav-1 
levels were significantly reduced in keratinocytes from patients with psoriasis and psoriasis model 
mice. Cav-1 was co-localized with pSTAT3, and bound Cav-1. Cav-1 silencing in vitro enhanced 
phosphorylation of STAT3 in IL-22- or EGF-stimulated keratinocytes. Finally, restoration of Cav-1 
using CSD peptides in IMQ-induced psoriasis model mice improved skin phenotype, moreover, 
significantly reduced epidermal thickness and numbers of infiltrating cells compared with those in 
psoriasis model mice treated with control peptides (P<0.001). Conclusion: Cav-1 appears to par-
ticipate in the pathogenesis of psoriasis. An increase of Cav-1 function employing a cell membrane 
permeable CSD peptide may be a novel therapeutic approach to inhibit the progression of psoriasis.   
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Resiquimod gel, a potent activator of the innate immune response, leads to systemic immune 
activation and regression of treated lesions in patients with CTCL: Results of a phase I trial
AH Rook,1 M Wysocka,1 B Benoit,1 R Watanabe,2 A Troxel,1 J Teague,2 R Elenitsas,1 E Kim,1 
C Surber,1 R Clark2 and J Gelfand1 1 Dermatology, University of Pennsylvania, Philadelphia, 
PA and 2 Dermatology, Brigham and Women’s Hospital, Boston, MA
Previous in vitro studies have demonstrated that the TLR 7/8 agonist resiquimod can markedly 
enhance cellular immune responses among patients with advanced cutaneous T-cell lymphoma 
(CTCL). We initiated a phase I open-label trial of varying doses of topical resiquimod gel for the 
treatment of patients with stage IA-IIA CTCL. To date, 10 highly refractory patients (1 stage 1A; 8 
stage IB; 1 stage IIA) who had failed on average more than 4 previous treatments including IFN, 
PUVA and oral bexarotene, applied 500 mg or less 0.06% or 0.03% resiquimod gel to up to 5 
target lesions at varying frequencies for two 8 week cycles with a 4 week rest period in between. 
Several patients experienced several days of low grade fever upon initiation of study drug; 8 of 10 
(2 CR, 6 PR) had decreased pruritus and clearing of treated target lesions as well as improvement in 
non-treated distant lesions. Analysis of peripheral blood demonstrated that therapy was associated 
with increased myeloid dendritic cell CD80 expression and NK cell CD107 expression in most, 
suggesting activation of both circulating mDC and NK cells. Analysis of T cells isolated from skin 
biopsies before and after treatment demonstrated that therapy was associated with intralesional 
influx of NK and cytotoxic CD8 T cells with enhanced IFN gamma production in some patients. 
Taken together, results suggest that topical resiquimod induces systemic immune activation, is highly 
efficacious in the treatment of refractory CTCL skin lesions and leads to regression of both treated 
and distant untreated lesions. The capacity of topical resiquimod to enhance systemic immune 
responses to cancer suggests it may be useful in other human skin cancers.    
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Tolerability and encouraging clinical activity of SHP-141, a topical skin-restricted HDAC 
inhibitor, in a phase 1B study in cutaneous t-cell lymphoma
YH Kim,1 MS Krathen,1 M Duvic,2 H Wong,3 P Porcu,3 J Tacastacas,4 NJ Korman,4 J Guitart,5 
SB Landau7 and JE Bradner6 1 Stanford U, Palo Alto, CA, 2 MD Anderson Cancer Center, 
Houston, TX, 3 Ohio State U, Columbus, OH, 4 UH Case Med Center, Cleveland, OH, 
5 Northwestern U, Chicago, IL, 6 Dana Farber Cancer Institute, Boston, MA and 7 Shape 
Pharmaceuticals, Cambridge, MA
The efficacy of histone deacetylase inhibitors (HDACi) as systemic therapy in CTCL is well-estab-
lished, but class-associated toxicities have limited use to advanced or refractory disease. SHP-141 
is a novel first-in-class topical HDACi intentionally designed to maximize activity in the skin but 
limit systemic exposure by rendering the drug inactive via endogenous serum esterases. A phase 1b 
multi-center, double-blind, placebo (PBO)-controlled, randomized trial in stage IA-IIA CTCL was 
conducted to assess safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy 
with SHP-141 applied twice daily for 28 days. Six patients were enrolled (5 SHP-141: 1 PBO) at 
each dose level (0.1%, 0.5%, 1.0%) in the dose-escalation phase. Of 18 total patients enrolled, the 
SHP-141 arm had 3 stage IA, 11 IB, 1 IIA; PBO arm had 2 stage IA and 1 IB. No discontinuations, 
DLTs, or serious adverse events (AEs) were recorded. Most AEs were mild; SHP-141 related AEs were 
limited to skin without any systemic toxicities. IHC of skin biopsy specimens confirmed evidence 
of a dose dependent augmented HDACi activity using a specific acetyl–lysine antibody. PK results 
confirmed lack of SHP-141 exposure in peripheral blood supporting the higher exposures. Nota-
bly, 4 of 15 patients randomized to SHP-141 attained an objective response (> 50% improvement 
by CAILS) and 6 had weekly incremental CAILS improvement over 28 days; neither feature was 
observed in the PBO arm. This initial clinical study of a skin-optimized topical HDACi demonstrates 
excellent tolerability and encouraging early clinical efficacy, even with dosing limited to 28 days. 
SHP-141 may address an important unmet medical need in early stage CTCL by providing a topical 
HDACi devoid of systemic toxicities.    
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In pemphigus vulgaris patients ongoing disease and relapse is associated with persistence of 
the same non-tolerant B-cell clones which are eliminated in long-term clinical and serologic 
remission
CM Hammers,1 J Chen,1 C Lin,1 S Kacir,2 AS Payne,1 DL Siegel2 and JR Stanley1 1 
Dermatology, U of PA, Philadelphia, PA and 2 Path&Lab Medicine, U of PA, Philadelphia, 
PA
In pemphigus vulgaris (PV) anti-desmoglein 3 (Dsg3) IgG autoantibodies cause loss of keratinoctye 
adhesion with severe blistering. Most patients who achieve clinical remission subsequently relapse. 
In this study we asked why patients relapse. Specifically, is there an ongoing escape from tolerance 
of new IgG+ anti-Dsg3 B-cell clones, or do the same B-cell clones persist over time? We studied 3 
patients (PV3, PV1, and COL-JA) over time and used antibody phage display (APD) to characterize 
the clonal IgG+ anti-Dsg3 B-cell response. APD allows nucleotide cloning of the anti-Dsg3 variable 
heavy chains (VH). The VH-CDR3 region (formed from the variable-diversity-junctional gene somatic 
rearrangement in B cells) is unique for each clonal lineage (including its progeny). If clones in any 
patient were found at one time point by APD but not another, we used PCR with primers designed 
from APD clonally-specific sequences to find if clones persisted at the second time point. In PV3, 
treated with prednisone and mycophenolate, the same 6 IgG+ B-cell clones persisted for 5 years, 
even after clinical remission and relapse. In PV1 the same 5 clones persisted over 8 years, even after 
relapse after rituximab (anti-CD20) therapy. However, after a 4th course of rituximab, at which time 
this patient went into clinical and serologic remission for 2 years, anti-Dsg3 B cells were no longer 
detected by either APD or PCR. With one exception, no new anti-Dsg3 B-cell clones were detected 
over 14 patient years in these 2 patients. Finally, COL-JA had no anti-Dsg3 B cells detectable after 
a single course of rituximab resulted in a 56 months clinical and serologic remission. These data 
indicate that, in general, there is not an ongoing escape of new IgG+ B-cell clones from tolerance 
in PV patients, and that relapses occur due to persistence of clones. These results suggest that PV 
therapy should aim at eliminating all anti-Dsg3 IgG+ B-cell lineages.    
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Botulinum toxin improves quality of life and may ameliorate pain associated with cutaneous 
leiomyomas
HB Naik, SM Steinberg, HH Kong and EW Cowen National Cancer Institute, Bethesda, MD
Cutaneous leiomyomas are characterized by severe paroxysmal pain in which nerve conduction 
may play a key role. We assessed the efficacy of intralesional botulinum toxin-A for the management 
of pain associated with cutaneous leiomyomas. Participants (age≥18, n=18) were enrolled in a single 
center, randomized, double-blind, placebo-controlled study comparing intralesional botulinum 
toxin-A (BTX, 5 units/0.1cm2) with saline control (CON). Outcomes measured included differences 
calculated as week 4 minus baseline in: average lesional pain based on Brief Pain Inventory (BPI), 
pain based on visual analogue scales (VAS) before and after ice provocation test and Dermatology 
Life Quality Index (DLQI) scores. Participant-reported global impression of change (GIC) at week 
4 was also evaluated. Trends toward reduced pain were found by VAS before ice provocation in 
BTX vs CON (BTX median=0.0, range -3.3 – 0.7, n=9; CON median=0.4, range -1.3 – 1.5, n=9; 
p=0.06), and specific skin pain-related question on DLQI (BTX=-1.0, -2.0 – 1.0; CON=0.0, -1.0 – 
0.0; p=0.048). A strongly significant difference was found between treatment arms in skin-related 
quality of life by total DLQI score (BTX=-4.0, -8.0 – 2.0; CON=0.0, -1.0 – 4.0; p=0.0072). There 
was no significant difference between arms in: 1) change in pain after ice provocation (BTX=-1.6, 
-6.4 – 0.7; CON=-1.0, -6.3 – 5.7; p=0.67); 2) average lesional pain (BTX=0.0, -6.0 – 2.0; CON=0.0, 
-5.00 – 3.0; p=0.70); or 3) pain status of treated lesions as ascertained by GIC at week 4 (BTX=3.0, 
1.0 – 4.0; CON=4.0, range 2.0 – 4.0; p=0.34). No serious adverse events related to botulinum 
toxin were reported. In this small pilot study, botulinum toxin-A was associated with improved 
quality of life and demonstrated a trend towards ameliorating pain at rest associated with cutaneous 
leiomyomas, suggesting that BTX-A may benefit some patients with significant skin-related pain 
through mechanisms not fully understood. The etiology of pain caused by cutaneous leiomyomas 
warrants further investigation.    
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IL-10 is upregulated in advanced mycosis fungoides and is required for maximal tumor 
development in a murine model of CTCL
X Wu,1 Y Zhou2 and S Hwang1 1 Dermatology, Medical College of Wisconsin, Milwaukee, 
WI and 2 Dermatology, Univ. BC, Vancouver, BC, Canada
IL-10 is a potent immunosuppressive cytokine that has been reported to be increased in lesional skin 
of patients with advanced stages of cutaneous T cell lymphoma (CTCL). It is unclear, however, if 
IL-10 is a marker of advanced disease or if it is required for tumorigenesis. Herein, we first confirmed 
using cytokine PCR arrays that IL-10 expression was increased (~6 fold compared to normal skin) in 
the skin samples of mycosis fungoides patients, the most common type of CTCL population, and that 
IL-10 mRNA level was significantly higher in plaque than in patch stage (p=0.0428). Next, utilizing a 
published inflammation-dependent model of CTCL, we showed that IL-10 was markedly upregulated 
in skin lymphoma tumors that developed in skin of mice that had been inoculated with MBL2 T 
lymphoma cells and treated one time topically with di-nitro-fluoro-benzene, a contact sensitizer. 
To determine if IL-10 played a key role in MBL2 tumor development, we compared tumor devel-
opment of MBL2 tumors in IL-10 gene KO (IL10KO) mice vs. wild-type (WT) mice. Tumors arising 
in ILKO mice were 50% smaller (n=15, p=0.0026) than those of control mice. Immunostaining 
revealed a striking increase of 20.5-fold more infiltrating-CD8+ T cells and a decrease of 9.7-fold 
fewer F4/80+ macrophages in IL10KO vs. WT tumors (p=0.038 for CD8, and p=0.048 for F4/80). 
CD31, a vascular marker, was also decreased in IL10KO vs. WT mice. Our patient data confirm 
that IL-10 is upregulated in the skin of advanced CTCL patients. Importantly, the availability of IL-10 
KO mice allowed us to show that IL-10 is required for maximal tumor development, possibly due 
to its influence on the number and function of F4/80+ macrophages and CD8+ T cells. These data 
support the potential use of anti-IL-10 as therapy for advanced CTCL.    
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Antibody titers to Merkel cell polyomavirus oncoproteins predict Merkel cell carcinoma 
recurrence with high sensitivity and specificity
KG Paulson,1,2 AE Lisberg,1,2 A Blom,2 C Lewis,2 AS Moshiri,2 W Simonson,4,5 JG Iyer,2 
S Bhatia,3 L Yelistratova,2 D Galloway,6 C Morishima,5 M Wener5,1 and P Nghiem2,6,4 1 
Department of Medicine, University of Washington, Seattle, WA, 2 Division of Dermatology, 
Department of Medicine, University of Washington, Seattle, WA, 3 Division of Medical 
Oncology, Department of Medicine, University of Washington, Seattle, WA, 4 Department 
of Pathology, University of Washington, Seattle, WA, 5 Department of Laboratory Medicine, 
University of Washington, Seattle, WA and 6 Fred Hutchinson Cancer Research Center, 
Seattle, WA
A preliminary study has shown that approximately half of newly diagnosed Merkel cell carcinoma 
(MCC) patients produce antibodies specific to Merkel cell polyomavirus (MCPyV) oncoproteins and 
that the titer of these antibodies may reflect disease burden. We aimed to verify these findings in a 
much larger cohort and to further characterize the specificity, sensitivity, and clinical utility of this 
biomarker, which is now available (http://www.merkelcell.org/sero). Between January 2008 and 
October 2013, we enrolled 131 patients presenting with local or nodal MCC and who had an initial 
positive oncoprotein antibody titer. This group contributed 599 blood samples and 199 person-years 
of follow-up time. We found that oncoprotein antibody titers steadily fell or remained stably neg-
ative in 226 of 231 samples from those patients that remained disease-free throughout the study 
(specificity = 97.8%). Of the 18 patients that progressed within 30 days of a blood draw, 14 had at 
least a 20% increase in oncoprotein antibody titer (sensitivity = 77.8%). In four of these patients, the 
increasing titers preceded recognition of recurrent disease and initiated further workup that revealed 
the metastasis. These results suggest that, for patients that produce them at the time of diagnosis, 
antibodies to MCPyV oncoproteins can be used to monitor MCC patients for initial recurrence, 
and in some cases reduce the need for frequent surveillance by computed tomography imaging.   
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Long-term prospective study of skin condition changes by daily topical applications of retinol: 
Results of 1-year follow up
H Park,1 S Park,1 E Kim,1 H Kim,1 S Jang,1 J Hwang,2 J Kim,2 H Lee1 and J Lee1 1 Skin Research 
Institute, AMOREPACIFIC Corporation R&D Center, Yongin, Republic of Korea and 2 Skin 
Care Research Institute, AMOREPACIFIC Corporation R&D Center, Yongin, Republic of 
Korea
Purpose: The aim of this study was to investigate the facial skin condition of daily topical retinol 
application in Korean women. And we compared with aging and control groups in long-term 
follow-up of prospective study. Methods: A total of 115 healthy Korean females were enrolled 
in this study from Dec 2012 to Dec 2013 in this study. This was a randomized, double-blinded, 
vehicle-controlled test. The subjects were divided into 2 groups as test group with retinol cream 
(2500IU) treatment and the control group with vehicle cream treatment. The skin condition as 
wrinkle, water contents, sebum contents, skin color, melanin, erytherma, pH and skin elasticity 
were measured on the eye rim and crow’s feet. Results: On initial 6 months, the wrinkle, water 
content, melanin, erythema and pH were changed significantly in test group’s crow’s feet. The 
elasticity and moisture content, melanin, erythema and redness in eye rim were showed significant 
differences compared to before treatment. On 12 months, the wrinkle and water content were 
showed significantly improvement. The elasticity was increased significantly then before usage, but 
was showed no significantly difference compared to control group. Conclusion: Even considering 
the effect of seasonal changes, the skin conditions such as wrinkle, hydration, and elasticity were 
improved by daily topical application of retinol. And also we considered that the long-term usage 
of retinol can affect skin aging status.    
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Polyphenols extracted from apples improve acne lesions by inhibition of sebum production
K Lee,1 H Kim,1 M Jung,2 E Choi,2 W Lee3 and J Youm1 1 R&I Center, Cosmax Co. Ltd., 
Seongnam, Republic of Korea, 2 Dermatology, Yonsei University Wonju College of 
Medicine, Wonju, Republic of Korea and 3 Dermatology, Kyungpook National University 
School of Medicine, Daegu, Republic of Korea
Polyphenols extracted from apples are known to have beneficial actions on oxidative stress and 
inflammation in skin. The main ployphenols from apples are procyanidins. We have studied another 
role of the polyphenols extracted from apples (Applephenon®) in acne treatment. First, effects of 
Applephenon on lipid synthesis in primary cultured human sebocytes were investigated. Apple-
phenon inhibited not only sebum production in oil red O staining but also the expression of lipid 
synthesis-related genes (SREBP-1a, SREBP-1c, acetyl coenzyme A carboxylase, fatty acid synthase) 
elevated by dexamethansone in dose-dependent manner in primary cultured sebocytes. Next, a 
formula containing 0.5% Applephenon and 2% niacinamide was topically applied on the face of 
acne subjects twice a day for 4 weeks. Niacinamide was also reported to reduce facial sebum pro-
duction. Total 31 acne subjects (the average age: 21.8±4.0) were recruited, and acne lesions were 
counted. The formula reduced both non-inflammatory lesions and inflammatory lesions significantly 
in acne subjects. Inflammatory papules were reduced from 5.0±1.6 (mean±std) to 1.6±0.4, and 
non-inflammation papules were reduced from 15.3±1.8 to 6.5±1.2 in 4 weeks. Total reduction rate 
of acne papules was 64.4±3.0%. In addition, independent dermatologists evaluated the improve-
ment rate of acne vulgaris with 5 grade scales (0; aggravation to 4; remarkable improvement) by 
comparing clinical photographs of acne subjects before and after the formula application. 67.8% 
subjects showed the improvement of acne vulgaris from grade 2 to grade 4 in 4 weeks. Therefore, 
Applephenon may have beneficial actions on acne treatment by regulating sebum production.   
538
Circulating central memory T cells are negatively correlated with lesional Foxp3+ regulatory 
T cells in psoriasis patients
E Nishida, S Kasuya, A Nishioka, T Furuhashi and A Morita Geriatric and Environmental 
Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Psoriasis is a chronic inflammatory skin disease mediated by T helper type-17 (Th17) expressing 
IL-17A and IL-22. There are two distinct populations of memory T cells. Effector memory T cells 
(TEM) are similar to effector cells, express tissue homing receptors, develop effector function, and 
rapidly produce cytokines upon restimulation. Central memory T cells (TCM) are similar to naive T 
cells and express the lymph node homing receptor L-selectin (CD62L) and CCR7, but generally lack 
receptors for homing to peripheral tissues. TCM have lower effector function levels but proliferate 
vigorously and develop into effector T cells when restimulated with antigens. Approximately 20-25% 
of CD4+CCR7+ TCM in human blood express CXCR5. CD4 and CCR7 are also expressed on naive 
T cells, making CXCR5 a more suitable marker than CD45 for differentiating naive T cells and Th22. 
In our previous study, circulating CD4+CCR7+CXCR5+ T cell levels were significantly higher in pso-
riasis patients than in healthy controls. TCM were correlated with IL-22 producing T cells in patients 
with severe psoriasis. TCM might be precursors of pathogenic T cells such as peripherally infiltrating 
resident memory T cells (TRM) in psoriasis. In this study, we further examined the relationship of 
TCM in the peripheral blood and the number of Foxp3+ regulatory T cells of skin lesions from 10 
psoriasis patients (7 men, 3 women). The Psoriasis Area Severity Index (PASI) score was positively 
correlated with the number of lesional Foxp3+ T cells (r=0.577). Th17 population among CD4 cells 
in the peripheral blood did not correlate with the number of lesional Foxp3+ T cells (r=0.305) nor 
PASI scores (r=0.166). However, circulating CD4+CCR7+CXCR5+ T cells are negatively correlated 
with PASI scores and the number of lesional Foxp3+ T cells (r=-0646,-0.601), but not correlated 
with circulating Th17 (r=0.267). These data suggested that TCM might be precursors of TRM which 
can be suppressed by Foxp3+ regulatory T cells in psoriasis.    
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Acne Core Outcomes Research Network (ACORN): Standardizing outcome measures in 
acne trials
D Thiboutot,1 J Tan,2 M Chren,3 A Eady4 and A Layton4 1 Dermatology, Penn State University, 
Hershey, PA, 2 Windsor Clinical Research, Windsor, ON, Canada, 3 University of California 
San Francisco, San Francisco, CA and 4 Harrogate and District NHS Foundation Trust, 
Harrogate, United Kingdom
Acne is a globally burdensome condition with deleterious effects on individuals and substantial 
financial impact on societal resources. A major question facing dermatology providers is how 
new acne treatments compare to each other. Resources to conduct comparative efficacy trials 
to guide treatment decisions are limited. Statistical analysis of trial data can be done using meta 
analysis, but the quality of these analyses depends upon consistency in the measures used to assess 
acne. Recognizing the need for standardization of acne outcome measures moving forward, an 
international group of dermatology clinicians, researchers and statisticians formed the Acne Core 
Outcomes Research Network (ACORN). The overarching goal of ACORN is to identify a validated 
and standardized set of core outcome measures for universal use in acne trials. The ACORN team 
is assessing existing instruments and will devise and validate new ones. The goal is to capture and 
quantify changes in those outcomes measures of the most importance to patients, clinicians and 
other stakeholders. ACORN is launching a dedicated website, seeking to grow its international 
membership and initiating its first specific projects. These include an online training module to 
standardize acne lesion counting, a systematic review of patient-based outcomes and a Delphi 
exercise complemented by one-to-one interviews to capture outcomes that matter most to people 
with acne. These data will inform the design of a better instrument to capture treatment effects on 
patients’ wellbeing. The ACORN team has also formed partnerships with industry colleagues to 
correlate manual lesion counting by experts with novel computerized methodologies to advance 
the science of assessing acne. ACORN will continue to engage with a broad range of stakeholders 
on an international level to ensure that the core outcome measure set can be used globally.    
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IL-17A induces inflammation-associated gene products in blood monocytes and treatment 
with ixekizumab reduces their expression in psoriasis patient blood
CQ Wang,1 M Suarez-Farinas,1 KE Nograles,1 CA Mimoso,1 D Shrom,2 ER Dow,2 
MP Heffernan,2 RW Hoffman2 and J Krueger1 1 Rockefeller University, New York, NY and 
2 Lilly, Indianapolis, IN
IL-17A (IL-17) is a central cytokine in psoriasis pathogenesis, but what effects it has on circulat-
ing blood leukocytes and establishing systemic inflammation remain unclear. We explored the 
impact of IL-17 on blood monocytes, and how neutralization of IL-17 by ixekizumab (IXE) may 
impact systemic inflammation. Monocytes isolated from 3 healthy volunteers were treated with 
IL-17 (200ng/mL, 24h), and microarray analysis was performed. Gene profiling indicated that IL-17 
induced the expression of proinflammatory cytokines (e.g CCL24, IL-8, CXCL5, IL-1A, IL-1B) and 
receptors involved in monocyte chemotaxis (e.g. CXCR4, CCR2, CCR1) (p<0.1). CXCR4 and IL-8 
are known markers of cardiovascular disease risk. Ingenuity Pathway Analysis (IPA) revealed signif-
icant enrichment of pathways involved in proinflammatory responses such as IL-17 and IL-6/STAT3 
signaling and leukocyte transendothelial migration including cell adhesion molecules associated 
with platelet accumulation in atherosclerosis (e.g. ITGA4, ITGB1, PECAM-1, CD99, MMP9). We 
next analyzed the blood transcriptome of psoriasis patients (week 2, 150mg IXE vs. baseline). Many 
genes for proinflammatory cytokines were downregulated with IXE treatment (e.g. IL-1A, IL-1B, IL-8, 
CXCR4). IPA revealed significant repression of IL-17 signaling, IL-6/STAT3 signaling and leukocyte 
transendothelial migration. Similarly, gene set enrichment analysis showed broad suppression of 
genes involved in inflammatory response, integin-mediated cell adhesion molecules, leukocyte 
transendothelial migration and blood coagulation and atherosclerosis (e.g. ALOX5, THBS1, F2RL2). 
Overall, IL-17 induced genes and signaling pathways associated with inflammation, atherosclerosis 
and cardiovascular disease in monocytes, while treatment with IXE alleviated inflammation in 
psoriasis patient blood, suggesting that neutralization of IL-17 with IXE might impact the biology 
of psoriasis associated-co-morbidities.    
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 The role of VEGFR-3 in the regression of benign lymphangioendothelioma following treat-
ment with sirolimus 
KM Hunt1 and J Herrmann2 1 University of Alabama School of Medicine, Birmingham, AL 
and 2 University of Alabama at Birmingham Department of Dermatology, Birmingham, AL
Benign lymphangioendothelioma (BL), also known as acquired progressive lymphangioma, is a rare 
lymphatic neoplasm with few treatment options. Its clinical appearance is most commonly that of an 
asymptomatic, singular, well-circumscribed patch or plaque with red to bruise-like coloration. BL 
has most commonly been reported on the thigh (33%) but has also appeared on the head and neck 
region (20.5%), upper limb (20.5%), trunk (18%), and shoulder (8%). Though its pathophysiology 
has yet to be elucidated, vascular endothelial growth factor (VEGF) has been shown to promote 
lymphangiogenesis. BL treatment has typically been limited to surgery for small lesions with disease 
reoccurrence being common. We present the case of a 48-year-old male with a large BL of the 
thigh that demonstrated remarkable regression upon initiation of sirolimus treatment. This review 
evaluates the role of sirolimus in the inhibition of lymphangiogenesis and the possible mechanism 
by which this is accomplished. We conclude that current evidence suggests the downregulation 
of VEGF receptor 3 expression by sirolimus may have lead to improvement of our patient’s lesion 
and warrants further investigation.    
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Gene expression profiling of T-cell signaling in cutaneous T-cell lymphoma and the effect of 
extracorporeal photopheresis
B Yang,1,2 M Duvic,1 L Shiue,1 M Goswami,1 T Langridge1 and X Ni1 1 Dermatology, 
University of Texas MD Anderson Cancer Center, Houston, TX and 2 University of Texas 
Medical School at Houston, Houston, TX
Cutaneous T-cell lymphomas (CTCL) are malignances of skin-homing T-helper (Th) cells. Multiple 
impairments related to T-cell signaling cascades have been reported individually. Extracorporeal 
photopheresis (ECP) is an effective therapy for leukemic-CTCL (L-CTCL), but its mechanisms are 
not fully understood. To better understand the immunopathogenesis of CTCL and the mechanism 
of ECP in CTCL, we used the novel multi-gene expression array and profiled the gene dysregula-
tion pattern of T-cell signaling in peripheral blood cells from patients with L-CTCL and monitored 
changes over a 6-month course of ECP treatment. Peripheral blood samples from 8 L-CTCL patients 
who underwent ECP were collected under IRB-approved protocol. Expressions of 151 genes were 
assessed at baseline, at Day 2, and 6 months post-ECP using T-cell activation and T-cell anergy 
PCR Arrays. The top dysregulated genes and top canonical pathways were explored using Ingenuity 
Pathway Analysis. All 8 patients studied had > 50% circulating tumor cells. At baseline, 41 genes 
were dysregulated, especially pathways related to hematopoiesis (9 genes), Th cell differentiation (9 
genes), altered T cell and B cell signaling (9 genes), and immune cell communication (9 genes). The 
top upregulated genes were TNFSF10, CD27, CCR2, CCR3, and BTLA, and the top downregulated 
genes were IL-8, Jun, ICOSLG, CSF1, and CXCR4. STAT6, IL-4 and IL-5 were also upregulated. 
After ECP, multiple dysregulated genes at baseline were changed significantly (p<0.05). In addition, 
genes related to IL-12 signaling, IL-2 signaling, and crosstalk between dendritic cells and NK cells 
were activated. These results suggest that abnormal hematopoiesis, Th cell differentiation, T cell 
and B cell signaling, immune cell communication, and Th2 cytokine polarization may contribute 
to the immunopathogenesis of CTCL. ECP treatment exerts a favorable effect on reversing them. A 
larger sample size is needed to further confirm these findings.    
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Distinct allergen-dependent immune polarization suggested by molecular analyses of patch-
tested skin to common sensitizers
N Dhingra,1,2 A Shemer,3 J Correa da Rosa,1 M Rozenblit,1,4 M Suarez-Farinas,1 J Fuentes-
Duculan,1 T Czarnowicki,1 J Krueger1 and E Guttman-Yassky1,4 1 Investigative Dermatology, 
Rockefeller University, New York, NY, 2 College of Physicians & Surgeons, Columbia 
University, New York, NY, 3 Dermatology Department, Tel-Hashomer, Tel-Aviv, Israel and 
4 Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
Allergic contact dermatitis (ACD) is the most common occupational disease. While murine con-
tact hypersensitivity (CHS) provides a general framework for understanding ACD pathogenesis, 
it carries important differences. Unlike CHS, which is induced by potent sensitizers (i.e. DNFB), 
human ACD is induced by weaker sensitizers (i.e. nickel), which do not produce reactions in mice. 
Distinct hapten-specific immune-polarizing responses to potent inducers were described in mice, 
with unclear relevance to human ACD. We explored the possibility of distinct T-cell polarization 
responses in skin to common clinically relevant ACD allergens. Real-time PCR, gene arrays, and 
immunohistochemistry were performed on skin biopsies of sites patch-tested to common aller-
gens (nickel, fragrance, rubber) and petrolatum-occluded skin. Despite similar clinical reactions 
in all allergen groups, distinct polarizations characterized different allergens. While the collective 
ACD transcriptome consisted of 149 common differentially expressed genes across all allergens 
versus petrolatum, much larger gene sets were uniquely altered by individual sensitizers. Nickel 
demonstrated the highest immune activation, with potent induction of innate immunity, Th1/Th17 
and a Th22 component. Fragrance, and to a lesser extent rubber, demonstrated a strong Th2 bias, 
some Th22 polarization, and smaller Th1/Th17 contributions. Our study offers new insights into 
ACD pathogenesis, expanding our understanding of T-cell activation and associated cytokines in 
allergen-reactive tissues. It is the first study that defines the common transcriptome of clinically 
relevant sensitizers in human skin and identifies unique allergen-dependent pathways, suggesting 
that ACD cannot be considered a single phenomenon.    
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A combination of PPARα activator and ceramide improves red face originated from variable 
skin diseases
Y Nho,1 H Kim,1 Y Jung,2 S Kim,2 Y Kim,3 S Lee3 and J Youm1 1 R&I Center, Cosmax Co. 
Ltd., Seongnam, Republic of Korea, 2 Natural Medicine Center, KIST Gangneung Institute, 
Gangneung, Republic of Korea and 3 Dermatology, Soonchunhyang University College of 
Medicine, Bucheon, Republic of Korea
Red face (facial erythema) may not only present a distinct clinical entity, but also be a distressed 
symptom of variable skin conditions including sensitive skin (SS). Symptoms of SS range from 
visible signs such as erythema and scaling to subjective neurosensory forms such as stinging, 
burning, itching and tightness. Abnormal barrier function in SS is resulted from an impairment of 
intercellular lipids in stratum corneum. PPARα activation exerts anti-inflammatory effects in various 
skin conditions such as irritant or allegic contact dermatitis, atopic dermatitis and UV-induced 
erythema. In this study, we have investigated the effect of a moisturizer combined PPARα activator 
and ceramide on red face accompanied SS. Three PPARα activators (Euryale ferox, Euphorbia 
lathyris, Rosa multiflora) extracted by supercritical CO2 were screened by the transactivation assay 
in HaCaT cells. Physiologic lipid mixture composed of ceramide, cholesterol and fatty acid was 
formulated. Total 31 subjects with red face were recruited, who consisted the patients with atopic 
dermatitis (5), seborrheic dermatitis (7), irritant contact dermatitis (3), allergic contact dermatitis (4), 
rosacea (9) and acne (3). The improvement of facial erythema was evaluated by Mexameter MX18® 
and DermaVision-PRO®. After dividing the face to left and right, moisturizers with/without PPARα 
activators and ceramide were randomly applied on half of the face respectively twice a day for 2 
weeks. Both erythema level measured by Mexameter and erythema index measured by DermaVi-
sion-PRO were significantly reduced in the test compared to the control. In addition, independent 
dermatologists compared facial erythema by clinical photographs of the subjects before and after 
moisturizers application. 75.8% subjects in the test showed the improvement of facial erythema 
after 2 weeks. Therefore, the combination of PPARα activator and ceramide could be useful for the 
treatment of red face accompanied SS.    
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Successful treatment of recalcitrant necrobiotic xanthogranuloma using intravenous immu-
noglobulin and electron beam radiation
VE Nambudiri,1,4 T Lo,2 A Zembowicz3 and S Moschella4 1 Harvard Combined Dermatology 
Program, Boston, MA, 2 Radiation Oncology, Lahey Clinic, Burlington, MA, 3 Pathology, 
Lahey Clinic, Burlington, MA and 4 Dermatology, Lahey Clinic, Burlington, MA
We report a viable multi-modal treatment strategy for necrobiotic xanthogranuloma (NXG), a rare 
inflammatory disorder characterized by cutaneous yellow-red papules, plaques and nodules often 
associated with an underlying paraproteinemia. A 61-year-old man with a 30-year history of NXG 
and associated IgA-kappa paraproteinemia presented for treatment of recalcitrant disease and intense 
pruritus in the torso and extremities. Previous treatment with intralesional and systemic cortico-
steroids, chlorambucil, and thalidomide achieved limited success. Treatment with intravenous 
immunoglobulin (IVIg) 2gm/kg in divided doses every 4 weeks was initiated and the patient achieved 
good clinical response. IVIg was discontinued due to insurance coverage lapse and worsening 
plaques on the arms were treated with a single dose of 10Gy using a 6 MeV electron beam. The 
patient demonstrated significant improvement in symptoms of pruritus and marked reduction in size 
of cutaneous plaques. He successfully underwent electron beam treatment of 1500 cGY delivered 
via 5 consecutive daily fractions to the left shoulder one month later with similar results. This 
treatment regimen was repeated for areas on the right chest wall and right arm two months with an 
uneventful treatment course and sustained clinical response until IVIg could be re-initiated. While 
case reports of IVIg for NXG are increasingly reported, this is the first report to our knowledge of 
using IVIg in combination with radiation therapy for NXG; radiation therapy has been reported in 
only four prior cases of NXG. Electron beam radiation for NXG may have its effect by targeting the 
dense lympho-histiocytic inflammation characteristic of cutaneous lesions. Further investigations 
are necessary to explore the mechanism and role of multi-modality treatments for NXG.    
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Improvement in CDASI activity score is associated with a better quality of life in patients 
with dermatomyositis
ES Robinson,1,2 R Feng3 and V Werth1,2 1 VAMC, Philadelphia, PA, 2 Dept of Derm, U Penn, 
Philadelphia, PA and 3 Dept Biostatistics and Epidemiology, U Penn, Philadelphia, PA
Dermatomyositis (DM) can significantly impair quality of life more than many other skin diseases. 
This prospective study assessed whether a change in quality of life, as measured by the Skindex-29 
and patient reported itch and pain on a 10 point visual analog scale (VAS), correlates with a change 
in cutaneous DM activity. Patients with a completed cutaneous DM disease area and severity index 
(CDASI) at two visits separated by at least two months were classified into responder (n=15) and 
non-responder (n=30) groups according to the point change in CDASI between visits. Responders 
had at least a four-point improvement in CDASI, indicating clinically relevant improvement. The 
Wilcoxon rank sum test was used to inspect the change in each component of the Skindex-29, as 
well as itch and pain VAS scores. The median Skindex-29 emotions score of responders decreased 
from 45 to 25 (P=0.004), functioning score from 15 to 4 (P=0.006), and symptoms score from 50 
to 14 (P=0.002). Changes in the median Skindex-29 scores of non-responders were not statistically 
significant: emotions from 33 to 30 (P=0.76), functioning from 13 to 17 (P=0.13), and symptoms from 
32 to 43 (P=0.65). The median itch score for responders decreased from 2.8 to 0.5 (P=0.03). There 
was no significant difference in itch scores for non-responders, or in pain scores in either group. 
Because of the significant difference in baseline scores between responders and non-responders 
linear regression was performed, and it did not change the significance of the above results. Variation 
between responders and non-responders in disease subtype, sex, race, treatment for DM, age, and 
history of malignancy within five years of DM diagnosis were not statistically significant. These 
results demonstrate a strong relationship between cutaneous disease activity and quality of life 
measures in DM, and encourage the development of more effective therapies to improve patients’ 
disease activity and quality of life.    
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Video patient education about systemic corticosteroids is more effective than verbal educa-
tion: A randomized controlled trial
C Correnti,1 L Cassidy,1 SC Chen2,1 and B Stoff1,2 1 Emory, Atlanta, GA and 2 VAMC, Atl, GA
OBJECTIVE: Studies show video patient education is superior to verbal/written materials. Education 
about long-term (>6 weeks) systemic corticosteroids (CS), a treatment with risk for serious adverse 
effects, has not been studied. The current study sought to compare video to verbal education regard-
ing long-term CS among complex medical dermatology patients. METHODS: 75 English-speaking 
adults (≥18 years) seen from March-August 2013 at Emory Dermatology Clinics were allocated to 
video vs. verbal education using clinics as the unit of randomization. A 12-item survey assessed 
baseline and post-education knowledge. Demographics included age, sex, ethnicity, education, first 
language, reading level, and prior CS use. Verbal subjects (36) were educated with a script based on 
the standard disclosure of two top CS prescribers at Emory Dermatology. Video subjects (39) were 
educated with a video developed by the investigators. The main outcomes were post-education 
score differences by paired t-test and between-groups score differences. Secondary outcomes were 
between-groups comparison of scores on 7 adverse effect items, and overall satisfaction. RESULTS: 
Mean age was 51.7±18.3 years; 50.7% female; 78.7% white; 76% completed ≥ 4-years of college; 
96% scored ≥ 9th grade reading level; 53.3% prior CS users. Baseline knowledge scores were 
7.2±2.2 (of 12) overall and 3.1±1.6 (of 7) for adverse effects, with no between-group difference. 
Post-education, video group scores increased by 3.7±2.2 (p<0.01) vs 2.8±1.8 for verbal (p<0.01). 
Between-groups, the video group scored 0.9±2.0 higher than verbal (p<0.04). On adverse effects, 
the video group scored 0.9±1.1 higher than verbal (p<0.01). After Bonferroni correction, more video 
subjects identified a hypotensive crisis as a risk of stopping CSs (72% vs. 33%). Overall 97% were 
satisfied, 3% felt neutrally, none were unsatisfied. CONCLUSION: Video education was superior 
to verbal education regarding long-term CS treatment and maintains patient satisfaction. The video 
imparted greater knowledge of adverse effects such as adrenal crisis.    
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FAS: Potential lipogenesis target in acne
A Gupta,1 X Wang,1 S Compton,3 J Klein,2 J Moore,2 B Buehrer3 and S Frey1 1 Center of Skin 
Biology, Stiefel, a GSK company, Research Triangle Park, NC, 2 GlaxoSmithKline, Research 
Triangle Park, NC and 3 Zen-Bio, Research Triangle Park, NC
Excessive sebum production is a hallmark of acne pathogenesis and has been shown to correlate with 
acne severity in humans. Sebum excretion is attributed to sebaceous lipogenesis and accumulation 
of lipid droplets in sebaceous gland cells (sebocytes). We developed an in vitro model for screening 
compounds with activity in modulating lipid production using human sebocytes expressing the 
temperature-sensitive SV40 mutant (tsA58) and hTERT. After culture at non-permissive tempera-
tures (33°C), lipogenesis was induced in sebocytes following a 24h treatment with an LXR agonist 
and 4h stimulation with insulin. Compounds were added along with the LXR agonist at varying 
concentrations. Lipid production was measured by the incorporation of 14C-acetate into lipids and 
normalized to cell viability as determined by CellTiter-Blue assay. We hypothesized that targeting 
enzymes in lipogenesis pathway such as Fatty Acid Synthase (FAS) would impact lipid synthesis 
in this model system. Upon pharmacological inhibition of FAS, lipid synthesis was dramatically 
reduced (EC50=~1-50 nM) in sebocytes. To further confirm the activity of the FAS inhibitors, these 
compounds were tested in human primary adipocytes because adipocytes and sebocytes express 
similar lipogenic factors during their differentiation. We found that FAS inhibitors were also active 
in modulating lipid production in adipocytes with similar potency.    
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The role of galectin-12 in sebaceous gland function
W Hsieh,1 R Yang,2 C Zouboulis3 and F Liu1 1 Institute of Biomedical Science, Academia 
Sinica, Taiwan, Taipei, Taiwan, 2 Department of Dermatology, University of California-
Davis, Sacramento, CA and 3 Departments of Dermatology, Venereology, Allergology and 
Immunology, Dessau Medical Center, Dessau, Germany
Enhanced sebocyte proliferation and sebum production, along with abnormal lipogenesis, has 
been shown to be involved in the pathogenesis of sebaceous gland disorders, such as acne vul-
garis. Galectin-12, a member of a β-galactoside–binding lectin family preferentially expressed by 
adipocytes, has been shown to function as an intrinsic negative regulator of lipolysis. To investigate 
its function in sebocytes and involvement in the pathogenesis of sebaceous gland disorders, we 
examined sebaceous glands in wild type and galectin-12 null mice. Moreover, we studied the role 
of galectin-12 in human sebocyte proliferation, differentiation, and lipid synthesis in vitro, by tran-
siently knocking down galectin-12 in human SZ95 sebocyte cell line and overexpressing galectin-12 
in human HaCaT keratinocyte cell line. Here we find galectin-12 is expressed in sebaceous glands 
and the sebaceous gland size in male galectin-12 null mice is smaller than that of male wild-type 
mice. When galectin-12 is overexpressed in HaCaT cells, a sebocyte-like differentiation pattern is 
induced. When galectin-12 is down-regulated in SZ95 cells, androgen-stimulated proliferation is 
reduced. Moreover, galectin-12 is associated with lipid droplets and knocking down of galectin-12 
in SZ95 sebocytes reduces lipogenesis stimulated by the natural PPAR ligands, arachidonic acid 
(AA) and linoleic acid (LA). Taken together, these data indicate that galectin-12 regulates sebaceous 
gland size and sebocyte proliferation, differentiation, and lipid synthesis, suggesting that galectin-12 
may be a novel target for modulating sebaceous differentiation and treatment of acne vulgaris.   
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Utility of high-throughput sequencing of T cell receptor gene rearrangement to improve 
diagnosis in cutaneous T cell lymphoma
S Rozati,1 W Weng,2 M Tavallaee,1 J Kim,3 K Rieger,3 R Armstrong,2 I Kirsch4 and YH Kim1 1 
Dermatology, Stanford U School of Med, Stanford, CA, 2 Medicine/BMT, Stanford U School 
of Med, Stanford, CA, 3 Pathology, Stanford U School of Med, Stanford, CA and 4 Adaptive 
Biotechnologies Corp, Seattle, WA
Mycosis fungoides (MF) and Sézary syndrome (SS) are clonal T cell lymphomas (TCLs) primarily 
involving the skin. The diagnosis is often difficult because of significant clinical and histopathologic 
overlap with inflammatory disease, lymphoma mimics, or other TCLs. Suspected peripheral blood 
involvement by Sézary cells (SC) is routinely evaluated by multiparametric flow cytometry and/or 
T-cell receptor (TCR) gene rearrangement assessed by polymerase chain reaction (PCR). In cases 
with blood involvement, establishment of same clone in blood and skin is often essential for optimal 
interpretation and diagnosis. However, routine TCR PCR may not identify true clonal TCR gene 
rearrangement especially in low-burden disease. High-throughput sequencing (HTS) is a technol-
ogy that analyzes TCR gene rearrangement with real-time high sensitivity that can detect 1 SC in 
>50,000 PBMCs. Previously, we have shown that TCR HTS is superior to other clinical methods in 
monitoring minimal residual disease after allogeneic transplantation. In this study, we assess the 
utility and performance of this emerging technique in the diagnostic setting by examining genomic 
DNA extracted from PBMC’s and paraffin-embedded or fresh tissue specimens with TCR HTS, 
against standard diagnostic TCR PCR and flow cytometry in patients with MF or SS and inflammatory 
conditions. TCR HTS confirmed identical dominant sequences in blood and/or skin in all cases 
where a clonal process was suggested by TCR PCR and/or flow cytometry. Furthermore, TCR HTS 
was able to identify tumor clones where standard TCR PCR failed. Finally, we demonstrate that in 
cases with low clinical suspicion, TCR HTS revealed polyclonality whereas TCR PCR indicated a 
false positive clonal process. Our results highlight the broadening translational potential of TCR 
HTS and its clinical application to improve the diagnosis of T cell malignancies.    
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Evaluation of a novel emollient balm containing Aquaphilus dolomiae extract in atopic der-
matitis children: Effect on clinical parameters, skin barrier and microflora
P Bianchi,1 C Villeneuve,1 J Theunis,1 C Casas,1 A Patrizi,2 A Bacquey,1 C Phulpin,1 
D Redoules,1 V Mengeaud1 and A Schmitt1 1 Dermo-cosmetique, Laboratoires Pierre-Fabre, 
Toulouse, France and 2 Dermatology, Bologna University, Bologna, Italy
Use of emollient skin care products is widely recommended in the atopic dermatitis (AD) care 
between flares. This clinical study evaluates the effect of a novel emollient balm on skin micro-
flora biodiversity, Staphylococcus aureus (Sa) and epidermidis (Se) balance, clinical parameters 
(SCORAD, xerosis and pruritus) and skin barrier function (involucrin expression) in children from 1 
to 4 years old. 54 children (2.5±1.0 years) with mild AD (SCORAD:11.70±3.15) have been enrolled 
in a randomized versus control group study. Half subjects applied, twice a day during 28 days, a 
hygiene care product and an emollient balm containing Aquaphilus dolomiae extract, whose effi-
cacy has been demonstrated in vitro on inflammation, innate immunity and pruritus. The other half 
of subjects was a control group, using only the hygiene care product. Regarding Sa and Se balance 
we showed, after 28 days of application compared to baseline, a significant increase of Sa (6.6 fold, 
p=0.0128) in the control group whereas emollient group is protected from Sa proliferation. We 
also found that Se is not affected by emollient or hygiene care product as microflora biodiversity. 
Concerning clinical parameters we showed a difference in favor of emollient group after 28 days 
of application, on SCORAD (-48%, p=0.0009), pruritus (-75%, p=0.0599) and xerosis (p=0.0562). 
Moreover, involucrin expression is significantly decreased by emollient (-37%, p=0.001) which is 
a sign of function barrier restoration. This study shows for the first time, that a bi-daily application 
of this novel emollient balm in children with mild AD can protect the skin from SA proliferation 
without affecting microflora biodiversity. This emollient also significantly improves SCORAD, xero-
sis, pruritus and restores the altered skin barrier.    
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Transcript analysis of interferon pathway associated genes in genital human papillomavi-
rus infection treated with 16-weeks of topical sinecatechins: An open-label, mechanism of 
action study
MK Ramirez-Fort,1,2 LE French,3 HQ Doan,1 S Au,2 PL Rady,1 H Nguyen1 and SK Tyring1 1 
Center for Clinical Studies, Houston, TX, 2 Dermatology, Tufts Medical Center, Boston, MA 
and 3 Dermatology, Zürich University Hospital, Zürich, Switzerland
Transcript analysis of interferon genes in genital human papillomavirus-infected tissue was evaluated 
in human subjects receiving topical sinecatechin treatment three times daily for 16 weeks. Lesional 
biopsy tissue was obtained at baseline (B1) (prior to treatment), at the first visit with 50% or more 
clearance of target warts (B2), and at the first visit with complete clearance of target warts (B3) or 
after trial completion. Viral load elicited with real time PCR was used to determine viral response 
to treatment. Gene expression changes between virological responders (VRs) and non-responders 
(VNRs) were assessed using the TaqMan Human interferon pathway array (Applied Biosystems), 
compared and normalized to the respective baseline for B1_3, B1_2 and B2_3. 18 subjects com-
pleted the trial. Although, there was an overall downregulation of interferon pathway associated 
genes in both groups, 64/69 (92%) in the VRs and 61/69 (88%) in the VNRs, interferon pathway 
genes were on average less strongly downregulated in the VNRs (average expression level 0.67) 
compared to the VRs (average expression level 0.54). Proportionally, 66% of interferon pathway 
associated genes were less downregulated in VNRs than VRs. Specifically, select interferon path-
way associated genes were two or more times more strongly downregulated in VRs as compared 
to VNRs and may signify molecular markers of viral response to sinecatechins: HIST3H3, IFNA16, 
IFNA4, IFNA5, IFNA6, IFNA7, IRS2, and MAPK12. Conversely, interferon-pathway associated genes 
IFN-gamma and EIF4E exhibited a two-fold greater downregulation in VNRs as compared to VRs. 
Stronger IFN-gamma expression is known to be an indication of present cytotoxic T cells or a TH1 
type immune response; both are hallmarks of an antiviral immune response and may indicate viral 
response to sinecatechins.    
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Increased insula functional connectivity by MRI in the brain of mice with induced psoria-
siform dermatitis
X Liu, Y Imai and ST Hwang Dermatology, Medical College of WI, Milwaukee, WI
Functional connectivity MRI (fcMRI), a specific form of MRI imaging, quantitatively assesses con-
nectivity between brain regions that share functional properties. FcMRI has already provided unique 
insights into changes in the brain in patients with conditions such as depression and pain, symptoms 
that have been reported by psoriasis patients and are known to impact quality of life. To identify 
the central neurological impact of psoriasiform inflammation of the skin, we applied fcMRI analysis 
to mice that had been topically treated with the toll-like receptor agonist, imiquimod-(IMQ), to 
induce psoriasiform dermatitis. Age-matched C57BL/6 mice were treated with 4 daily topical IMQ 
applications to the skin of both ears and the head. A Bruker 9.4 T spectrometer and a custom-built 
1.0cm surface coil were used for MR imaging. Under sedative anesthesia, both IMQ- and vehi-
cle-treated mice (as controls) underwent fcMRI scans with MRI parameters set at TR= 1s, TE= 18ms, 
NR= 600, and FOV= 2.0x2.0cm2. Physiological parameters of mice were continuously monitored 
and kept within normal range throughout scans. Brain insula regions, due to their suggested role 
in stress, were chosen as seed regions for fcMRI analysis. Mouse ear and head skin developed 
psoriasiform epidermal thickening (up to 4 fold, P< 0.05) and dermal inflammation after 4 days of 
topical treatment with IMQ. After fcMRI analysis, IMQ-treated mice showed significantly increased 
insula fc with wide areas throughout the brain, including, but not limited, to the somatosensary 
cortex, anterior cingulate cortex, caudate putamen, and hippocampus (P<0.03). The whole brain 
insula fc voxel count increased 2.6 fold (P<0.05), reflecting a potential central neurological impact 
of IMQ-induced psoriasis-like skin inflammation. These data indicate that fcMRI may be valuable 
tool to quantitatively assess the neurological impact of skin inflammation in patients with psoriasis.   
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A clustering of Asian pemphigus vulgaris patients in Iowa
MH Noe,1 J McKillip1 and JA Fairley1,2 1 Department of Dermatology, University of Iowa 
Hospitals and Clinics, Iowa City, IA and 2 Department of Veterans Affairs, Iowa City, IA
Pemphigus vulgaris (PV) is an autoimmune blistering disease characterized by autoantibodies 
directed against the desmosomal proteins desmoglein 3 and desmoglein 1. The incidence of PV 
varies by ethnicity and geography, from 0.5-3/100,000, with the highest incidence in people of 
Ashkenazi Jewish ancestry. The incidence in Taiwan has been estimated at 0.47/100,000. Over a 
3 month period in 2012, 3 new cases of pemphigus vulgaris were identified in young men of Asian 
ancestry; over a 20 month period, 4/7 new-onset PV patients at the University of Iowa were Asian. 
This is a 150x increase in the expected number of cases in this racial group, given the incidence of 
PV and low representation of Asians in Iowa’s population (2%). To investigate this cluster further, 
demographics, social history and family history were collected. In addition, intermediate resolution 
HLA testing was performed by PCR for HLA Class II haplotypes DQB1, DPB1, DRB1, DRB3 and 
DRB4, since loci within these alleles have been associated with PV. Geographically, the patient’s 
families were from Taiwan, China (Canton), and Thailand (n=2). Compared to all of the PV patients 
in our database, the age at onset was younger in the cluster (43 vs 53 years) and male predominance 
was stronger (3:1 vs 1.4:1). Three of the 4 individuals were available for HLA testing; all three had 
both HLA-DQB1*05 and HLA-DRB1*14 alleles, previously identified as risk factors. These results 
indicate genetic susceptibility, likely accompanied by an as yet unidentified environmental trigger, 
played an important role in development of this cluster.    
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Anetoderma, an example of primary thrombophilia
EA Arenas,1 DV Hernandez,1 GJ Ruiz-Arguelles2 and B Moncada1 1 Dermatology/
Immunology, University of San Luis Potosi School of Medicine Hospital Central, San Luis 
Potosi, Mexico and 2 Clinica Ruiz, Puebla, Mexico
A 22 years old single female complained of skin lesions on her trunk of 2 years duration. There 
were no pain or itching related to them and she has not had previous treatment for that purpose. 
They consisted of six areas of depressed tissue of 2.5 centimeters in diameter and 1.5 in depth with 
moderate hypo pigmentation. Past personal medical history was unremarkable but on the other 
hand it was notorious that her paternal grandmother had 5 miscarriages among nine pregnancies 
and that her paternal aunt has had ten lesion similar to those of the patient, all of them in her trunk. 
Skin biopsy showed a normal epidermis with the some sort of collagen fibers diminution but very 
scanty elastic fibers. Routine laboratory work up was unremarkable. Thrombophilia profile (23 test) 
revealed only an abnormal increased platelet adhesion when challenged with both epinephrine 
and ADP in decreasing quantities, and the 677C-T gene mutation for the methylen tetrahydro 
folate reductase . The first findings allow to make the diagnosis of sticky platelet syndrome (SPS) 
first described in 1988 by Mammen as a dominant autosomic entity capable of inducing abnormal 
coagulation in any place of the circulatory system. Patients with anetoderma should be subjected 
to a complete search for thrombophilia, and avoid the concept that anetoderma is due to anti-
phospholipid antibodies exclusively. SPS has to be added to clinical conditions related to primary 
thrombophilia. Since this condition can be found in normal relatives it is necessary to know that 
fact in order to prevent thrombotic incidents in them.    
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Low-dose methotrexate as an alterative treatment option for refractory cutaneous lupus 
erythematosus
J Lin,1 V Sharon,2 M Patel,1 JF Merola,1 AA Qureshi1 and R Vleugels1 1 Dermatology, Brigham 
and Women’s Hospital, Boston, MA and 2 Dermatology, University of California, Davis, 
Sacramento, CA
Background: Cutaneous lupus erythematosus (CLE) is a chronic inflammatory skin disease that is 
challenging to treat and can be refractory to multiple therapies. Topical corticosteroids and first-line 
systemic therapy with antimalarials are often insufficient in controlling CLE. Methotrexate (MTX) 
has been observed to be an effective option for CLE. We investigated the clinical response to MTX 
in patients with cutaneous disease refractory to topical and antimalarial therapy. Methods: Retro-
spective chart review was conducted using the Partners Healthcare Research Patient Data Registry 
in an outpatient university setting. Patients with CLE who received MTX between January 2000 and 
October 2013 specifically for the treatment of cutaneous lupus were identified. Response was based 
on improvement in skin disease 8-16 weeks after initiation of MTX, defined as: good response (GR, 
>75% improvement), partial response (PR, 25-75% improvement), and no response (NR, <25% 
improvement or progression). Results: 24 patients (20 women and 4 men) had refractory CLE: 12 
discoid lupus, 9 subacute cutaneous lupus, and 3 tumid lupus. Mean age was 41 years old (±10.3; 
range: 25-57). 54.2% were Caucasian, 20.8% Black, 16.6% Asian, and 8.3% Hispanic. All patients 
received low dose oral or injectable MTX, 7.5 to 25mg weekly. Eleven of 24 patients (45.8%) had 
good response, 10 patients (41.7%) had partial response, while 3 (12.5%) had no response. Most 
patients (58.3%) tolerated methotrexate without side effects, while 21% had nausea. Other side 
effects noted were reversible liver enzyme elevation, leukopenia, and transient telogen effluvium. 
Medication discontinuation due to side effects occurred in 3 of 24 patients (12.5%). Conclusion: This 
is the largest series of patients treated with MTX for refractory CLE reported in the U.S., demonstrating 
that low dose MTX can be effective and well tolerated in patients with refractory CLE.    
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Matrilin-2 is upregulated in the peritumoral stroma of basal cell carcinomas
Z Wang,1 F Xiong1 and S Iwamoto1,2 1 Dermatology and Skin Cancer Therapy, Roger 
Williams Medical Center, Providence, RI and 2 Boston University School of Medicine, 
Providence, MA
The tumor microenvironment, including the surrounding stroma, has been increasingly implicated in 
tumor growth, invasion, and metastasis. Matrilin-2, an extracellular matrix protein known to inhibit 
keratinocyte migration. We wondered whether matrilin-2 could play a role in inhibiting tumor inva-
sion by altering the tumor microenvironment. We therefore investigated the expression of matrilin-2 
in the stroma surrounding basal cell carcinomas. Tissues of basal cell carcinomas from fourteen 
patients were immunolabeled with matrilin-2 and matrilin-4 antibody. In addition, the cytokeratin 
17 antibody was used to immunolabel the tumor itself. Furthermore, squamous cell carcinomas and 
melanomas were also studied. In all cases of basal cell carcinoma, the peritumoral stroma (including 
peritumoral fibroblasts and peritumoral extracellular matrix) expressed dramatically high levels of 
matrilin-2. In contrast, the stroma surrounding adnexal structures showed little or no matrilin-2 
labeling. Matrilin-4 exhibited the same labeling pattern as matrilin-2 but the intensity of expression 
was lower. We did not find upregulation of matrilin-2 in the peritumoral stroma of squamous cell 
carcinomas or of melanomas. Western blots comparing matrilin-2 protein expression around basal 
cell carcinomas and around tumor-free tissue confirmed higher levels of matrilin-2 in the tissues 
associated with basal cell carcinomas. Basal cell carcinoma is strongly stroma-dependent, in that 
the stroma can influence tumor growth and invasion. Our results show a dramatic increase within 
the peritumoral stroma of matrilin-2, a protein known to inhibit keratinocyte migration. Such a 
stromal response is absent in the more invasive tumors including squamous cell carcinomas and 
melanomas, and our findings may explain the relative lower invasiveness of basal cell carcinomas.   
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Novel topical cream delivers safe and effective alternative to traditional psoriasis phototherapy
A Goren,1,2 A Salafia,1 J McCoy1 and T Lotti2 1 Applied Biology, Inc., Irvine, CA and 2 
University of Rome (“G.Marconi”), Rome, Italy
In today’s environment of shrinking reimbursement and coverage for many health care proce-
dures, phototherapy for psoriasis has experienced a major decline. Once hailed as the cornerstone 
of psoriasis therapy, the increasing cost and demanding treatment regimen has resulted in poor 
compliance, limiting access to this safe and effective mode of treatment. Here we report on the 
development of a topical cream that selectively filters solar radiation to deliver narrow-band UVB. 
Additionally, we present the results of a pilot study in psoriasis patients. After an average of 38 
sessions, all patients in the treatment arm responded to therapy. In particular, 43% of the treatment 
group experienced complete clearance and the remainder experienced at a minimum 50% lesion 
clearance. In contrast, none of the patients in the placebo arm experienced more than 20% lesion 
clearance. Our preliminary results demonstrate that the novel topical cream could provide a safe, 
effective, and convenient alternative to artificial light phototherapy.    
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Computerized planimetry as a tool to measure area of individual lupus lesions: A reliable 
and responsive method
LG Okon,2 R Feng3 and V Werth1,2 1 Philadelphia VA Medical Center, Philadelphia, PA, 2 
Dermatology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 
and 3 Biostatistics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, 
PA
The Cutaneous Lupus Area and Severity Index (CLASI) has been validated as an outcome measure 
for cutaneous lupus involving the whole body for use in clinical trials testing systemic medications. 
There is currently no validated outcome measure to assess the severity of individual lupus lesions for 
trials involving topical medications. We evaluated a technique to measure area of individual discoid 
lupus lesions, which likely represents an important parameter in disease activity assessment. Two 
blinded raters determined discoid lesional area using computerized planimetry. Assessments were 
made on 43 patients with either DLE or SLE with before and after randomly ordered photographs of 
discoid lesions treated with an experimental topical treatment or placebo from 2012-2013, which 
were provided by a completed multicenter clinical trial. The Pearson r for inter-rater reliability of 
normalized area measurements was 0.95 (95% CI=0.91 to 0.97) for the first group of photographs, 
and 0.86 (95% CI= 0.75 to 0.92) for the second group of photographs. Clinical responsiveness was 
assessed by comparison with a Physician Global Assessment (PGA) score as an external gold stan-
dard, and lesion sets were classified as “responders” or “nonresponders.” There was a statistically 
significant difference (p=0.0009) in mean change in raw area between the two photographs for the 
“responders” and “nonresponders.” Our results support the reliability of computerized planimetry 
as a tool to assess area, as well as the use of area as an important component of disease respon-
siveness. Future studies can incorporate this useful method into a unified tool to measure clinical 
severity of individual lupus lesions.    
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Age-related variance in skin properties: A novel means to predict drug delivery windows 
after microneedle insertion?
P Kinn,1 G Holdren,1 K Brogden2 and N Brogden1 1 Pharmaceutical Sciences, University of 
Iowa, Iowa City, IA and 2 Periodontics, University of Iowa, Iowa City, IA
The purpose of this open-label pilot study is to identify age-related differences in baseline skin cyto-
kine concentration, barrier function, and erythema. We predict that these factors will influence drug 
delivery windows after microneedle insertion. Healthy human subjects (n=23) were divided into 
3 age groups: 18-44 years (Group 1, n=6), 45-64 years (Group 2, n=8), and 65-95 years (Group 3, 
n=9). Transepidermal water loss (TEWL) and tristimulus colorimetry (a*) measurements were made 
to assess barrier function and erythema, respectively. Of the subjects, 19 were randomly selected 
for preliminary cytokine analysis. Phosphate buffered saline (500 μl) was incubated in fabricated 
chambers on the intact skin surface for 30 minutes, removed, and the wash fluid was analyzed for 
the presence of chemokines and cytokines with a multiplexed fluorescent bead-based immunoassay. 
An analogous two-way fixed effects ANOVA was fit to mediator concentration, TEWL, or a* (fixed 
factors were group and time). Pairwise group comparisons were conducted using the method of 
Tukey’s Honest Significant Differences. p<0.05 was considered significant. Significant differences 
(p<0.05) between groups were seen for TEWL and a* values. Preliminary differences among con-
centrations of GM-CSF, IL-8, MIP-1α, MIP-1β, and TNF in skin wash fluid were determined, and 
all markers were detected for all subjects. There were no significant differences in concentrations 
of GM-CSF, IL-8, MIP-1α, or MIP-1β (p>0.05). Group 1 had a significantly lower mean (±StdErr) 
concentration of TNF (0.60±0.04 pg/ml) than Groups 2 (0.66±0.04 pg/ml) and 3 (0.81±0.04 pg/ml), 
p<0.05. These data confirm that our methods can detect chemokines and cytokines with high sensi-
tivity in human skin wash fluid, and that baseline differences among cytokine concentrations, barrier 
function, and erythema may be age related. The second aim of this pilot study will correlate these 
age-related differences with healing times after microneedle insertion for transdermal drug delivery.   
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Patient-centered, direct-access online care model for follow-up management of atopic der-
matitis: A randomized controlled trial
AW Armstrong, M Johnson, S Lin, T Nesbitt, R Kravitz and F Liu University of Colorado 
Denver, Aurora, CO
In the U.S., many patients with chronic skin diseases, such as atopic dermatitis, lack regular access 
to specialist care and experience worse clinical outcomes. We aimed to determine the effectiveness 
of a direct-access online model for follow-up dermatology care to patients with atopic dermatitis 
compared to in-person care in a randomized controlled equivalency trial. In the direct-access online 
model, the patients are able to communicate directly with dermatologists asynchronously online 
regarding clinical recommendations for follow-up care. A total of 156 children and adults (ages 4 
and above) with atopic dermatitis were randomized to receive follow-up care either in-person or 
via the direct-access online model over a 12-month period. Patients randomized to the direct-access 
group underwent standardized training on capturing high-quality digital images of their atopic 
dermatitis skin lesions and transmitting these images and clinical history to a dermatologist online 
asynchronously. The dermatologist performed asynchronous, online evaluation, provided recom-
mendations, and e-prescribed directly to the patients. We used clinically validated disease severity 
and quality-of-life measures to assess effectiveness between the models. Both online and in-person 
groups showed improvement in atopic dermatitis disease severity as measured by mean improve-
ment in the patient-oriented eczema measure (POEM) (online group: mean = -5.1, in-office: mean 
= -4.9). The direct-access online care resulted in similar improvement in atopic dermatitis severity 
compared with in-person follow-up care (mean difference in POEM=0.2, 95% confidence interval 
-1.8 to 2.2, within the a priori equivalence margin of 3). Clinically meaningful improvements in 
DLQI and CDLQI were observed in both the direct-access online and the in-person groups (all 
mean improvements >5). Direct-access online model may be an effective alternative to in-person 
care for follow-up management of atopic dermatitis in children and adults.    
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DC-HIL+ myeloid-derived suppressor cells (MDSC) may down-regulate severity of psoriasis
L Cao, J Chung, PD Cruz, BF Chong, H Jacobe and K Ariizumi Dermatology, UT 
Southwestern Medical Center, Dallas, TX
Psoriasis is an autoimmune disease caused by inappropriate T cell activation regulated by positive/
negative mechanisms. MDSC are the most potent T cell suppressors and are expanded in patients 
with cancer and autoimmune disease. While their pathogenic role in cancer is well-established, 
their role (protective or pathogenic) in autoimmune disease is unclear. Having shown that DC-HIL 
mediates MDSC’s suppressor function and that DC-HIL+ MDSC in psoriatic (vs. melanoma) patients 
have significantly reduced capacity to suppress function of CD8+ T cells, we further characterized 
MDSC properties in patients with plaque psoriasis. CD14+ HLA-DRno/low MDSC within PBMC was 
significantly increased in psoriatics (3.2% ± 2.8, n=22) vs. healthy controls (0.1% ± 0.1, n=15, 
p<0.01). DC-HIL+ cells among MDSC and DC-HIL+ MDSC among PBMC were also significantly 
elevated in psoriatics vs. controls (67% ± 31 vs. 3.1% ± 6.9; and 2.2% ± 2.2 vs. 0% ± 0, respectively; 
p<0.01). Morphology of psoriatic MDSC was heterogeneous and differed from melanoma-MDSC in 
that 90% of monocytes exhibited more mature phenotype (n=3, by Giemsa-staining). Do DC-HIL+ 
MDSC home to psoriatic skin? Psoriatic MDSC highly expressed the skin-homing receptor, cuta-
neous leukocyte-associated antigen (CLA) (range 91-99%, n=5) indicating an ability to home to 
skin. Skin-infiltrating monocytes were harvested from psoriatic skin (6 mm biopsy, n=2) cultured 
ex vivo for 10 days with GM-CSF/IL-4 and tested for CD14, HLA-DR, and DC-HIL expression (by 
immunofluorescence). In lesional skin, 60% of CD14+ cells were HLA-DRneg and DC-HIL+, whereas 
in nonlesional skin all CD14+ cells were HLA-DRhi and DC-HILdul. Finally, we analyzed % blood 
MDSC and DC-HIL expression against psoriasis severity (PASI) and found negative correlations for 
MDSC/PBMC (R= -0.13), DC-HIL+ cells/MDSC (R= -0.23), and DC-HIL+ MDSC/PBMC (R= -0.23). 
Thus DC-HIL+ MDSC may be recruited into lesional skin to temper psoriatic severity via mechanisms 
disparate from those for MDSC in melanoma patients.    
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Characterization of cutaneous T-cell lymphoma using in-vivo reflectance confocal microscopy
SE Mancebo, M Cordova, S Jawed, A Skripnik, PL Myskowski, K Busam, M Rajadhyaksha and 
C Querfeld Memorial Sloan-Kettering Cancer Center, New York, NY
Mycosis fungoides/Sezary Syndrome (MF/SS) remains a diagnostic challenge due to heterogeneous 
and nonspecific clinical and histological presentations. Multiple skin biopsies are often required to 
establish a definitive diagnosis. In-vivo reflectance confocal microscopy (RCM) is a non-invasive 
imaging technique that provides high-resolution cellular detail of the epidermis and superficial 
dermis. The objective of this study was to characterize the RCM findings in skin lesions of MF/SS 
and to assess the utility of RCM in selecting an optimal skin biopsy site. Twenty-eight patients were 
prospectively recruited and a total of 51 lesions (median 2 per patient) were imaged with RCM. En 
face confocal images were analyzed and correlated to transverse hematoxylin and eosin stained 
sections from biopsies. The most commonly identified RCM features included atypical lymphocytes 
appearing as weakly reflective cells with an irregular cellular contour in the epidermis and superficial 
dermis and Pautrier’s microabscesses appearing as dark round, sharply demarcated intra-epidermal 
structures containing reflective cells. In the upper dermis, dilated capillary vessels, fibrosis and 
inflammatory cells were also commonly identified. Several novel RCM findings were observed. 
Among patients with folliculotropic MF, atypical weakly reflective cells surrounding hair follicles 
were identified along with follicular mucin deposits appearing as a hypo-reflective structure within 
the follicular epithelium. Patients with hyperpigmented lesions presented with hyper-reflective rings 
of basal cells on dermal papillae and atypical cells infiltrating and disrupting the dermal-epidermal 
junction. In conclusion, our findings validate the diagnostic applicability of RCM in evaluating 
MF/SS. These results may help guide clinicians in selecting a biopsy site with the most diagnostic 
histopathology and to monitor treatment response among patients with varied clinical presentations.   
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Expression of the T cell-inhibitory DC-HIL receptor by myeloid-derived suppressor cells 
(MDSC) is induced by DC-HIL-bearing melanoma cells
JE Turrentine, J Chung, T Teshima, A Kodama, T Vandergriff, D Harker, K Ariizumi and 
PD Cruz Dermatology, UT Southwestern Medical Center, Dallas, TX
MDSC are expanded in cancer and are the most potent T cell suppressors promoting its progression. 
We discovered the DC-HIL receptor that inhibits T cell activation and promotes melanoma growth. 
Melanoma patients express DC-HIL at 3 sites: cell surface of melanoma cells and the monocytic 
(CD14+HLA-DRno/low) MDSC subset, and a soluble form secreted into blood. Our mouse studies 
showed all 3 forms of DC-HIL cause T cell suppression. To assess impact of DC-HIL in early human 
melanoma, we characterized DC-HIL expression in cases of melanoma in situ (MIS). By immuno-
histochemistry, DC-HIL in normal skin was expressed weakly by some melanocytes perinuclearly, 
granularly, and intra- (but not inter-) follicularly. By contrast, DC-HIL in melanoma-affected skin 
(n=5) was expressed highly by most malignant cells on their surface and within. Also DC-HIL+CD14+ 
histiocytes surrounded lymphocytes in dermal papillae. Intensity of DC-HIL staining (by color image 
analysis) correlated positively with % blood DC-HIL+CD14+HLA-DRno/low cells. To determine if 
melanoma stimulated proliferation of DC-HILhi MDSC, we assayed these blood cells in 9 patients 
with MIS at 0, 1, 3, and 6 mos after excision of the melanoma and in 6 healthy controls. At 0 mo, 
8 patients had levels higher than controls that trended significantly downward during follow-up (p 
= 0.045). In 1 patient the relevant cells fell a mo after resection but climbed back to a high level 
at 3 mos, coinciding with discovery of a new MIS, and then fell back after resection of this cancer. 
Finally, we assayed soluble DC-HIL from sera of 5 MIS patients (n=5) whose median was much 
higher than normal controls’ (172 ± 68 vs. 55 ± 8.6 ng/ml). Thus DC-HIL+ melanoma cells cause 
CD14+HLA-DRno/low cells to acquire DC-HIL responsible for inhibiting T cell function, strengthening 
the rationale for making these cells a blood marker and treatment target for melanoma.    
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Combination treatment with romidepsin and nitrogen mustard demonstrates synergy in 
cutaneous T-cell lymphoma
BO Dulmage,1 S Story1 and LJ Geskin2 1 Dermatology, University of Pittsburgh, Pittsburgh, 
PA and 2 Dermatology, Columbia University, New York, NY
Cutaneous T-cell lymphomas (CTCL) are often treated with combination therapies, though many 
combinations are derived empirically. Romidepsin is a histone deacetylase inhibitor, FDA-approved 
for therapy of advanced CTCL, which may improve access to DNA by direct DNA-damaging che-
motherapeutic drugs, especially alkylating agents. Nitrogen mustard, an alkylating agent capable 
of crosslinking DNA and inducing apoptosis in rapidly dividing cells, is a well-established topical 
therapy for CTCL; however, response rates decrease as disease advances. We present a novel 
anticancer therapeutic strategy of combining romidepsin with nitrogen mustard in patients with 
Sézary syndrome and mycosis fungoides. In vitro analysis of this novel combination using both a 
CTCL cell line and patient samples showed reduced cell viability and increased apoptosis in cells 
treated with combination therapy over cells treated with either single agent. Using the Comet assay 
to detect DNA damage, we show increased DNA crosslinking in the combination group compared 
with either agent alone. Further, we also investigated the response to combination treatment in 
series of patients who failed monotherapy with romidepsin. This patient cohort achieved partial 
and complete clinical responses with this novel combination. The in vitro effects of the romidepsin 
and nitrogen mustard combination as well as our preliminary clinical observations are suggestive 
of their synergistic efficacy in CTCL. Future randomized prospective clinical trials are warranted to 
investigate the potential synergistic effect of these drugs.    
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Metastatic Merkel cell carcinoma presenting as a subcutaneous breast nodule: An uncommon 
presentation of a rare cutaneous malignancy
VE Nambudiri,1 A Watson,1 M Thakuria,1 M Vivero,2 C Fletcher,2 A Ng,3 S Russell,4 
G Rabinowitz5 and N Leboeuf1 1 Dermatology, Brigham and Women’s Hospital, Boston, 
MA, 2 Pathology, Brigham and Women’s Hospital, Boston, MA, 3 Radiation Oncology, Dana 
Farber Cancer Institute, Boston, MA, 4 Surgical Oncology, Dana Farber Cancer Institute, 
Boston, MA and 5 Medical Oncology, Dana Farber Cancer Institute, Boston, MA
We present the clinical, radiologic, and pathologic findings of a primary Merkel cell carcinoma 
(MCC) – an aggressive neuroendocrine neoplasm with an estimated incidence of 2.2-3.2 cases per 
million person-years – arising in the subcutaneous breast tissue to raise awareness of this unusual 
presentation and highlight the treatment course. A 76 year old woman presented with a tender, 
self-detected breast lump and subtle epidermal erythema. No cutaneous lesions were noted. Fine 
needle aspiration cytologic analysis suggested a poorly differentiated small, round blue cell neuro-
endocrine tumor suggestive of MCC. Immunohistochemistry was positive for CK20 and NFP, both 
in a dot-like pattern, as well as MIB-1, pan-Keratin, Cam5.2, and synaptophysin; CK7, TTF-1, ER, 
PR, HER2, GCDFP, mammaglobin, EMA, and S-100 were all negative. PET/CT imaging confirmed 
a highly FDG-avid breast tumor (SUVmax 11.1) along with two FDG-avid axillary lymph nodes, 
consistent with regional spread. Initial treatment consisted of partial mastectomy and axillary lymph-
adenectomy, followed by combination chemotherapy with cisplatin (75 mg/m2) and etoposide (80 
mg/m2) and postoperative radiation (5000 cGY over 25 fractions). Primary MCC of the breast is an 
uncommon presentation of this rare malignancy with 6 cases previously reported in the literature. 
The subcutaneous nature of this lesion speaks to the ongoing question regarding the exact nature 
of the progenitor tumor cells in MCC and their location, as well as the differentiation of MCC from 
neuroendocrine carcinoma of the breast based on clinical, radiologic, and pathologic features. 
We share this case to call attention to this atypical presentation of MCC and the multidisciplinary 
diagnosis and treatment of this challenging malignancy.    
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A proof-of-concept study with pharmacokinetics demonstrating anti-pruritic activity of oral 
nalbuphine in hemodialysis patients with uremic pruritus
A Hawi,1 J Berg,2 H Alcorn,2 C Hines,3 F Terschan,2 G Zunkel2 and T Sciascia1 1 Trevi 
Therapeutics, New Haven, CT, 2 DaVita Clinical Research, Minneapolis, MN and 3 PPD, 
Richmond, VA
Nalbuphine is a synthetic mixed μ-antagonist and κ-agonist opioid that may be effective in treatment 
of itch. There is no commercial oral formulation of nalbuphine available in the market place and 
thus development of nalbuphine HCl extended release (ER) tablets was undertaken. The impact of 
nalbuphine on uremic pruritus was explored in an unblinded investigation following oral admin-
istration of nalbuphine in hemodialysis subjects (N=14) with pruritus as measured by twice daily 
self-reported Visual Analogue Scale (VAS). Subjects were administered oral nalbuphine HCl ER 
tablets and doses escalated from 30 mg to 240 mg BID every three days over 17 days. Pharmaco-
kinetic parameters (Cmax and AUC0-12h) were obtained after the first dose and at steady state at 
each dose level. Subjects reported their worst daytime and nighttime itch on a scale of 1-10 (least 
to worst). Mean pre-dose VAS score (average of daytime and nighttime score) was 4.0 and ranged 
from 1.2 (mild) to 6.6 (severe pruritus). A dose-dependent decrease in itch was noted in 13 out 
of 14 patients with a mean change in VAS score from baseline ranging between -0.9 at 30 mg to 
-2.8 at 240 mg BID dose. A relationship between AUC, Cmax, and Cmin and change in VAS score 
following a simple direct effect model reasonably described the effect and provided the basis for 
further PK/PD model construction.    
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Trajectories of water, sebum transepidermal water loss and melanin changes due to breast 
cancer chemotherapy
D Kang,1 H Park,2 E Kim,2 H Lee,2 D Lee3 and J Cho1 1 Health Sciences and Technology, 
SAIHST, Sungkyunkwan University, Seoul, Republic of Korea, 2 Skin Research Institute 
AMOREPACIFIC Corporation R&D Center, Yongin, Republic of Korea and 3 Dermatology, 
Samsung Medical Center, Seoul, Republic of Korea
We aimed to evaluate trajectories of water, sebum, transepidermal water loss (TEWL) and melanin 
changes due to breast cancer chemotherapy using validated skin testing equipment. This is a 
prospective cohort study of 81 breast cancer patients. Water, sebum, melanin index, and TEWL on 
skin of face or hands using Corneometer, Subumeter, Mexameter and Vapometer were assessed 
before-, during-, 1 month-, 3 months- and 6 months- after chemotherapy as well as patient reported 
skin dryness and pigmentation. To examine changes overtime, mixed effect analysis was performed 
using STATA 12.0. Of total 61 patients (75.3%) received chemotherapy, and their water, sebum 
and TEWL were significantly decreased during chemotherapy compared to the baseline (P<0.01). 
These changes were significantly different from patients without chemotherapy (P=0.002). Sebum 
and water contents were observed the poorest condition 1 month after chemotherapy and theses 
conditions were not fully recovered until 6 month after chemotherapy. The melanin index on 
cheek and on hand were significantly increased (P<0.05) during chemotherapy then decreased 
after completion of the treatment. Similarly, patients began to report dryness (49.2%) and darkness 
(47.5%) during chemotherapy and reported most changes 1 month after chemotherapy (57.9% and 
49.1% for dryness and darkness).Patients with poor water (OR, 0.98, P=0.014) and sebum contents 
(OR, 0.90, P=0.003) were more likely to report dryness and patients with high melanin index (OR, 
1.01, P=0.02)were more likely to report darkness after adjusting age, stage, type of treatment, and 
seasonal change. Water, sebum, and TEWL decreased due to breast cancer chemotherapy and they 
did not regain even 6 months after completion of the treatment. Melanin index was increased during 
chemotherapy but decreased beyond the baseline at 6 months after completion of the treatment.   
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Sensitive skin in Mexico: Prevalence, biophysical response and its relationship with TRPV1
A Rodríguez-Arámbula,1,2 A Ehnis-Pérez Duarte,1,2 D Hernández-Blanco,1,2 JP Castanedo-
Cázares1,2 and B Torres-Alvarez1,2 1 Hospital Central Dr. Ignacio Morones Prieto, San Luis 
Potosi, Mexico and 2 Universidad Autónoma de San Luis Potosí, San Luis Potosi, Mexico
Sensitive skin (SS) is defined as the presence of stinging or burning secondary to external factors, 
without evidence of skin lesion. It has been associated to an alteration in the skin barrier function, 
and recent studies have suggested that transient receptor potential vanilloid 1 (TRPV1) could be 
implicated in the pathophysiology of this condition. To determine the prevalence of SS in a Latin 
American population and describe the biophysical characteristics of their skin, as well as to explore 
the role of TRPV1 in this syndrome. We included 246 healthy volunteers, 18 years of age or 
older, both sexes, to whom a questionnaire and the lactic acid stinging test (LAST) were applied. 
Presence and intensity of adverse sensations were evaluated through a 10-point visual analogue 
scale. Colorimetry, transepidermal water loss (TEWL) and capacitance were measured at baseline, 
and at 3, 5, 8 and 10 minutes after the test. We performed skin biopsies in 10% of the subjects to 
determine the presence of mRNA for TRPV1 with real time PCR. Fifty-two percent of our subjects 
were positive to the LAST, and thus had SS. Prevalence was significantly higher in women (60% 
vs 34%, p < 0.001) and lighter skin phototypes (II-III 84%, IV 55%, V 40%, p< 0.001, OR = 0.88). 
We observed a higher a* and TEWL at 3 and 5 minutes. Subjects with SS have higher expression 
of mRNA TRPV1 (p 0 =.031) and this correlated with the intensity of the symptoms (p = 0.01). 
Sensitive skin is a prevalent condition in Latin American populations, and skin phototype seems 
to play a role, since darker skin phototypes are less prone to present irritative symptoms. TRPV1 
expression is elevated in this subjects and it correlates well with the degree of adverse sensations.   
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Childhood eczema is associated with injury requiring medical attention
N Garg and J Silverberg Dermatology, Northwestern University, Chicago, IL
Children with eczema have multiple risk factors for accidental injuries, including sleep impairment 
and sedating anti-histamine usage. We used the 2007-2008 National Survey of Children’s Health 
to determine the prevalence of injuries requiring medical attention from a nationally representative 
sample of 27,556 children age 0-5 years. Children with eczema compared to those without eczema 
had a higher 1-year prevalence of injury requiring medical attention compared with those that 
had no eczema (12.9% vs. 10.0%; Rao-Scott chi square test, P<0.0001). Children with eczema 
had higher odds of sustaining injuries requiring medical attention even after controlling age, sex, 
household income, family structure, and highest level of parental education in multivariate logistic 
regression models (adjusted odds ratio [95% confidence interval] = 1.65 [1.08–3.26]). In particular, 
eczema was associated with higher odds of injury in the home (2.69 [1.26–5.77]), but not at child 
care (1.44 [0.45–4.62]) or other place (0.28 [0.13–0.63]). In contrast, children with diabetes, another 
chronic disease of childhood, did not have higher odds of sustaining injuries (0.88 [0.17–4.43]). 
The results of this study suggest that children with eczema have higher rates of accidental injuries. 
Further, this association appears to be specific to eczema and perhaps other atopic disorders, but 
not merely related to chronic disease in general. Future studies are needed to better understand the 
reasons behind and develop interventions to prevent injuries in eczema.    
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A self- diagnosis system for herpes zoster
D Peng,1 Y Lin,1 C Chen,1 F Fan1 and Y Liao2 1 HTC Corporation, Xindian, Taiwan and 2 
National Taiwan University Hospital, Taipei, Taiwan
Herpes zoster is more and more concerned in skin diseases. However, the public medical resources 
will be limited and even lacked in crowded city or back country. Most of persons will spend a lot of 
time to wait for doctors’ diagnosis or a lot of money in medical testing and monitoring when they 
need to do those processes in the hospital. Therefore, we propose a “self-diagnosis system” to be 
applied in personal initial diagnosis for herpes zoster. Our proposed system has integrated the image 
analysis and a questionnaire to achieve our target. For the image analysis, our system will locate 
abnormal skin distribution by global viewing image and user interface. In addition, our system also 
applies the texture and color analysis algorithms to help patients judge the abnormal skin texture. 
About the questionnaire, our system will list several essential and standard questions by derma-
tologists’ professional viewpoints to be filled in by users. Finally, our system will integrate those 
diagnosis results and do the cross-reference analysis to achieve the highest diagnostic accuracy. 
Therefore, our purposed systems will be very helpful to do the initial diagnoses of herpes zoster and 
monitor follow-up recovering effects at home in order to get the great cost saving and high privacy.   
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Sleep disturbances in adults with eczema are associated with poor overall health
J Silverberg,1 N Garg,1 A Fishbein,2 P Zee3 and AS Paller1 1 Dermatology, Northwestern 
University, Chicago, IL, 2 Allergy and Immunology, Northwestern University, Chicago, IL 
and 3 Neurology, Northwestern University, Chicago, IL
Eczema is associated with multiple extra-cutaneous comorbidities. However, little is known about 
the impact of eczema on sleep patterns in adults. We used the 2012 National Health Interview 
Survey, a nationally representative sample of 34,613 adults age 18-85 years, to determine the prev-
alence of sleep disturbance in eczema and its impact on overall health. Adults with eczema had sig-
nificantly higher rates of prolonged fatigue (32.8% vs. 14.1%), daytime sleepiness (26.0% vs. 11.7%) 
and insomnia (34.4% vs. 18.2%) than those without eczema (Rao-Scott chi square, P<0.0001). 
These associations remained significant in multivariate models controlling for history of other atopic 
disorders and socio-demographics. There was a significant interaction between eczema and sleep 
disturbance as predictors of overall health status. Adults with eczema and sleep disturbance had 
poorer overall health than those with either eczema or sleep disturbance. These data suggest that 
sleep disturbance weighs heavily on adults with eczema. Future studies are warranted to better 
characterize sleep disturbances in eczema and develop strategies for treatment and prevention.   
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Calcipotriol and clobetasol propionate cooperate in suppression of chemokine production 
in cultured human epidermal keratinocytes
M Karakawa, M Komine, H Nakayama, A Adachi, T Oshio, H Tsuda and M Ohtsuki 
Dermatology, Jichi Medical University, Shimotsuke, Japan
[Background] Calcipotriol is one of synthetic active vitamin D3 compounds, clinically used in 
topical treatment of psoriasis. Psoriatic epidermal keratinocytes produce various chemokines, which 
attract lymphocytes and dendritic cells, forming “vicious” circle of inflammation. Combination 
therapy of topical calcipotriol and topical glucocorticoid ointment has been shown more effective 
in treating psoriatic plaques than monotherapy of each ointment. [Objectives] We tried to investigate 
the additive effect of calcipotriol and clobetasol propionate (CP), the most potent glucocorticoid used 
in topical treatment, on the production of chemokines in keratinocytes. [Materials and Methods] 
Normal human epidermal keratinocytes (NHEKs) were starved for EGF and BPE, HaCaT cells were 
starved for FCS for 24 hours, stimulated with TNFα with or without calcipotriol (10-11M to 10-6M) 
and/or CP (10-11M to 10-6M). The supernatants were harvested and subjected to ELISA for CCL17, 
CCL20, CCL27, CXCL9, CXCL10, and CXCL11. The cells were collected, total RNA was extracted, 
reverse transcribed, and subjected to real time PCR. [Results] CCL17, CXCL9 and CXCL11 were not 
detected in the supernatant of NHEKs, but were detected in that of HaCaT cells. Calcipotriol alone 
suppressed production of CCL20, CXCL10, but not CCL27 in NHEKs in a concentration dependent 
manner. It also suppressed production of CCL17, CXCL9 and CXCL11, but not CCL27 in HaCaT 
cells. CP alone suppressed production of CCL27, CXCL10, but enhanced that of CCL20 in NHEKs 
in a concentration dependent manner. It suppressed production of CCL17, CCL27, CXCL9, CXCL10, 
CXCL11, but enhanced CCL20 in HaCaT cells. When CP and calcipotriol were added together, 
they suppressed all of the chemokines investigated in HaCaT cells, and they suppressed all of 
the investigated chemokines detected in NHEKs. [Conclusions] Calcipotriol and CP, when added 
together, are more potent in the suppression of inflammatory chemokine production in keratinocytes.   
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Effect and molecule pychophysical mechanism analysis of tacrolimus ointment in treating 
male patients with pruritus ani
Z Xie and Y Lan Peking University Third Hospital, Beijing, China
Objective To investigate the effect and mechanism of tacrolimus ointment 0.1% in treating adult 
male patients with pruritus ani. Methods The severity of pruritus (SP) and a basic syntax and molec-
ular substrate (molechlar psychophysics) of nociception and pruriception established by tempera-
ture-sensitive transient receptor potential (TRP) channels were used to evaluate the severity of pru-
ritus and skin sensory phenomenon. Results The SP score were found to be reduced significantly in 
41 patients with pruritus ani after using topical tacrolimus ointment 0.1%. Among them,34 (82.9%) 
patients showed positive capsaicin-like response(i.e. burning with consequent rapid amelioration 
of pruritus or burning sensation). Seven (17.1%) patients showed negative capsaicin-like response. 
Conclusion Topical tacrolimus may rapidly inhibits or alleviates itch of patients with pruritus ani.
The therapeutic effect of topical tacrolimus is relevant to the mechanism that activate or sensitize 
TRPV1 and desensitizes TRPV1 in the skin sensory afferents.    
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A novel single-fraction radiation approach for metastatic Merkel cell carcinoma is well tol-
erated and demonstrates strong efficacy linked to intact cellular immunity
JG Iyer,1 U Parvathaneni,2 N Miller,1,3 T Gooley,4 E Markowitz,1 S Bhatia,5 K Paulson,1,5 
A Blom,1 J Liao,2 K Parvathaneni,1 C Lewis,1 R Doumani1 and P Nghiem1,4 1 Dermatology, 
University of WA, Seattle, WA, 2 Radiation Oncology, University of WA, Seattle, WA, 3 
Pathology, University of WA, Seattle, WA, 4 Fred Hutchinson Cancer Research Ctr, Seattle, 
WA and 5 Medicine, University of WA, Seattle, WA
Over 30% of Merkel cell carcinoma (MCC) patients eventually develop distant metastatic dis-
ease that is typically treated with chemotherapy despite toxicity and short duration of response. 
Because cellular immunity is important for MCC-specific survival and mouse model data suggest 
that single-fraction radiotherapy (SFRT) promotes tumor immunity, we began treating patients with 
an 8 Gray SFRT approach in 2010. 93 tumors were targeted in 26 patients (median age: 68 years). 
Median follow up among living patients was 252 days (range: 76-699 days) and median tumor 
size was 4 cm (range: 1 – 19 cm). The average number of tumors treated per patient in this study 
was 3.5 (range: 1 – 28). Patients were categorized as high-risk (HR) or low-risk (LR) based on their 
presumed immune function. There were 60 tumors among 13 HR patients who had known immune 
suppression and/or preceding chemotherapy (3.5 month median interval from chemotherapy to 
SFRT). There were 33 tumors among 13 LR patients (no known immune suppression or preceding 
chemotherapy). 81% percent of tumors in LR patients had a complete response compared to 52% 
in HR patients (p=0.008). Regardless of risk category, no tumor that had a complete response ever 
recurred. Only 9% (3/32) of LR patient tumors recurred compared with 30% (17/57) for HR (p=0.02). 
Importantly, only 2 of 26 patients had even transient side effects (flare pain that resolved within 72 
hours). SFRT was highly effective, durable, and convenient for patients with metastatic disease as 
compared to the multiple visits required for chemotherapy or fractionated radiation. SFRT could 
be combined with emerging systemic immune stimulants to improve outcomes for this aggressive 
disease by lowering tumor burden and exposing viral/tumor antigens.    
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Rosacea is associated with chronic systemic inflammatory diseases in a skin severity-de-
pendent manner
BM Rainer, AH Fischer, D Luz, S Kang and AL Chien Dermatology, Johns Hopkins University, 
Baltimore, MD
Rosacea has been linked to systemic comorbidities, but systematic studies to address this association 
are lacking. Thus, we performed a case-control study to investigate the risk of comorbidities in 
rosacea patients compared to matched controls (by race, sex, and age [+ 5 years]) and examined 
whether this risk is altered by rosacea severity. Standardized questionnaires were administered to 
participants and a study dermatologist completed clinical evaluations. Rosacea characteristics were 
assessed using the National Rosacea Society’s standard grading system. 130 participants (65 rosacea 
cases, 65 controls) were enrolled. In the 65 rosacea patients (M=22, F=43, mean age=50.6 years 
old, Caucasians = 62), 41 (63%) had erythematotelangiectic and 24 (37%) papulopustular type. 
Phymatous changes were present in 10 (15%), and 30 (46%) had ocular involvement. Rosacea 
severity was mild in 37 (56.9%) patients and moderate-to-severe in 28 (43.1%). The mean (SD) 
duration of disease was 11.8 (9.6) years. Using conditional logistic regression models, we found 
that overall, patients with rosacea, as compared to controls, had higher risk of gastrointestinal 
reflux disease (GERD) (odds ratio, 4.2; 95% CI, 1.7-10.2; p=0.002), gastrointestinal disorders (3.0; 
1.2-7.6; p=0.02), respiratory diseases (4.0; 1.3-12.0; p=0.01), urogenital disorders (7.5; 1.7-32.8; 
p=0.007), allergies [airborne (4.6; 1.7-12.1; p=0.002), food (10.0; 1.3-78.1; p=0.03)], female hor-
mone imbalance (3.2; 1.2-8.7; p=0.02), and hypertension (2.8; 1.1-7.2; p=0.03). Compared to mild 
severity, moderate-to-severe rosacea was associated with increased risk of GERD (4.57; 1.58-13.23; 
p=0.005), metabolic disorders (4.38; 1.49-12.89; p=0.007), and cardiovascular diseases (4.07; 1.42-
11.68; p=0.009). Our data demonstrate that rosacea is associated with chronic systemic diseases 
and thus may share similar mechanisms that underlie chronic inflammatory disorders. Physicians 
should be aware of these associations in order to provide comprehensive care to patients with 
rosacea, especially those with more severe disease.    
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IL-37, an inhibitor of innate inflammation and adaptive immunity, is elevated in the blood 
of melanoma patients and is related with poor prognosis
Y Luo,1 S Liu,1 J Lee,1 SE Robinson,2 WA Robinson,2 DA Norris,1,3 CA Dinarello2 and 
M Fujita1,3 1 Dermatology, University of Colorado Denver, Aurora, CO, 2 Medicine, 
University of Colorado Denver, Aurora, CO and 3 Denver Veterans Affairs Medical Center, 
Denver, CO
Developing methodologies to identify biomarkers in easily accessible body fluids is valuable for 
the early diagnosis and management of cancer patients. Here, using microarray analysis, we iden-
tified 6 highly upregulated transcripts in melanoma blood samples compared with healthy blood 
samples (>5-fold; P<0.01). Of particular interest was IL-37, a member of IL-1 family. IL-37 reduces 
innate inflammation and adaptive immune responses. We examined IL-37 gene expression of 
whole blood cells from 14 healthy individuals and 45 melanoma patients (5 from stage I, 8 from 
stage II, 11 from stage III and 21 from stage IV). While IL-37 expression was very low in healthy 
individuals, the level was 6.3-fold increased in melanoma patient samples (P<0.001). IL-37 levels 
among melanoma patients from different stages were overall constant. Fourteen melanoma patients 
whose blood samples were analyzed for IL-37 levels were clinically followed for up to 22 months. 
Whereas 100% (5 out of 5) of melanoma patients whose IL-37 expression was high showed disease 
progression, 66.7% (6 out of 9) of melanoma patients whose IL-37 expression was low remained 
stable, suggesting that elevated IL-37 levels were related with poor prognosis. To understand cell 
subsets responsible for the elevated IL-37 in blood, we used microbeads to fractionate blood samples 
into CD3, CD14, CD15, CD19, CD45 and CD56. IL-37 was almost exclusively expressed in CD45+ 
cells but undetectable in CD45- cells. Among CD45+ cells, higher levels of IL-37 were detected in 
CD3+ cells and CD19+ cells in melanoma blood samples, suggesting IL-37-mediated suppression 
of adaptive immunity in melanoma patients. In conclusion, IL-37 may not only be a biomarker of 
melanoma but also serve as a therapeutic target in melanoma.    
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Efficacy and safety of a low-level laser device in the treatment of male and female pattern 
hair loss
J Jimenez,1 TC Wikramanayake,1 W Bergfeld,2 M Hordinsky,3 J Hickman,4 M Hamblin5 and 
L Schachner1 1 University of Miami Miller School of Medicine, Miami, FL, 2 Cleveland Clinic 
Foundation, Cleveland, OH, 3 University of Minnesota, Minneapolis, MN, 4 The Education 
& Research Foundation, Inc., Lynchburg, VA and 5 Massachusetts General Hospital, Boston, 
MA
Male and female pattern hair loss are common chronic dermatologic disorders with limited thera-
peutic options. In recent years, a number of commercial devices utilizing low-level laser therapy 
have been promoted, but there has been little peer-reviewed data on their efficacy. In this study, 
randomized, sham device-controlled, double-blind clinical trials were conducted to determine 
whether low-level laser treatment is effective for male and female pattern hair loss. Subjects were 
treated with a lasercomb (one of 3 models) or a sham device three times a week for 26 weeks, 
and terminal hair density of the target area was evaluated at baseline and at 26 weeks. A total of 
122 female and 103 male subjects participated in 4 clinical trials (9-beam lasercomb treatment 
in females, 12-beam in females, 7-beam in males, and 9- and 12-beam in males) and were in the 
efficacy analysis. Statistically significant difference in terminal hair count increase was detected at 
26 weeks in all 4 trials between laser- and sham-treated subjects (p<0.05). Additionally, higher per-
centage of laser-treated subjects reported overall improvement of hair loss condition and thickness 
and fullness of hair in self-assessment. No serious adverse events were reported in lasercomb-treated 
subjects. The increase in terminal hair density at 26 weeks was comparable to that observed in some 
short-term (~6 months) trials of 5% minoxidil solution or 1mg/day finasteride treatment of male pat-
tern hair loss, but lower than observed in longer term studies. Our results suggest that low-level laser 
treatment may be an effective option to treat pattern hair loss in both men and women. Additional 
studies should be considered to determine its long-term effects, and to optimize laser modality.   
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Reduced sweat gland function underlies slowed reepithelialization in elderly skin
L Rittié, JS Orringer, EA Farr, MJ Karshner, JJ Voorhees and GJ Fisher Department of 
Dermatology, Univ. of Michigan, Ann Arbor, MI
Clinical observations indicate that skin heals more slowly in aged vs young adults, but the mecha-
nism for this delay is unclear. It was recently shown that during human skin repair, eccrine sweat 
glands (ESGs) and hair follicles (HFs) underlying wounds generate keratinocyte outgrowths that later 
form the new epidermis. Thus, we hypothesized that aging alters the reepithelialization function of 
ESGs and/or HFs. To test this hypothesis in vivo, we performed shallow wounds on the forearm of 
healthy young (<40yo) and aged (>70yo) human subjects using a CO2 laser. Full thickness biopsies 
were obtained from healing wounds at precise times during the first week of repair. Consecutive 
sections of the topmost 2-mm of wounded skin were stained to distinguish appendageal structures. 
Each section was digitally imaged, and computer software was used to create 3D animations of 
the biopsies to study reepithelialization overtime. Our results confirm that outgrowth of cells from 
ESGs is a major feature of repair in young skin. HFs also contribute epithelial outgrowths that form 
the new epidermis, but are outnumbered by ESGs 3 to 1 in young adult skin (14.3±0.6 ESGs vs 
5.5±0.6 HFs per 4-mm biopsy, n=13, p=1.9x10-8). In aged skin, although ESG density is similar, 
less than 20% of the ESGs generate epithelial outgrowths during repair (vs 100% in young). In 
contrast, outgrowths from HFs grew similarly in the two age groups. However, HFs appear more 
evenly distributed in aged vs young skin. This altered spatial organization causes HF-outgrowths to 
be more spread-out in aged vs young skin. Redistribution of HFs in aged skin partially compensates 
for altered ESG reepithelization function, reducing the deficit in aged skin to 23% less coverage 
than in young skin (88.1±1.7% vs 65.6±7% coverage at day 7 in young vs aged, respectively). These 
results show that decline of ESG function is responsible for slowed reepithelialization in aged skin. 
Our observations suggest that therapeutical stimulation of ESG activity may be a novel strategy to 
improve wound closure in aged skin.    
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Open-label pilot study of LDE225 in advanced basal cell carcinoma patients who have been 
treated previously with a non-LDE225 Smoothened inhibitor
AS Chang and A Oro Dermatology, Stanford University School of Medicine, Redwood City, 
CA
Currently, there is only one US FDA approved Smoothened inhibitor drug, vismodegib, approved 
for advanced basal cell carcinomas. Over half of patients are refractory to this treatment, while over 
20% of initial responders develop recurrent disease. The purpose of this pilot study (NCT01529450) 
was to assess the progression-free survival of LDE225, a different Smoothened inhibitor, in advanced 
basal cell carcinoma patients who were refractory or recurred after a non-LDE225 Smoothened 
inhibitor. The study was open-label and utilized oral LDE225 at 800 mg daily. Inclusion criteria 
consisted of adults with biopsy-proven advanced basal cell carcinoma, World Health Organization 
performance status ≤2, and who had not used an anti-neoplastic therapy for at least 2 weeks prior 
to study drug initiation. Tumor responses were assessed by Response Evaluation Criteria in Solid 
Tumors, version 1.1. A total of 9 patients were enrolled at a single academic site, with mean duration 
of treatment of 7.3 weeks (standard deviation 4.2 weeks). Four patients experienced progressive 
disease, with average exposure to LDE225 of 11.3 weeks (standard deviation 3.0 weeks) prior to 
progression. The remaining five patients discontinued the study for the following reasons: grade 
4 creatine kinase elevation (n=1), grade 3 weight loss (n=1), patient decision to undergo surgical 
resection due to perceived lack of tumor response (n=2), and development of squamous cell car-
cinoma (n=1). None of these 9 patients demonstrated partial or complete response. This study was 
terminated due to lack of response in these initial patients, obviating calculation of progression free 
survival. These cases are the first in humans to suggest that Smoothened inhibitor chemoresistance 
may occur across two different drugs in the same class.    
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Eccrine syringometaplasia secondary to vemurafenib at sites of radiation recall
EK Moioli, S Kenkare and K Soltani University of Chicago, Chicago, IL
Eccrine syringometaplasia (ESS) is a known potential complication of chemotherapy. Vemurafenib, 
a selective BRAF inhibitor used in the treatment of metastatic melanoma as well as other cancers 
including adenocarcinomas harboring the V600E mutation has recently been reported to induce ESS. 
Metaplasia appears to be mostly in a non-inflammatory setting indicating a direct cytotoxic effect 
on eccrine gland cells. Interestingly, radiation therapy has also been implicated in the development 
of ESS in only 1 case of radiation recall 20 years ago. We illustrate the potential synergistic effect 
of vemurafenib and radiation recall in the development of ESS in a case of combination therapy for 
stage IVb lung adenocarcinoma. The histologic findings of squamous metaplasia and dyskeratosis 
on the eccrine ductal epithelium presented clinically as a pruritic papular eruption on the chest and 
back at the site of prior radiation therapy. Vemurafenib therapy interruption and subsequent dose 
adjustment were required to hasten clinical improvement of dermatosis. The increased therapeutic 
use of vemurafenib for multiple malignancies warrants careful monitoring for serious cutaneous 
side effects especially in the setting of previously irradiated patients as prior therapy may reduce the 
threshold for metaplasia and dysplasia leading to increased vulnerability to neoplasia. Longitudinal 
follow-up is necessary and dose reductions considered early. In addition, it may be postulated that 
the more commonly observed development of squamous cell carcinoma during vemurafenib therapy 
may originate from early metaplastic changes within adnexal structures such as in eccrine glands. 
The present case may provide a background for future studies of the underlying pathomechanism 
of radiation recall and vemurafenib-induced ESS in a large cohort of patients.    
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An open-label, phase 2 trial of itraconazole for basal cell carcinoma
DJ Kim,1,5 J Kim,2 K Spaunhurst,1 J Montoya,3 R Khodosh,1 T Fu,1 A Gilliam,4 M Molgo,3 
PA Beachy5 and JY Tang1 1 Dermatology, Stanford, Stanford, CA, 2 Oncology, UT 
Southwestern, Dallas, TX, 3 Dermatology, Universidad Católica de Chile, Santiago, Chile, 
4 Dermatology, Palo Alto Medical Foundation, Palo Alto, CA and 5 Institute for Stem Cell 
Biology and Regenerative Medicine, Stanford University, Stanford, CA
All BCC tumors have malignant activation of the Hedgehog signaling pathway. We performed a 
chemical library screen of FDA approved drugs and identified itraconazole as a potent inhibitor 
of the Hedgehog pathway. Previously, we demonstrated that itraconazole suppresses murine BCC 
carcinogenesis. To assess the mechanism of action and clinical efficacy of itraconazole on human 
BCC, we performed an open-label, phase II trial in 29 patients with sporadic BCC. The primary goals 
were to evaluate whether itraconazole-induced inhibition of HH pathway activity (GLI1 mRNA) can 
reduce tumor proliferation and tumor size in human BCC. Subjects with at least one BCC tumor 
greater than 4 mm in diameter were enrolled in 2 cohorts to receive oral itraconazole 200mg BID 
for 1 month (Cohort A) or 100 mg BID for an average of 2.3 months (Cohort B). A total of 29 subjects 
were enrolled, of whom 19 were treated with itraconazole. Itraconazole treatment was associated 
with two adverse events (grade 2 fatigue and grade 4 congestive heart failure). Itraconazole reduced 
cell proliferation by 45% (P=0.04), HH pathway activity by 65% (P=0.03), and reduced tumor area 
by 24% (95% CI: 18.2% to 30.0%). Of 8 subjects with multiple non-biopsied tumors, 4 subjects 
had partial response and 4 had stable disease. Tumors from untreated control subjects and from 
subjects previously treated with vismodegib showed no significant changes in proliferation and 
tumor size. In conclusion, itraconazole has anti-BCC activity in humans. These results provide the 
basis for larger trials of longer duration to measure the clinical efficacy of itraconazole especially 
relative to other Hedgehog pathway inhibitors.    
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Persistent expression of IL-17A in active psoriatic plaques of patients treated with ustekinumab
C Jack,1 M Sarfati,2 N Arbour2 and R Bissonnette3 1 Dermatology, McGill University, 
Montreal, QC, Canada, 2 Immunoregulation, Université de Montréal, CRCHUM, Montreal, 
QC, Canada and 3 Innovaderm Research, Montreal, QC, Canada
Ustekinumab, an anti-p40 subunit human monoclonal antibody, is one of the most effective sys-
temic treatments for psoriasis. However, less than 30% of patients have complete clearance with 
ustekinumab used as monotherapy. Cytokine expression in active psoriatic plaques compared to 
normal skin in ustekinumab-treated patients remains unexplored. Our goal is to investigate the 
expression of typical inflammatory mediators in active plaques of ustekinumab-treated patients. A 
total of 20 patients with psoriasis were studied: 10 treated with active moderate-to-severe plaques 
despite ustekinumab for >12 weeks and10 untreated, as well as ten control subjects. Punch biopsies 
were collected from lesional and non-lesional skin or from normal-appearing skin (control subjects) 
and real-time PCR was performed. Our data indicate that the pro-inflammatory cytokine IL-17A 
and the anti-microbial peptide hBD2 are significantly (p〈0.05) elevated in plaque skin relative to 
non-lesional skin despite ustekinumab treatment in these patients. Although reduced in non-lesional 
skin, IL-17A and IFN-gamma are present at higher levels than in normal skin of subjects without 
psoriasis. Levels of IL-22 are similarly elevated from both lesional and non-lesional skin in both 
treated and untreated patients when compared to normal subjects, highlighting that this cytokine 
is generally enhanced in psoriasis patients. Together, these data indicate that active plaques in 
patients treated with ustekinumab have persistent expression of the pro-inflammatory cytokine 
IL-17A despite systemic p40 blockade.    
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 Excimer laser in combination with clobetasol spray and calcitriol ointment for the treat-
ment of generalized psoriasis: Interim results 
M Malakouti, G Brown, A Leon, E Levin, E Sorenson, E Wang and J Koo University of 
California, San Francisco, San Francisco, CA
Purpose: Psoriasis is a chronic inflammatory skin disease that affects 2-3% of the US population. 
The treatment of psoriasis is dependent on the amount of body surface area (BSA) involved such 
that topical agents or targeted phototherapy are used for localized disease and systemic agents or 
whole body phototherapy for generalized disease. Excimer laser confers an advantage over whole 
body phototherapy by selectively irradiating psoriasis plaques, thus causing less photodamage. To 
extend the utility of excimer laser for the treatment of generalized psoriasis patients, we sought to 
evaluate its efficacy when combined with clobetasol spray and calcitriol ointment. Methods: This 
12-week study recruited plaque-type psoriasis patients with 10-30% BSA. The study was divided 
into three four-week treatment periods: clobetasol spray, calcitriol ointment, and finally simultane-
ous application of both agents. Laser treatments were conducted twice weekly with the XTRAC® 
Velocity 308nm excimer laser until week six, and thereafter as needed if <75% improvement in 
Psoriasis Area Severity Index (PASI-75) was achieved. The primary endpoint was the percentage of 
patients achieving PASI-75 by week 12. Results: Currently, 27 patients of 30 have completed the 
study. By week 12, 77.7% of patients achieved PASI-75 with an average of 11 treatments. Treatments 
were well tolerated; the most common side effects reported were pruritis, burning and superficial 
blistering. Conclusions: We report the novel use of excimer laser in combination with clobetasol 
spray and calcitriol for the treatment of generalized psoriasis. By week 12, 77.7% of patients 
achieved PASI-75, which is superior to the efficacy of currently available biologics at the same 
time point without the serious side effects associated with systemic agents. Although the excimer 
laser has been generally reserved for localized psoriasis, the results of this study support its use for 
the treatment of generalized psoriasis when combined with topical agents.    
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A novel camera device captures tryptophan autofluorescence in rapid epidermal proliferations
AE Ortiz,1,2 W Franco,2 SJ Taghados,2 E Gutierrez-Herrera,2 W Farinelli,2 B Jiang,1 
A Doukas2 and R Anderson2 1 Medicine/Dermatology, UC San Diego, San Diego, CA and 2 
Dermatology, Wellman Center for Photomedicine/Massachusetts General Hospital/Harvard 
Medical School, Boston, MA
Tryptophan autofluorescence of intact skin has never been imaged. The purpose of this study was 
to determine the efficacy of a prototype ultraviolet charge-coupled device (CCD) camera to cap-
ture tryptophan autofluorescence in rapid epidermal proliferations. The CCD camera was filtered 
to detect 340 nm (10 nm bandwidth), and coupled to a 300 nm light emitting diode source, for 
imaging the excitation/emission pair of 300/340 nm characteristic of the tryptophan fluorophore. 
An in vivo murine tumor model for basal cell carcinoma (Ptch1+/-) was used in a preclinical study. 
Clinical imaging was then performed in an open-label pilot study on 23 subjects with various skin 
lesions. Images were also taken of frozen sections and compared to histology, when biopsies were 
taken as part of standard care. The 300 nm excitation source delivered 0.03 mJ/cm2 during a 162 
ms flash exposure, two orders of magnitude below the 3 mJ/cm2 permissible exposure for skin at this 
wavelength. Skin tumors in the murine model failed to demonstrate tumor-specific autofluorescence 
images. In contrast, human skin lesions with rapid epidermal proliferation consistently showed 
increased autofluorescence compared with surrounding normal skin, including psoriasis, actinic 
keratoses, verruca vulgaris, and non-melanoma skin cancers. Tape stripping and contact dermatitis 
to induce cell proliferation also showed increased autofluorescence. This is the first study to image 
tryptophan autofluorescence in humans. The technique appears to be useful for detecting and/or 
evaluating proliferative skin lesions including skin cancers. Limitations include small pilot sample 
size and a simple point-and-shoot camera system that does not fully isolate tryptophan from other 
UV skin fluorophores. The fundamental basis for apparent increased tryptophan autofluorescence 
of proliferative skin lesions remains unknown.    
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TRPV1 antagonist 4-t-butylcyclohexanol inhibits capsaicin induced nerve fiber activation 
in vitro and in vivo
E Grönniger, AC Worthmann, M Sulzberger, D Roggenkamp, KA Jung, B Buck, R Wolber and 
G Neufang Beiersdorf AG, Hamburg, Germany
The thermo Ca2+ channel TRPV1 has been shown to play a relevant role in regulating the sensitivity 
of the skin. More precisely, its lowered activation threshold correlates with symptoms like tingling, 
burning or stinging. Sensitive skin is one of the most common skin conditions with more than 50 % 
of adults claiming to be affected. Therefore, reducing the hyper-responsiveness of sensory neurons 
by inhibiting TRPV1 could be an effective strategy to soothe unpleasant skin feel. To investigate 
the efficacy of 4-t-butylcyclohexanol as a TRPV1 antagonist and thus being a potential new active 
ingredient in skin care formulations for sensitive skin, the capsaicin induced activation of the 
TRPV1 channel was analyzed via Ca2+-imaging in vitro. Results showed that the Ca2+ influx was 
significantly reduced after treating the cells with 4-t-butylcyclohexanol. Moreover, the treatment 
with 4-t-butylcyclohexanol resulted in a reduced release of neuronal CGRP, which also serves as 
an indicator for nerve fibre activation. Additionally, the skin calming effect of 4-t-butylcyclohexa-
nol was tested in a double-blind, randomized, vehicle-controlled in vivo study. Using a modified 
stinging test (n=24) with nasolabial application of capsaicin, 4-t-butylcyclohexanol was observed 
to significantly suppress capsaicin induced stinging on a visual analog scale (VAS), thus alleviating 
subjective skin symptoms by reducing the hyper-responsiveness of sensory neurons. Taken together, 
the results provide evidence that 4-t-butylcyclohexanol might relieve symptoms of sensitive skin by 
blocking TRPV1 channel and thus nerve fiber activation.    
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Successful treatment of dyshidrosiform pemphigoid with minocycline monotherapy
O Ogbechie,1 AB Eastham,2 SR Granter,3 AN Femia2 and RA Vleugels2 1 Harvard Medical 
School, Boston, MA, 2 Department of Dermatology, Brigham and Women’s Hospital, Boston, 
MA and 3 Department of Pathology, Brigham and Women’s Hospital, Boston, MA
Dyshidrosiform pemphigoid (DP), a rare variant of bullous pemphigoid (BP), is an autoimmune 
bullous dermatosis characterized by tense, and often hemorrhagic, subepidermal bullae and vesicles 
with a palmoplantar distribution. Skin biopsy is warranted for diagnosis; salt-split skin analysis of a 
subepidermal bulla with direct immunofluorescence (DIF) demonstrates linear IgG and C3 staining 
on the epidermal roof. Patients with DP also have positive serum antibodies to BP180 and BP230. 
Given the palmoplantar distribution and potential for functional disability, DP is most often treated 
with high-dose systemic corticosteroids. However, this therapeutic approach may have adverse 
effects, particularly in elderly patients in whom DP is more prevalent. Alternative therapies reported 
in the literature include immunosuppressive agents and tetracyclines. Herein, we present a case 
of a 79-year-old man with a two-week history of bullae on the hands and feet, diagnosed as DP 
based on clinical and histologic findings. Histology revealed spongiosis with numerous eosino-
phils and subepidermal clefting, as well as tagging and degranulation of eosinophils along the 
dermal-epidermal junction. DIF revealed focal strong linear staining of C3. Salt-split skin analysis 
and serum serology were diagnostic of DP. Our patient was initially treated with minocycline and 
nicotinamide, a successful regimen reported in the literature. However, he discontinued the latter 
due to flushing and dizziness after only one dose. Thus, he was treated with minocycline 100mg 
twice daily and experienced rapid improvement of his lesions and subsequent resolution. To our 
knowledge, we present the first case of DP treated successfully with minocycline monotherapy in 
a patient who experienced complete resolution. Due to the increased incidence of DP among the 
elderly, we propose that minocycline monotherapy should be considered as a therapeutic option 
to avoid adverse effects of systemic corticosteroids.    
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Atrophic acne scars can undergo spontaneous regression
Y Balagula,1 H Pasieka,1 P Mattei,1 D Kuhn,1 S Leung,1 D Luz,2 AL Chien1 and S Kang1 1 
Dermatology, Johns Hopkins School of Medicine, Baltimore, MD and 2 San Paulo Medical 
School, San Paulo, Brazil
Atrophic acne scars develop as a result of damage to the dermal matrix, and once formed their 
permanence had been assumed. To our knowledge no systematic study has investigated the natural 
evolution of atrophic acne scars to ascertain whether the assumption of scar permanence holds true. 
Thus, the aim of our study was to determine if acne scars undergo spontaneous regression over time. 
Two dermatologists independently examined high quality clinical photographs of untreated facial 
acne (N=20, average Leeds score=3.8) taken at week 0 and week 12. A blinded third evaluator 
was used to reach a consensus opinion when needed. These were taken professionally with stan-
dardized patient positioning and lightening. Subsequently, the two images from each patient were 
made superimposable by a software program (Picture Window Pro 4.0), and matching regions of 
interest (ROI = 2x2 cm) were studied. Atrophic scars measuring greater than 0.5 mm in ROI were 
counted and sizes measured. A total of 179 scars were identified and measured at baseline: 0.5mm 
(n=30), 1.0mm (n=83), 1.5mm (n=39), >1.5mm (n=27). A total of 24 (13%) scars resolved by week 
12: 0.5mm (14/30 = 47%), 1.0mm (9/83 = 11%), 1.5mm (1/39 = 3%), >1.5mm (0/27). A logistic 
regression with fixed effects was performed to determine if the initial scar size affected spontaneous 
regression at week 12. We found that scars measuring greater than 1.0mm were unlikely to sponta-
neously resolve 12 weeks later. Holding other variables constant, a 0.5 mm increase in the size of 
the scar at week 0 was associated with a significant change in the odds (9.6; p<.001) that the scar 
would be present at 12 weeks. Our results suggest that there is ongoing dermal remodeling in atro-
phic acne scars, especially in the small ones, which can lead to spontaneous regression over time.   
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Dynamic thermal infrared imaging non-invasively detects skin cancer with high sensitivity 
and specificity
S Myers,1 SE Godoy,1,2,3 D Ramirez,1 G von Winckel,1 SS Krishna,1 M Berwick,4 RS Padilla5 
and S Krishna1,2,3 1 SKINfrared, LLC, Albuquerque, NM, 2 CHTM, UNM, Albuquerque, NM, 
3 ECE, UNM, Albuquerque, NM, 4 Div. of Epidemiology, UNM, Albuquerque, NM and 5 
Dermatology, UNM, Albuquerque, NM
An Advanced Long-wave-infrared Imaging System (ALIAS) is being developed that utilizes infrared 
imaging to detect dynamic thermal signatures (DTS) of suspicious lesions with respect to healthy 
surrounding skin after the application of a temperature stimulus. This DTS is then used to classify 
lesions as malignant or benign. The ALIAS consists of an infrared and a visible camera, registration 
marker, cold air source, computer and software for controlling the image acquisition and analysis. 
Data is collected by first applying the registration marker over the lesion in question and acquiring 
a visible image of the lesion. The lesion and surrounding skin is then cooled and imaged as the 
lesion and surrounding skin warm up by natural convection with the air. The differences between 
the DTS of the lesions and healthy skin are then mathematically compared to distinguish malignant 
and benign conditions. This device was developed using an observational pilot study of 74 human 
subjects, 53% of which were male, and the average age was 55 years with a standard deviation of 
17. Patients with suspicious lesions were given the opportunity to volunteer to have their lesions 
imaged prior to their biopsy. The biopsy results were then correlated with the ALIAS results in order 
to benchmark our approach. Malignant skin lesions were distinguished from benign lesions with a 
sensitivity of 96.97% and a specificity of 78.05%. The receiver operating curves (ROC) had an area 
under the curve (AUC) of 95.31%. It is noted that the malignant skin lesions include such cases as 
melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC). 55% of lesions were 
benign, 34% were BCC, 7% were SCC, and 4% were melanoma. These results suggest the technique 
is promising as a non-invasive screening tool and is worth continued research and development to 
further improve the sensitivity, specificity, and statistical confidence.    
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Clinical and immunologic factors associated with remission and relapse in patients with 
bullous pemphigoid applying topical corticosteroids
M Xu, H Zhu, X Zhao, W Li, R Shi, J Zheng and M Pan Dermatology, Ruijin Hospital, 
Shanghai Jiaotong University School of Medicine, Shanghai, China
Bullous pemphigoid is the most common autoimmune bullous disease mainly affecting the elderly. 
Systemic corticosteroids have been considered the first-line therapy for half a century. There have 
been studies comparing the appliance of systemic and potent topical corticosteroids in BP patients 
and data demonstrate the effectiveness and less side effects that topical steroids have brought. So 
far, a pattern of “more topical, less systemic” is more likely to be practiced in BP treatment. Though 
it minimizes a great amount of mortality, recurrent cases are also growing meanwhile. It seems that 
there exist some patients who don’t respond well after a long-term topical treatment which prolongs 
active period of the disease and cause not only patients’sufferings but other complications. This study 
is to find out the characteristics of these patients so that a better treatment can be chosen at initial 
stage. A total of 33 BP patients were assigned to receive simply topical 0.05% Halometasone cream. 
Associations of clinical, biological and immunologic variables with disease control and clinical 
relapse were assessed by means of univariate and multivariate analyses. At month 12, 2 patients 
were dead, 29 were in remission and 10 had had relapses. Factors predictive of hard chance of 
remission were young age, extensive condition of the disease, extensive erythema area, score of 
pruritus, higher blood eosinophil counts, and high-titer of anti-BP180 IgE. Factors associated with 
relapse were erythema area, pruritus, higher blood eosinophil counts and high-titer of anti-BP180 
IgE. Young age, severe disease, large area of erythema, pruritus, higher blood eosinophil count 
consist hard chance of remissions and erythema area, pruritus, higher blood eosinophil counts and 
high-titer of anti-BP180 IgE are indicators of further relapse of BP. If a patient has risk factors in 
remissions and relapses, it takes much more discretion in therapeutic regimen in order to achieve 
the balance of efficacy and safety problem.    
Human Clinical Research and Therapeutics | ABSTRACTS
www.jidonline.org   S103
591
WITHDRAWN    
592
Time course classification of response to treatment in psoriatic patients
JM Corrêa da Rosa,1 S Tian,2 C Brodmerkel,3 AB Gottlieb,4 J Krueger1 and M Suarez-Farinas1 
1 Laboratory of Investigative Dermatology, Rockefeller University, New York, NY, 2 Division 
of Clinical Epidemiology, First Hospital of Jilin University, Changchun, China, 3 Immunology 
Research, Johnson & Johnson, Spring House, PA and 4 Tufts Medical Center, Boston, MA
Psoriasis is caused by the complex interaction of genetic, environmental and immunological factors. 
Deeper understanding of psoriasis has been acquired with the availability of high throughput tech-
nologies for molecular characterization. Prediction of response at early time points, after starting a 
new treatment, may accelerate translational clinical studies of new agents. The goal of this study 
is to build a genomic classifier to select, based on 4 earlier time points, genes that predict late 
response to treatment in psoriatic patients. We also sought to determine the earliest time point that 
provides accurate classification of patients’ responses. The analysis was based on gene expression 
data of lesional psoriasis taken at baseline, and after 1,2 and 4 weeks of treatment with etanercept, 
methotrexate or adalimumab from 43 patients with known PASI75 status at the end of treatment. 
Another cohort of 24 patients treated with ustekinumab had data available only at baseline and 1 
week post-treatment. Two classifiers were used: Time Prediction Analysis of MicroArrays (T-PAM) 
and Threshold Gradient Descent Regularization (TGDR). Results indicated that changes in gene 
expressions from baseline to 1st week did not provide accurate predictions with error rate of 
30.23%. Similar result (35%) was found for the ustekinumab cohort. Inclusion of gene expression 
at the 2nd week of treatment decreased error rate to 23.25%. By adding gene expression after a 
month of treatment, the T-PAM algorithm identified a set of 56 genes that resulted in an error rate 
of 4.6%. TGDR algorithm led to a selection of 36 genes of which 14 had been selected by T-PAM. 
Both algorithms selected the genes KIF18A and PI4K2A as the most discriminative. The results 
suggest that a molecular classifier for response could be applied in 4 week translational studies of 
novel therapeutics for psoriasis.    
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Interim results of a study evaluating the psychological well-being of psoriasis patients fol-
lowing treatment with ustekinumab
G Brown, M Malakouti, A Leon, E Levin, E Sorenson, E Wang and J Koo Dermatology, 
University of California, San Francisco, San Francisco, CA
Purpose: Patients with psoriasis experience substantial psychosocial and occupational effects that 
are comparable to those experienced by patients with heart disease, diabetes, and cancer. While the 
primary goal of treatment is generally aimed at improving the physical appearance and discomfort 
associated with psoriasis, it is vital to also consider the value of improving the quality of life. The 
development of biologic agents, such as ustekinumab, has greatly improved therapeutic options for 
patients with psoriasis. The objective of this study is to assess the improvement in patient quality of 
life after 36 weeks of treatment with ustekinumab in order to gain further insight in to the psychoso-
cial impact of psoriasis. Methods: To date, 19 of 35 patients have completed the study. Patients with 
moderate-to-severe (≥10% BSA) plaque-type psoriasis received ustekinumab injections on weeks 0, 
4, 16, & 28 and were assessed every 4 weeks for psoriasis severity and quality of life for a total of 
36 weeks. Psoriasis severity was measured using the Psoriasis Area and Severity Index (PASI) while 
quality of life was assessed using multiple validated psychometric instruments. The primary endpoint 
was the improvement in quality of life measured by change in Psychological General Well Being 
scale (PGWB) after 36 weeks of treatment. Results: At 36 weeks of treatment with ustekinumab, 
patients reported marked reduction in occupational impairment as demonstrated by 22% improve-
ment in PGWB compared to baseline. Improvement in PGWB and other psychometric scale scores 
correlated with improvement of PASI scores, with 78.9% of patients achieving PASI 75 at week 
36. Discussion: Following 36 weeks of treatment with ustekinumab, psychological well-being in 
psoriasis subjects improved tremendously in accordance with improvement of cutaneous lesions. 
These results validate the merit of effective dermatological care for patients with psoriasis in order 
to improve the psychological well-being and quality of life in these patients.    
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Investigation of the effects of induced perspiration on pruritus
LA Nattkemper,1,2 R Valdes,1,2 H Lee1 and G Yosipovitch1,2 1 Dermatology, Temple 
University, Philadelphia, PA and 2 Temple Itch Center, Temple University, Philadelphia, PA
Perspiration has been reported by atopic dermatitis patients as a major factor for exacerbating itch 
intensity. However, the association between sweat and itch induction is unclear. In the current 
study, we evaluated the effects of induced perspiration on itch for healthy subjects and subjects with 
atopic dermatitis. We also investigated putative mechanisms by which such effects occur, including 
the potential influence of secreted neuropeptides and sweat pH. Sweat was induced using 0.5% 
pilocarpine nitrate, and itch was induced immediately after in the same location using cowhage 
spicules, which activate a non-histaminergic itch pathway through PAR2 receptors. Sweat produced 
during the itch sensation was collected and analyzed using ELISA for acetylcholine and opioids. In 
addition, three artificial sweat solutions with different pH levels were applied to the skin following 
itch induction. During each condition, psychophysical measurements of itch intensity were taken. 
Data will be presented on the effect of sweat on itch intensity as well as the levels of pro-pruritic 
mediators found in the sweat of atopics and healthy subjects.    
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Allogeneic stem cell transplant for CD8+ cytotoxic and γδ cutaneous T cell lymphomas
J Fraser,1 A Subtil,1 O Alpdogan,2 S Seropian,2 D Cooper,2 M Xu,2 M Girardi1 and F Foss2 1 
Dermatology, Yale School of Medicine, New Haven, CT and 2 Oncology, Yale School of 
Medicine, New Haven, CT
Cutaneous T cell lymphomas (CTCL) in which activated cytotoxic markers are expressed include 
primary cutaneous γδ T cell lymphoma (PCGD-TCL) and CD8+ aggressive epidermotropic T-cell 
lymphoma (CD8+ AETL) are associated with a poor prognosis and refractoriness to conventional 
therapies. We describe treatment and outcomes for 17 patients (12 PCGD-TCL, 5 CD8+ AETL). 
Median age was 40 (26-70) and 43 (19-58) in PCGD-TCL and CD8+ AETL, respectively. 2 PCGD-
TCL and 1 CD8+ AETL patients were on long term immunosuppression for renal transplant (2) 
or RA (1). All cases were CD3+ and all but 1 CD8+ AETL histologically demonstrated activated 
cytotoxic markers (TIA-1 or granzyme). All CD8+ AETL patients showed a CD8+CD4- phenotype; 
1 patient showed loss of CD5 and one loss of CD7. 4 of 8 PCGD-TCL patients who received CHOP 
partially responded, and 2 responded to salvage chemotherapy (pentostatin + doxil; gemcitabine). 
3 of 5 CD8+ AETL patients progressed with first line therapy. The median number of therapies was 
3 (0-9) in the PCGD-TCL and 9 (5-15) in the CD8+ group. 7 of 12 PCGD-TCL and 1 of 5 CD8+ 
AETL underwent allogeneic hematopoietic stem cell transplantation (SCT) and 2 PCGD-TCL patients 
underwent autoSCT. At a median of 4.5 years (range 0.1- 8.67), 7 PCGD are alive (3 alloSCT, 2 
autoSCT) and 5 CD8+ AETL are alive (1 NED, 1 alloSCT with recurrence, 3 on salvage regimens). 
The median survival following alloSCT was 2.73 years (range 0.24-5.68). Of 8 patients undergoing 
transplant, 2 died from infection, 1 relapsed, and one died from GVHD. Of the entire group of 17 
patients, 5 of 7 patients with PCGD-TCL who are alive are s/p auto (1) or allo (2) SCT while only 
one with CD8+ is s/p alloSCT, as all other patients failed to obtain CR with both standard and 
salvage chemotherapy regimens. Both PCGD-TCL and CD8+ AETL are treatment refractory and 
our experience suggests worse outcomes for AETL. Our data suggest that alloSCT may be curative 
in patients with PCGD-TCL who attain remission with chemotherapy.    
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Phenotypic analysis of PBMCs from IFN-alpha-treated melanoma patients: mechanisms of 
melanoma tumor containment
ML Tschernitz,1 B Reininger,1 K Rappersberger,2 M Neumann2 and G Stingl1 1 Department 
of Dermatology, Medical University of Vienna, Vienna, Austria and 2 Department of 
Dermatology, Rudolfstiftung, Vienna, Austria
Recombinant IFN-alpha is the only adjuvant treatment for stage II/III melanoma patients that was 
shown to increase disease-free and, when used at high doses, also overall survival. The effect of 
IFN-alpha is attributed to its direct antiproliferative and cytotoxic activity on melanoma cells and 
its indirect immuno-activating properties. Its exact mode of action, however, is not clear. We and 
others have previously shown that IFN-alpha induces the upregulation of the cytotoxic molecule 
TNF-related apoptosis-inducing ligand (TRAIL) on immune cells, which both in its membrane-bound 
and soluble form lyses tumor targets in vitro. In melanoma patients undergoing IFN-alpha treatment 
we now observed that TRAIL is significantly upregulated on peripheral blood NK cells, monocytes 
and, in some cases, also on dendritic cells (DCs), as assessed by flow cytometry. These changes 
were paralleled by an increase of soluble TRAIL in the serum (ELISA). Phenotypic analysis showed 
that plasmacytoid DCs of melanoma patients express higher levels of the activation markers CD40 
and CD86 when compared to healthy controls. Myeloid DCs, in contrast, exhibit elevated levels of 
CD62L, CCR6 and CXCR4, and a down-regulation of CCR7, compared to healthy controls. These 
changes were even more pronounced during IFN-alpha therapy, albeit not at statistically significant 
levels, and were consistent with phenotypic properties of DCs endowed with the ability to migrate 
into (tumor) tissue. Indeed, we observed a significant reduction in the relative frequency of myeloid 
DCs, but not plasmacytoid DCs, in the peripheral blood of patients receiving IFN-alpha when com-
pared to numbers obtained before treatment. The IFN-alpha-mediated reduction in myeloid DCs 
most likely does not involve cell death. Taken together our findings suggest that IFN-alpha mediated 
anti-melanoma activity involves multiple and diverse immunological mechanisms.    
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Diffuse erythema is a positive predictor of complete remission after alemtuzumab therapy 
for leukemic CTCL
R Watanabe, J Teague, DC Fisher, M Tawa, TS Kupper and R Clark Cutaneous Lymphoma 
Program, Dana-Farber Brigham and Women’s Cancer Center, Brookline, MA
Low dose alemtuzumab (LDA) is a highly effective, generally well tolerated therapy for refractory 
leukemic cutaneous T cell lymphoma (L-CTCL), producing complete remissions (CR) in 50% of 
patients. Because it depletes by ADCC, LDA kills only T cells that enter blood. We find clinical 
appearance can be used to discriminate complete responders from those with persistent and/or 
worsening skin disease. Initial clinical presentation was the strongest predictor of CR after LDA. 
13/17 patients presenting with diffuse erythema without superimposed plaques or tumors had CR 
and the remaining 4 had residual/emergent skin disease controllable by skin-directed therapies. In 
contrast, 0/6 patients presenting with discrete patches, plaques or tumors had CR after LDA. One 
responded to electron beam therapy and five had recurrent/progressive disease including two with 
large cell transformation. Malignant T cells with a migratory TCM phenotype (CCR7
+/L-selectin+) in 
blood and skin also correlated with LDA responsiveness. 8/10 patients with >80% TCM in blood 
had CR after LDA and 2 more after skin therapies. 4/6 patients with >80% TCM in skin cleared with 
LDA alone and 1 cleared with LDA plus skin directed therapy. In two patients with worsening skin 
disease, biopsies showed non-clonal, activated IFNγ-producing CD8 T cells, suggesting benign T 
cell inflammation. Initial clinical presentation was more predictive of response than complex cellular 
phenotyping of T cells from blood and skin. On a scientific level, diffuse erythema is likely caused 
by migrating T cells and only T cells that migrate into blood that are cleared by LDA. Fixed skin 
lesions are more likely to be caused by TRM, cells that escape LDA clearance by remaining long 
term in skin. Based on our clinical and scientific findings, we recommend the use of LDA with or 
without adjuvant skin directed therapy in patients with diffuse cutaneous erythema but we caution 
against its use in patients with pre-existing plaques and/or tumors.    
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A multicenter, open-label, randomized, phase I/II study evaluating the safety and efficacy of 
low-dose (12 Gy) total skin electron beam therapy (TSEBT) combined with vorinostat versus 
low-dose TSEBT monotherapy in patients with mycosis fungoides
S Bashey,1 M Tavallaee,1 M Duvic,2 B Dabaja,2 R Talpur,2 L Wilson,3 M Girardi,3 F Foss,3 
S Li,1 S Rozati,1 L Million,1 R Hoppe1 and YH Kim1 1 Stanford U, Stanford, CA, 2 MDACC, 
Houston, TX and 3 Yale U, New Haven, CT
We have shown previously that the use of low dose total skin electron beam therapy (TSEBT) 
produces responses that are efficient and reliable with a minimal toxicity profile in patients with 
mycosis fungoides (MF). This prospective, open-label, randomized clinical trial was designed to 
determine if vorinostat (Vor), a potential radiation sensitizer, combined with low-dose TSEBT offers 
a superior clinical benefit when compared to low-dose TSEBT alone. A total of 28, stage IB-IIIB 
patients were stratified by stage and institution and randomized to receive TSEBT ± Vor. All patients 
received 12 Gy TSEBT over 3 wks. Patients on the Vor arm (n=14) took 400 mg daily for a total of 
8 wks from start of TSEBT. Primary efficacy endpoint was the complete response rate (CR) at wk 8. 
The clinical response rate (RR) in the TSEBT arm was 86% (12/14) with 5 CRs compared to a RR of 
93% (13/14) with 3 CRs in the Vor arm. Median time to response was 7 wks for TSEBT arm and 6 
wks in the Vor arm. A new clinical endpoint, the duration of clinical benefit (DOCB), was defined 
as the duration from response to initiation of next “TSEBT-equivalent treatment” or progressive 
disease. Median DOCB was 125 wks for TSEBT and 28 wks for Vor arm (p=0.03). Median maximal 
mSWAT reduction was 95% (TSEBT) and 96% (Vor), obtained at a median of 10 wks and 8 wks, 
respectively. Most common adverse events (AEs) on either study arm included: alopecia, extremity 
pain, fatigue, and radiation dermatitis. Fatigue was experienced more among Vor arm (p=0.02). 
There were no grade 3 or higher AEs in either arm. Our results support that the combination of Vor 
with low-dose TSEBT is a safe treatment option for patients with MF however no apparent overall 
clinical benefit is demonstrated by adding Vor.    
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Decreased collagen quantity rather than quality is more predictive of cutaneous manifesta-
tions in osteogenesis imperfecta
HB Pasieka,1 D Kuhn,1 AL Chien,1 J Shapiro2 and S Kang1 1 Dermatology, Johns Hopkins 
University, Baltimore, MD and 2 Osteogenesis Imperfecta, Kennedy Krieger Institute, 
Baltimore, MD
Osteogenesis imperfecta (OI) is a heterogeneous connective tissue disorder involving type I col-
lagen. Specifically, type I OI is a milder disease associated with insufficient production of normal 
collagen (quantity), whereas type III OI is a more severe variant due to mutations in type I collagen 
gene (quality) but in sufficient amount. Clinically, skin thinness, translucency, easy bruising, and 
impaired elasticity are commonly reported to be associated with OI; however, little is known 
about the frequency or severity of these findings. The aims of this study were to characterize skin 
changes in patients with OI and to ascertain whether OI subtypes influence cutaneous phenotypes. 
We conducted a web-based, self-administered patient survey by creating a series of dermatologic 
questions for registrants in the national OI Registry. Of the 302 respondents over the age of 18, 
220 knew their OI type. Using adult standing height of <48 inches as a proxy for severity of bone 
disease, the respondents’ OI was classified as “severe” (n=28) or “not severe” (n=192). Regression 
analysis revealed that type I OI was associated with easy bruising (p<0.01) and less severe bone 
disease (p<0.01). Type III OI was negatively associated with easy bruising (p<0.01) and poor wound 
healing (p<0.05), but positively associated with more severe bone disease (p<0.01). No significant 
relationships were found between OI severity and acne scars, striae, keloid, rosacea, skin cancer 
and anetoderma. None reported elastosis perforans serpiginosa. Our preliminary data demonstrates 
that type I OI patients, with impaired collagen production (quantity), had milder skeletal disease, 
but reported more skin manifestations. In contrast, type III OI patients, with structural defect in 
collagen (quality) but not in amount, were found to have more severe bone disease, but with fewer 
skin features of OI. Therefore, for normal human skin functioning, having enough type I collagen 
appears to be more important than its purity.    
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Improvement in atrophic acne scars by topical adapalene 0.3% gel is associated with induc-
tion of procollagen I and III
M Patel,1 S Leung,1 AL Chien,1 H Xu,1 F Audibert,2 N Kerrouche,2 M Rueda2 and S Kang1 
1 Dermatology, Johns Hopkins University, Baltimore, MD and 2 Galderma R&D, Sophia 
Antipolis, France
Finding non-procedural medical treatments for atrophic scars from acne has proven challenging, in 
part due to persistent dermal matrix loss. As studies have shown that topical retinoids improve the 
appearance of facial wrinkles by stimulating collagen production, we hypothesized that a retinoid 
intervention would have similar molecular effects on atrophic acne scars. We conducted a phase 
II, single-center, open-label pilot study in which 20 subjects (11 men, 9 women; age 18-50 years) 
with moderate to severe facial atrophic acne scars were treated for 24 weeks with 0.3% adapalene 
gel (once daily for the first 4 weeks and then twice daily for the following 20 weeks). We previously 
reported that clinical response observed in this study was significant: 56% of patients had a 1 to 2 
grade improvement from baseline and 88% reported satisfaction with the outcome. In light of posi-
tive efficacy and patient satisfaction data, a gene expression microarray and immunohistochemical 
studies were performed on a subset of skin biopsy samples collected at baseline and end of study. 
Gene expression level differences between wk 0 and wk 24 were significant for COL1A1 and 
COL3A1 (fold change ≥ 1.5; p <0.05). Retinoid responsive CRABP-2 gene was significantly upreg-
ulated (>50%; p <0.05). To validate changes in gene expression, immunostaining was used to detect 
protein expression of procollagen-1 and collagen-3. Each stain was analyzed with image analysis 
software that uses automated algorithms to quantify positive staining intensity in the dermoepidermal 
junction. Although not statistically significant, but consistent with the RNA data, staining intensity 
for both procollagen-1 and collagen-3 increased by 15% (n=8, p=0.4) and 58% (n=8, p=0.07), 
respectively. As wrinkles and atrophic scars are linked to degraded collagen loss, these data suggest 
that daily retinoid use can enhance collagen synthesis and may lead to clinical improvement.   
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Dupilumab improved all domains of Eczema Area and Severity Index (EASI) and 5-D pruritus 
scale in adults with atopic dermatitis in a phase 2 study
J Hamilton,1 H Ren,1 SP Weinstein,1 G Pirozzi,2 N Graham1 and A Radin1 1 Regeneron, 
Tarrytown, NY and 2 Sanofi, Bridgewater, NJ
Dupilumab, a fully human monoclonal antibody against IL-4 receptor-α, blocks IL-4 and IL-13 
signaling and inhibits Th2 pathways implicated in atopic dermatitis (AD). In a double-blind, pla-
cebo (PBO)-controlled trial in adults (N=109) with moderate-to-severe AD, weekly subcutaneous 
dupilumab 300 mg vs PBO for 12 wks resulted in greater improvements from baseline to wk 12 
in disease activity (change in EASI -74.0% vs -23.3%; P<.0001), and pruritus (change on 5-D 
Pruritus Scale [5D] -7.4 vs -1.9; P<.0001). ANCOVA with last-observation-carried-forward (LOCF) 
and mixed-effect model of repeated measures (MMRM) were used to analyze change to wk 12 on 
domains of EASI and 5D. Using LOCF, mean±SD improvement was greater with dupilumab on 
all EASI domains including Erythema (-67.3%±31.4% vs -25.8%±50.4%), Infiltration/Papulation 
(-73.6%±27.2% vs -21.4%±53.6%), Excoriation (-80.0%±28.8% vs 12.8%±66.8%), and Licheni-
fication (-74.1%±31.2% vs -24.1%±50.4%); LS mean difference significantly favored dupilumab 
(P<.0001 for all EASI items), with consistent results favoring dupilumab using MMRM (all P<.0001). 
LOCF analysis also showed significant absolute and % improvement with dupilumab vs PBO on 
all 5D domains: Degree, -1.4±0.9 (-36.6%±22.9%) vs 0.3±1.0 ( 5.9%±30.9%); Direction, -1.5±1.4 
(-32.7%±32.0%) vs -0.5±1.2 (-10.1%±30.5%); Disability, 1.7±1.3 (-41.4%±29.6%) vs -0.5±1.2 
(-11.6%±30.5%); Distribution, -1.4±1.2 ( 32.7%±32.0%) vs -0.3±0.8 (-5.5%±22.2%); and Dura-
tion, -1.4±1.0 (-43.1%±30.9%) vs 0.4±1.3 ( 8.1%±39.8%). MMRM results were consistent with 
the LOCF analyses; in both, LS mean differences for all 5D domains favored dupilumab (P<.05). 
Frequent adverse events (AEs) reported more with dupilumab vs PBO were injection site reactions 
(18.2% vs 9.3%) and nasopharyngitis (40.0% vs 18.5%); dupilumab in this 12-wk study had fewer 
skin infections (5.5% vs 25.9%) and serious AEs (1.8% vs 13.0%) vs PBO. Dupilumab improved 
objective signs of AD disease activity, AD-associated pruritus and was generally well tolerated.   
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Relative to obesity, negative effect of hidradenitis suppurativa is enhanced on quality of life 
in super obese patients
EB Koo,1,2 M Enamandram1,2 and AB Kimball1,2 1 Harvard Medical School, Boston, MA and 
2 Dermatology, Massachusetts General Hospital, Boston, MA
Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory disease characterized by painful, 
purulent nodules, and hypertrophic scarring of the skin. It is often associated with obesity, which 
likely adds to the morbidity caused by HS. To better understand the effect of each condition on the 
psychosocial burden of patients with both HS and obesity, we attempted to quantify the relative 
quality-of-life impairment associated with each disease. Via self-administered questionnaire, patients 
reported how many years of a 50-year remaining life expectancy they were willing to give up for 
HS-free living and obesity-free living; a time trade off utility score (TTO) was then calculated where 
1.00 meant patients were not willing to trade any years for disease-free life and 0.00 meant death 
(i.e. give up all years of life with disease). Patients (n=17) were 23.5‰ male and 76.5‰ female, 
with an average age of 33.9 years, BMI of 41.9, and physician global assessment (PGA) and Hurley 
scores of 3.4 and 2.5, respectively. Three patientswere of class I (BMI 30-34.9) with mean PGA 3.67 
and Hurley 2.33, 7 of class II (BMI 35-39.9) with mean PGA 2.71 and Hurley 2.29, and 7 of class III 
obesity (BMI^40) with mean PGA 3.86 and Hurley 2.86. TTO for HS and obesity in class I patients 
were the same at 0.47. Class II patients were willing to give up more years to live without obesity 
(TTO=0.21) than without HS (TTO= 0.34), respectively. Conversely, class III individuals were willing 
to give up more years to live without HS (TTO= 0.07) than without obesity (TTO= 0.17). Patients 
of the higher obesity classes were willing to give up more years, overall, for disease-free living. 
There was no correlation between TTO and HS severity in this small sample. This preliminary data 
shows that patients with higher BMIs, despite the severity of their condition, are more affected by 
HS regardless of disease severity, suggesting HS in super obese individuals augments the morbidity 
associated with this disease.    
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Condylomata acuminata: Novel treatment by topical ingenol mebutate
RE Schopf Dermatology, Johannes Gutenberg Univ., Mainz, Germany
Condylomata acuminata (genital warts, GW) are the most common form of sexually transmitted 
disease worldwide affecting 1-2% of the population. In 90%, GW are caused by human papilloma 
virus (HPV) type 6, type 11 to a lesser extent; HPV types 16 and 18 may lead to cervical cancer. 
Topical treatment includes podophyllotoxin, imiquimod, sincatechins, trichloroacetic acid, cryo-
therapy, cautery, scissor excision or CO2-laser all of which are unsatisfactory due to duration of 
treatment, pain, skin erosions, scarring and treatment failure in about 50% necessitating the need for 
novel treatment. For the first time, we have treated GW with ingenol mebutate (IM), a diterpen ester 
from the latex sap of the plant Euphorbia peplus exerting chemoablative and immunostimulatory 
properties being approved for treatment of actinic keratoses. IM lyses cytoplasmic and mitochon-
drial membranes leading to a loss of membrane potential, to cell necrosis, inflammatory cytokines, 
infiltration of neutrophils and destruction of treated tissue. Diagnosis of GW was ascertained by 
histopathology and polymerase-chain reaction (PCR) for HPV, all cases expressed HPV-type 6. In 
an investigator initiated, placebo (gel base) controlled trial we have treated 2 female and 8 male 
patients with GW persisting for at least 6 months. We applied ingenol mebutate gel (150 or 500 
microgram/gram) once only to the genital warts. After 3 to 7 days the genital warts were healed in 
all cases as documented by photography. Applying the gel base alone had no effect on the GW. 
Side effects did include a burning sensation in the treatment area that lasted no longer than from 
day 1 to 2. There was no recurrence of GW up to 3 months; follow-up examinations are underway. 
Our findings in 10 patients for the first time indicate that a single application of ingenol mebutate 
gel is efficacious for treatment of HPV-induced genital warts. We conclude that ingenol mebutate 
may become a novel treatment for condylomata acuminata.    
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Chilean oral grape seed antioxidants reduce redness in rosacea
PR Figueroa Dermatology, World Dermatology Institute, Santiago, Chile
Erythema and redness is a hallmark of rosacea and difficult to treat. In Chile ultraviolet radiation 
is very high. This high ultraviolet radiation induces an increased production of antioxidants by the 
grapevine. The purpose of the study is to explore the use of oral antioxidants derived from Chilean 
grape seeds in patients with rosacea in order to reduce or prevent symptoms of this disease. The 
study is a case and control study. The group consisted of 10 rosacea patients. Patients were given 
a capsule of 500 mg of grape seed antioxidants composed of procyanidines and resveratrol twice 
a day. A subjective assessment and a colorimetric measurement using a Skin ColorMeter (from 
Cortex) were done at the beginning and at 30 days of treatment. A substantial improvement was 
noticed in all the subjects. Patients noticed a reduction in discomfort and redness. A colorimetric 
measuring showed a 20 % reduction in erythema ( p= 001) as compared with the same patients 
not using oral antioxidants. Oral grape seed antioxidants compose of procyanidines and resveratrol 
may offer relief to rosacea patients.    
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Clinical presentation and management of scleredema: An academic medical center experience
S Girouard, AN Femia, A Eastham and R Vleugels Dermatology, Brigham and Women’s 
Hospital and Harvard Medical School, Boston, MA
Scleredema is a rare dermal mucinosis characterized by induration that typically affects the upper 
back, neck, and upper extremities. Three types of scleredema are recognized. Type 1 is associated 
with febrile respiratory illness, usually of streptococcal etiology, and generally self resolves. Type 
2 is associated with monoclonal gammopathy, and type 3 occurs in the setting of diabetes mellitus. 
Both types 2 and 3 are characteristically chronic and potentially debilitating, with resulting mor-
bidity due to limitation in range of motion. Treatment is challenging and there are no well-estab-
lished therapeutic regimens. Utilizing the Partners Healthcare Research Patient Data Registry, we 
reviewed the medical records of all patients diagnosed with scleredema between 2002 and 2013. 
Nine patients were identified. Of the 9 patients, 1 had type 1 disease, 1 had type 2 disease, and 
the remaining 7 had type 3 disease. Six of 9 patients were male, and the mean age was 57 years 
old (± 12.8; range 35-77). 44.4% were Caucasian, 44.4% Black, and 11.1% did not identify their 
race. Limited therapeutic options were offered. One patient received a course of oral corticosteroids 
without improvement, and another applied topical steroids with no improvement. Two patients 
were lost to follow-up; one had been prescribed topical steroids, and the other physical therapy. 
Three patients were not offered any treatment. Two patients, a female with type 2 disease refrac-
tory to thalidomide and extracorporeal photophoresis and a previously untreated male with type 
3 disease, received therapy with intravenous immunoglobulin (IVIG). Both patients experienced 
notable improvement in induration and range of motion, and IVIG was well tolerated. These data 
suggest that IVIG may be an effective treatment for both type 2 and 3 scleredema. Given its chronic 
nature and the potential for debilitating functional impairment, additional investigation is warranted 
to identify optimal therapeutic strategies for scleredema.    
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Gene expression profiling in alopecia areata reveals distinct molecular signatures
A Jabbari,1 JE Cerise,1 J Mackay-Wiggan,1 M Duvic,2 MK Hordinsky,3 VH Price,4 D Norris,8 
R Clynes1,5,6 and A Christiano1,7 1 Dermatology, Columbia University, New York, NY, 
2 Dermatology, MD Anderson Cancer Center, Houston, TX, 3 Dermatology, University 
of Minnesota, Minneapolis, MN, 4 Dermatology, UCSF, San Francisco, CA, 5 Internal 
Medicine, Columbia University, New York, NY, 6 Pathology, Columbia University, 
New York, NY, 7 Genetics & Development, Columbia University, New York, NY and 8 
Dermatology, University of Colorado, Denver, CO
Alopecia areata (AA) is a common autoimmune disease manifesting with hair loss that ranges from 
spontaneously resolving patches (patchy AA, AAP) to lifelong total scalp (alopecia totalis, AT) or total 
body (alopecia universalis, AU) involvement. Despite its high incidence and enormous psychosocial 
burden, research into AA has lagged behind that of other autoimmune diseases. Obstacles to identi-
fying efficacious treatments for AA include the lack of understanding of the pathogenic mechanisms 
that are critical to the disease process, as well as an incomplete understanding of the cellular and 
molecular factors present in affected lesions. In order to identify molecular gene expression signa-
tures that correlate with disease, we conducted a comprehensive expression analysis of affected 
scalp skin of patients with AA. Scalp biopsies from approximately 20 subjects with AAP, 20 subjects 
with either AT or AU, and 20 healthy control subjects were obtained from lesional/perilesional scalp 
skin of AA patients and normal scalp skin of healthy controls. Additionally, non-lesional samples 
were taken from patients with AAP. RNA was extracted from these samples and microarray anal-
ysis was performed. Further, GEDI (Gene Expression Dynamics Inspector) was used as a powerful 
computational tool that allowed us to correlate several predominant gene expression signatures with 
disease severity. Our findings uncovered new insights into distinct molecular signatures associated 
wtih the different forms of AA, and provide a framework for identifying biomarkers of disease and 
novel potential therapeutic targets.    
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Risk factors for new onset of psoriatic arthritis in a prospective cohort with psoriasis
CF Rosen,1,2 L Eder,2 A Thavaneswaran,2 V Chandran,2 A Haddad2 and DD Gladman2 1 
Medicine (Dermatology), University of Toronto, Toronto, ON, Canada and 2 University of 
Toronto Psoriatic Arthritis Clinic, Centre for Prognostic Studies in the Rheumatic Diseases, 
University of Toronto, Toronto, ON, Canada
To study patients with new onset of psoriatic arthritis (PsA), the Toronto Psoriasis Cohort (TPC) 
was established in 2006. Patients with psoriasis without inflammatory arthritis or spondyloarthritis 
(PsC), as determined by a rheumatologist, are enrolled and assessed annually to determine if they 
have developed PsA. 593 patients have enrolled in the TPC. To date, 40 patients have developed 
PsA. To compare these patients to those without arthritis, a 1:2 match was carried out. The 40 
patients with new onset PsA were each matched by the duration of psoriasis at their last visit to 2 
patients from the TPC who did not have arthritis when last assessed. The Wilcoxon test was used 
to test continuous variables and the McNemar test was used for categorical variables. The groups 
had a similar percentage of men (new onset PsA: 57.5% vs. PsC: 66.3%).The median (IQR) age 
at diagnosis of PsC was the same in the new onset PsA group as the PsC controls (26 (26) vs. 25 
(19) p=0.39). The percentage of those who ever smoked was the same (65.8%). There were similar 
numbers of patients with diabetes (5.1% vs. 5.0%) and a history of heart disease or hypertension 
(38.2%, new onset PsA vs. 25% in PsC ). There was no statistically significant difference in the use 
of DMARDs or biologic agents. There was a statistically significant difference in the PASI score 
measured at the last visit, with a higher median (IQR) PASI score noted in those who developed PsA; 
4 (9.2) for those with new onset PsA and 3.5 (4.5) for those with PsC (p=0.02). More of the patients 
who developed PsA had nail involvement, 72.5% of those with PsA, compared to 53.8% of those 
with PsC, p <0.0001. The median (IQR) BMI was found to be greater in those who developed PsA, 
29.7 (9.7) vs. 27.1 (5.5) in those with PsC alone. Thus, the risk of developing PsA in patients with 
psoriasis appears to be greater in those with a higher PASI score, nail disease and a higher BMI.   
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Integration of serum markers with gene expression signatures for use as an Alopecia Areata 
Disease Activity Index (ALADIN)
JE Cerise,1 A de Jong,1 A Jabbari,1 M Duvic,5 M Hordinsky,6 D Norris,7 V Price,8 J Mackay-
Wiggan,1 JL Januzzi,9 R Clynes1,2,3 and AM Christiano1,4 1 Dermatology, Columbia Univ, NY, 
NY, 2 Internal Medicine, Columbia Univ, NY, NY, 3 Pathology, Columbia Univ, NY, NY, 4 
Genetics & Development, Columbia Univ, NY, NY, 5 Dermatology, MD Anderson Cancer 
Center, Houston, TX, 6 Dermatology, Univ of Minnesota, Minneapolis, MN, 7 Dermatology, 
Univ of Colorado, Denver, CO, 8 Dermatology, UCSF, San Francisco, CA and 9 Medicine, 
Harvard Medical School, Boston, MA
Alopecia Areata (AA) is a highly prevalent autoimmune disease in which the hair follicle is attacked 
by cytotoxic T lymphocytes. The accessibility of the target organ within skin biopsies has provided 
the opportunity to develop a novel disease activity score based on quantitative composite gene 
expression signatures. Using both Affymetrix microarrays and RNA-Seq data analyzed using Inge-
nuity Systems IPA, we identified three striking gene expression signatures in total skin from both 
human AA and the C3H-HeJ mouse, namely, an IFN-γ response (IFN) signature, a cytotoxic T cell 
(CTL) signature, and a hair keratin (KER) signature. To generate a functional biomarker from the AA 
transcriptome, we developed the Alopecia Areata Disease Activity Index (ALADIN), a three-dimen-
sional quantitative composite score. ALADIN was derived from expression levels of representative 
genes from the IFN, CTL and KER signatures to generate a measure of the distance of AA transcrip-
tional levels from a baseline obtained from the scalp skin of healthy individuals. In our studies of 
mouse AA, we demonstrated that ALADIN scores provide a quantitative measure of pharmacologic 
prevention and treatment of disease. Here, we expanded ALADIN by integrating a panel of cytokines 
and chemokines and identified promising candidate markers whose concentrations are significantly 
increased in AA. ALADIN is currently being assessed in cross-sectional studies to validate its utility in 
human AA. We anticipate that ALADIN will be useful as a dynamic functional biomarker to stratify 
and longitudinally track patients enrolled in observational and interventional clinical studies of AA.   
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Cutaneous nerve function in healthy control subjects classified by Fitzpatrick skin type
L Swanson,1 E Hurliman,1 K Kane,1 J Connett2 and M Hordinsky1 1 Dermatology, University 
of Minnesota, Minneapolis, MN and 2 Clinical and Translational Science Institute 
Biostatistical Design and Analysis Cente, University of Minnesota, Minneapolis, MN
Changes in cutaneous nerve function have been found in many dermatologic diseases, including 
immune mediated scalp diseases, that affect small fibers of the peripheral nervous system, . Pain 
and itch are commonly associated with alopecia areata (AA) and lichen plano pilaris (LPP) and 
recent studies in our department have demonstrated that AA and LPP patients have a distorted 
organization of scalp nerve fibers. Different ethnic groups have been evaluated to study pain and 
sensation thresholds. However, it remains unknown whether skin pigmentation impacts cutaneous 
nerve fiber function. In this study, we aimed to assess epidermal nerve function in relation to 
Fitzpatrick skin type. 116 healthy controls across the six skin types underwent Current Perception 
Threshold (CPT) testing using the NEUROMETER® CPT stimulator. Due to ongoing data collection, 
skin types 5 and 6 were excluded from the current analysis. The Neurometer generates current at 
frequencies of 2000, 250, and 5 Hz to stimulate the A beta, A delta, and C nerve fibers respec-
tively which transmit touch, pain, temperature, and itch. CPT testing was completed on the index 
finger and the ophiasis and frontotemporal regions of the scalp. A CPT value is obtained for each 
frequency, which corresponds to the minimum amount of electrical stimulus needed to conduct 
sensation. For each site and frequency combination, difference in mean CPT was assessed through 
an analysis of variance. ANOVA and pairwise t-tests adjusted for multiple comparisons were done 
to evaluate for any significant group differences. Results show skin type specific CPT thresholds 
at the ophiasis region across A delta and C nerve fiber types. These findings provide data about 
normal cutaneous nerve fiber function including previously unknown thresholds for the scalp. In 
addition, these results point to the importance to stratify participants according to skin type when 
evaluating cutaneous nerve fiber function.    
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Expression of oxidative stress, cellular senescence and skin structure-related genes affected 
by aging in vivo is reversed by galactomyces ferment filtrate in vitro
R Osborne,1 M Alora Palli,2 M Tamura,1 J Tiesman,1 K Toyama,3 C Soh3 and AB Kimball2 
1 P&G Beauty, The Procter & Gamble Company, Cincinnati, OH, 2 Massachusetts General 
Hospital and Harvard Medical School, Boston, MA and 3 SK2, Kobe, Japan
Gene expression pathways affected by intrinsic and photoaging include protection from oxidative 
stress, induction of cellular senescence, and epidermal and dermal structure. In order to evaluate the 
onset of these changes with age, a large clinical study was conducted to obtain skin samples from 
20 to 70 year old female volunteers. Skin samples from both photoexposed (face, outer forearm) 
and photoprotected (buttocks) body sites were obtained from approximately 25 subjects in each 
age decile. RNA was extracted from full thickness biopsies and from laser capture microdissected 
skin samples, and transcriptomics profiling was conducted using Affymetrix GeneTitan® arrays. 
Biological pathway analysis revealed a decrease in expression of genes associated with protection 
from oxidative stress that commenced at the earliest age transition evaluated (20s to 30s) in both 
photoexposed (outer forearm) and photoprotected (buttocks) body sites, and progressed in later 
ages. These changes included genes associated with glutathione synthesis, e.g., GCLM, and those 
involved in cycling of glutathione and NADP+/NADPH, e.g., G6PD, GPD and IDH1. In contrast, 
genes associated with cellular senescence, such as p16INK4a, FAS and IL6ST, commenced a pro-
gressive increase in expression in older (40+) age groups, in parallel with decreased expression of 
permeability barrier including lamellar enzyme genes. Parallel studies with human skin-derived 
keratinocytes and fibroblasts suggest these age-related biomarker changes were reversed by treat-
ment with galactomyces ferment filtrate (GFF) in vitro. These results suggest that decline in antiox-
idant pathways in younger decades may be related to accumulated aging factors expressed in later 
years, such as cellular senescence and compromised skin structure, and exposure to ingredients 
such as GFF may be able to partially compensate for these changes.    
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Naftifine hydrochloride gel 2%: An effective topical treatment for moccasin-type tinea pedis
AB Fleischer, A Verma, B Olayinka and B Hardas Merz Pharmaceuticals, LLC, Greensboro, 
NC
Background: Well-controlled clinical data on topical antifungal therapy for moccasin-type tinea 
pedis is limited. The objective is to present data from two pooled randomized, vehicle-controlled 
studies that prospectively evaluated efficacy of once daily topical naftifine gel 2% and vehicle at 
end of treatment (week 2) and at 4 weeks post-treatment in subjects with moccasin-type tinea pedis. 
Methods: At visit 1, subjects were randomized to naftifine gel 2% or vehicle groups and subjects 
underwent baseline mycology culture and symptom (erythema, scaling, and pruritus) severity grad-
ing. Naftifine gel 2% and vehicle treatment were applied once daily for 2 weeks and the subjects 
returned at weeks 2 and 6 for efficacy evaluation (mycology culture and grading of symptom 
severity). 1174 subjects were recruited with interdigital-type tinea pedis with or without moccasin 
infection. 674 subjects had interdigital-type presentation while 500 subjects had moccasin infection 
in addition to the interdigital presentation. All 1174 subjects with interdigital presentation satisfied 
the inclusion criteria of a minimum of moderate erythema and scaling, and mild pruritus. Of the 
500 subjects who had moccasin presentation, 380 satisfied the same inclusion criteria as mentioned 
above. Since data was analyzed as observed cases, only 339 subjects had data available for analysis 
of efficacy. Mycologic cure is defined as a negative dermatophyte culture and KOH, treatment 
effectiveness is defined as mycologic cure and symptom severity scores of 0 or 1, and complete 
cure is defined as mycologic cure and symptoms severity scores of 0. Results: At week 6, the cure 
rates in the naftifine arm vs. the vehicle were statistically higher (p<0.0001) for mycological cure 
rate (65.8% vs. 7.8%), treatment effectiveness (51.4% vs. 4.4%), and complete cure rate (19.2% vs 
0.9%). Conclusions: Two weeks application of topical naftifine gel 2% is an effective monotherapy 
treatment for moccasin-type tinea pedis.    
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Maximal use systemic exposure (MUSE) study evaluating AN2728, a novel boron-based small 
molecule, for the treatment of pediatric and adolescent subjects with mild-to-moderate atopic 
dermatitis
L Kircik,1 L Zane2 and AA Hebert3 1 DermResearch, PLLC, Louisville, KY, 2 Anacor 
Pharmaceuticals, Inc, Palo Alto, CA and 3 Dermatology Clinical Research Unit, University of 
TX Health Science Center, Houston, TX
AN2728 is a novel boron-based compound. It inhibits phosphodiesterase-4 activity and reduces 
pro-inflammatory cytokine production that may be associated with atopic dermatitis (AD). This 
open-label, maximal use study evaluated the systemic exposure, pharmacokinetics, and safety of 
AN2728 Ointment, 2% applied twice daily for 28 days for the treatment of AD in children and 
adolescents (N=34) with mild-to-moderate AD based on the Investigator’s Static Global Assessment 
(ISGA) scale. Three patient cohorts were based on age and minimum percent of treatable body 
surface area (%BSA) affected: 2-5 years old (≥35%), 6-11 years old (≥35%) and 12-17 years old 
(≥25%). During 8-day pharmacokinetic assessment period, subjects were dosed in the clinic; dosing 
was performed at home thereafter. AD severity was measured using ISGA (0, clear to 4, severe), signs/
symptoms score (0, none to 3, severe) and %BSA affected. At Day 29, 65% of subjects achieved 
ISGA Clear/Almost Clear scores, 47% of subjects achieved Clear/Almost Clear scores with >2-grade 
improvement. Marked reductions were observed for all individual signs/symptoms of AD (pruritus, 
erythema, lichenification, excoriation, exudation). Mean pruritus scores improved by approximately 
60% from baseline as early as treatment day 5. Mean %BSA affected decreased by a mean of 78% 
across all subjects after 4 weeks of treatment. Common treatment-related adverse events were 
application site reactions (occurring in 12 subjects) which generally were mild or moderate in 
severity and resolved spontaneously. One patient withdrew from the study due to application site 
pain. Pharmacokinetic results demonstrated low blood levels of AN2728 similar to those previously 
observed in adults after adjusting for %BSA treated. AN2728 Ointment, 2% may be safe and effective 
in subjects 2 years of age and older with mild-to-moderate AD.    
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Analysis of imiquimod 5% cream vs tazarotene 0.1% for the treatment of lentigo maligna
N Blickenstaff,1,3 S Dowdle,1 M Hyde1,2 and G Bowen1,2 1 Dermatology, University of Utah 
SOM, Salt Lake City, UT, 2 Melanoma and Cutaneous Oncology Program, Huntsman Cancer 
Institute, Salt Lake City, UT and 3 Dermatology, University of California San Francisco, San 
Francisco, CA
The aim of this study was to determine if response rates of lentigo maligna (LM) to imiquimod 
5% cream could be improved by the addition of a topical retinoid. A retrospective review of 292 
patients with biopsy confirmed LM was conducted. Patients with LM treated with imiquimod alone 
were compared to patients treated with imiquimod plus a topical retinoid. Overall, 188 patients 
with 194 lesions received imiquimod 5% cream five days a week for one to three months versus 
94 patients with 98 lesions who received imiquimod on the same schedule, plus tazarotene 0.1% 
gel twice a week. Following topical therapy all patients underwent staged excisions with Melan-A 
immunostaining on frozen sections to confirm negative margins. The main outcome measure was the 
presence of residual LM at the time of staged surgical excision. Results demonstrated no difference 
between the monotherapy treatment group and the dual therapy treatment group. Inflammation 
scores were assigned to patients according to the degree of inflammation observed and scaled from 
0-3 where; 0 = no inflammation, 1= mild erythema, 2 = moderate erythema, 3 = severe erythema/
erosion. Treatment was given for 1-3 months depending on the degree of inflammation observed. 
Patients who achieved inflammatory scores of 2 or 3 were 2.8 times more likely to be clear of 
tumor at the time of surgery than those who did not achieve significant inflammation (p=.002). 
Patients with significant inflammation had decreased defect sizes after excision and required fewer 
stages to achieve clear margins (p=0.023, p=0.015). The rate of recurrence was 1.4% (n=4) at an 
average follow-up of 43 months. This data suggests that the addition of topical tazarotene to 5% 
imiquimod therapy does not increase clearance rates of LM. However, increased inflammation with 
topical therapy seems to lessen surgical defect size and the number of required stages, and improve 
clearance and recurrence rates.    
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A pilot study evaluating biomarker development for drug-induced chronic eczematous erup-
tions of aging individuals
G Coman, N Blickenstaff and E Summers Department of Dermatology, University of Utah, 
Salt Lake City, UT
The management of drug-induced chronic eczematous eruptions of aging (CEEA) individuals would 
be greatly facilitated by a biomarker for drug class-specific CEEA. We chose to perform a pilot study 
to examine the feasibility of using in-vitro, drug-specific T cell memory responses as a biomarker 
for drug-induced CEEA. It is believed that CEEA can result from drug hypersensitivity reaction to 
both calcium channel blocker medications (CCB) and hydrochlorothiazide (HCTZ). A total of 9 
study subjects and 3 control subjects were enrolled. In-vitro drug antigen-induced lymphocyte 
proliferation assays and ELISA-determined cytokine release assays (IL-2, IL-2 receptor, IL-12, IFN γ, 
IL-4, IL-5, IL-10, IL-13, IL-1β, IL-6, IL-8, and tumor necrosis factor) were performed before and after 
HCTZ and/or CCB stimulation. All study and control subject blood samples failed to demonstrate 
any detectable enhanced lymphocyte proliferation or cytokine release to in-vitro CCBs or HCTZ 
challenge even when tested with a wide range of drug concentrations. In addition, none of the 9 
study subjects and 3 control subjects developed a positive patch test to CCBs and/or HCTZ. Our 
pilot study was designed to test the hypothesis that CEEA occurring in individuals taking CCB or 
HCTZ have circulating T cells that can be shown to display specific adaptive memory responses 
to the drug antigenic structures. We had also hoped to develop a clinically-useful in-vitro assay 
that could readily confirm a drug-specific cause for CEEA occurring in individuals on multiple 
medications. Unfortunately, our pilot study was unsuccessful in this regard.    
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Pivotal phase 3 safety and efficacy results of tavaborole (AN2690), a novel boron-based 
molecule for the topical treatment of toenail onychomycosis
BE Elewski,1 P Rich,2 O Wiltz,3 R Aly,4 L Zane5 and RF Gonzalez Soto6 1 University of 
Alabama, Birmingham, AL, 2 Oregon Dermatology and Research Center, Portland, OR, 3 
FXM Research Miramar, Miramar, FL, 4 University of California, San Francisco, CA, 5 Anacor 
Pharmaceuticals, Inc, Palo Alto, CA and 6 Centro de Dermatologia de Monterrey, Monterrey, 
Nuevo Leon, Mexico
Two double-blind, randomized, controlled, phase 3 trials assessed the efficacy and safety of 
Tavaborole Topical Solution, 5% applied once daily for treating toenail onychomycosis in 
adults with distal subungual onychomycosis involving 20–60% of the target great toenail. Study 
301 enrolled 594 subjects; Study 302 enrolled 604 subjects. All were randomized 2:1 to apply 
Tavaborole Topical Solution, 5% or vehicle once daily for 48 weeks. Nail debridement was not 
allowed. All endpoints were assessed at week 52. The primary endpoint was completely clear nail 
and negative mycology. Secondary endpoints included completely clear/almost clear nail (≤10% 
clinical involvement; negative mycology); and completely clear/almost clear nail with negative 
mycology. Tavaborole topical treatment met all endpoints (p≤0.001). For tavaborole vs vehicle, 
respectively, the complete cure rates were 6.5% vs 0.5% in Study 301 (p=0.001) and 9.1% vs 
1.5% in Study 302 (p<0.001). Negative mycology was obtained in 31.1% of Tavaborole- vs 7.2% 
of vehicle-treated subjects in Study 301 and 35.9% vs 12.2% of subjects in Study 302 (p<0.001 
for both). In both studies, the subjects with completely clear/almost clear nail was superior with 
tavaborole (26.1% vs 9.3% in Study 301; 27.5% vs 14.6% in Study 302 [P<0.0001 for both]). A 
superior outcome was observed for completely clear/almost clear nail with negative mycology 
with tavaborole (15.3% vs 1.5% in Study 301; 17.9% vs 3.9% for Study 302 [p<0.001 for both]). 
Tavaborole Topical Solution, 5% was well tolerated: no serious drug-related AEs were reported 
and a low rate of discontinuation as a result of AEs was observed. Tavaborole Topical Solution, 5% 
appears to be a safe and effective treatment for toenail onychomycosis.    
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Skin cleansers alter the skin’s ability to retain antimicrobial peptides and impact the survival 
of surface bacteria
AM Two,1 TR Hata,1 T Nakatsuji,1 PF Kotol,1 AB Coda,1 D Audish,1 L Du-Thumm,2 
L Arvanitidou2 and RL Gallo1 1 Division of Dermatology, University of California San Diego, 
San Diego, CA and 2 Research and Development, Colgate-Palmolive Company, Piscataway, 
NJ
Antimicrobial peptides (AMPs) such as LL-37 play an important role in the skin where they serve 
as one of the first lines of defense against invading pathogens. The interaction between AMPs 
and commercially available skin cleansers is unknown. In this study, we investigated the impact 
of commercially available detergents on LL-37 retention at the skin surface and the survival of 
commensal and non-commensal bacteria. First, LL-37 abundance was measured by ELISA on pig 
skin and in vivo on human skin after washing with different commercially available detergents. 
The abundance and diversity of skin resident commensal bacteria after washing human skin with 
different detergents were measured next using PCR and pyrosequencing of 16S ribosomal DNA. 
Finally, the survival of a non-commensal bacterium on the skin, group A streptococcus (GAS), was 
measured using colony-counting methods after washing with antimicrobial and control detergents. 
Our results showed that the amount of LL-37 present on skin differed significantly after washing with 
certain detergents. There was no statistically significant change in the abundance or diversity of 
commensal bacteria on the skin surface 24 hours after a single wash, however GAS survival on the 
skin differed significantly after washing with antimicrobial soap versus control soap. These findings 
suggest that the innate antimicrobial function of the skin surface can be altered by washing with 
detergents found in commercially available hand soaps.    
617
Roles of TLR7 in activation of NF-κB signaling of keratinocytes by imiquimod
Z Li, K Sohn, D Choi, M Im, C Kim and J Lee Chungnam National University, Daejeon, 
Republic of Korea
Imiquimod is known to exert its effects through Toll-like receptor 7 (TLR7) and/or TLR8, resulting 
in expression of proinflammatory cytokines and chemokines. Keratinocytes have not been reported 
to constitutively express TLR7 and TLR8, and the action of imiquimod is thought to be mediated by 
the adenine receptor, not TLR7 or TLR8. In this study, we revealed the expression of TLR7 in kera-
tinocytes after calcium-induced differentiation.After addition of calcium to cultured keratinocytes, 
the immunological responses induced by imiquimod, such as activation of NF-κB and induction 
of TNF-α and IL-8, were more rapid and stronger. In addition, imiquimod induced the expression 
TLR7, and acted synergistically with calcium to induce proinflammatory cytokines. We confirmed 
that the responses induced by imiquimod were significantly inhibited by microRNAs suppressing 
TLR7 expression.These results suggest that TLR7 expressed in keratinocytes play key roles in the 
activation of NF-κB signaling by imiquimod, and that their modulation in keratinocytes could 
provide therapeutic potential for many inflammatory skin diseases.    
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Skin-specific expression of IL-33 causes atopic dermatitis-like inflammation with activation 
of group 2 innate lymphoid cells in mice
Y Imai,1,2 K Yasuda,3 H Mizutani,4 T Yoshimoto,5 K Nakanishi3 and K Yamanishi1 1 
Dermatology, Hyogo College of Medicine, Nishinomiya, Japan, 2 Dermatology, Medical 
College of Wisconsin, Milwaukee, WI, 3 Immunology and Medical Zoology, Hyogo 
College of Medicine, Nishinomiya, Japan, 4 Dermatology, Mie University, Tsu, Japan and 5 
Laboratory of Allergic Diseases, Institute for Advanced Medical Sciences, Hyogo College of 
Medicine, Nishinomiya, Japan
IL-33, a ligand for the receptor ST2, stimulates Th2 cells, basophils, mast cells and group 2 innate 
lymphoid cells (ILC2). In atopic dermatitis (AD), the up-regulation of IL-33 in the epidermis and 
the infiltration of ST2-positive cells in the dermis of the lesional epidermis have been reported. In 
this study, to elucidate the pathological role of IL-33 in cutaneous inflammation, we generated 
transgenic mice expressing the mouse IL-33 gene driven by a keratin 14 promoter (hK14mIL33tg 
mice). These mice spontaneously developed a pruritic dermatitis after 6 to 8 weeks of age. The 
lesional skin showed a markedly thickened epidermis with an increase in dermal eosinophils and 
mast cells. Blood histamine and IgE levels were significantly (P < 0.05) elevated 8.1 and 25.7 fold, 
respectively. In lesional skin, IL-5, IL-13, CCL5 and CCL11 were increased, whereas IL-25 and TSLP 
were unaltered. This dermatitis was suppressed by the administration of an anti-IL-5 antibody. The 
proportion of ILC2 was also significantly elevated in the lesional skin, peripheral blood and regional 
lymph nodes of these mice. Using intracellular staining, we confirmed that cells expressing IL-5 and 
IL-13 matched the Lin- ST2+ Sca-1+ ILC2. The surface markers of ILC2 increased in our mice were 
ST2, Sca-1, CD25, CD90.2, c-kit, CD127, and ICOS, which were compatible with those of natural 
helper cells. The numbers of skin-resident CD11b+ CD90.2+ c-kit- ILC2 cells were unaltered. In 
summary, the phenotype of the IL-33 transgenic mice closely resembled those observed in human 
AD. These results suggest that the expression of IL-33 in the skin activates ILC2 and that this process 
might play a crucial role in the pathogenesis of AD.    
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An ER stress-initiated sphingolipid metabolite, ceramide-1-phosphate, regulates epithelial 
innate immunity through stimulation of β-defensin production
Y Kim,1 K Park,1 J Kim,2 H Seo,3 K Shin,4 Y Lee,4 WM Holleran,1 P Elias1 and Y Uchida1 
1 Dermatology, University of California, San Francisco, San Francisco, CA, 2 Medicine, 
University of California, San Francisco, San Francisco, CA, 3 Radiation Research Division, 
Korea Atomic Energy Research Institute, Jeongeup, Republic of Korea and 4 College of 
Pharmacy Chungbuk National University, Cheongju, Republic of Korea
Antimicrobial peptides (AMP) are ubiquitous innate immune elements in epithelial tissues. We 
recently discovered that a signaling lipid, a ceramide metabolite, sphingosine-1-phosphate (S1P), 
regulates production of a major AMP, cathelicidin antimicrobial peptide (CAMP) in response to 
subtoxic level of endoplasmic reticulum (ER) stress that can be induced by external perturbants in 
keratinocytes (KC). We hypothesized that an ER stress-initiated signal could also regulate produc-
tion of another major class of AMPs; i.e., the human beta-defensin(s) (hBDs). KC stimulated with 
a pharmacological ER stressor, thapsigargin (Tg), increased hBD2/hBD3 as well as CAMP, but not 
hBD1 mRNA expression. While inhibition of S1P production by a specific inhibitor of ceramidase 
(N-oleoylethanolamine [NOE]) attenuated the expected increase in CAMP expression, coincubation 
with Tg and NOE further increased in hBD2/hBD3 production. Blockade of ceramide-1-phosphate 
(C1P), which is another ceramide metabolite, using siRNA or a specific inhibitor of ceramide 
kinase, suppressed hBD2/hBD3, but not CAMP expression following ER stress. Exogenous C1P 
also increased hBD2/hBD3 production, indicating that C1P stimulates hBD2/hBD3 expression. We 
further characterized a novel pathway of C1P-induced hBD2/hBD3 expression, in which C1P stim-
ulates downstream hBDs via a ÉcPLA2ÇÉ15d-PGJ2ÇÉPPARα/PPARβ/δÇÉSTAT1/STAT3 transcrip-
tional mechanism. Finally, conditioned medium from KC incubated with C1P showed antimicrobial 
activity against Staphylococcus aureus. In summary, our present and recent studies discovered two 
new regulatory mechanisms of key epidermal AMP, hBD2/hBD3 and CAMP, syntheses by C1P and 
S1P, respectively, signals to enhance innate immunity in response to ER stress.    
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Intradermal administration of norepinephrine and adenosine triphosphate increases the mast 
cell content of skin
LL Stohl, W Ding, G Desman, A Al-Nabti, S Coates and RD Granstein Weill Cornell Medical 
College, New York, NY
Several inflammatory skin disorders are characterized by increased numbers of mast cells. Amongst 
these is rosacea. The pathophysiologic significance of the increase in mast cells in rosacea remains 
unknown. However, mast cells are a significant repository of inflammatory mediators. As rosa-
cea reportedly worsens with stress, we examined the ability of the sympathetic neurotransmitters 
norepinephrine (NE) and adenosine triphosphate (ATP) to influence the number of mast cells in 
murine skin. Groups of 5 BALB/c mice were injected intradermally with NE, ATP, NE plus ATP or 
medium alone every 48 hours for 4 weeks. Two days after the last injection, mice were euthanized 
and the injected skin sites harvested. By light microscopy, there was a significant increase in the 
number of mast cells in the sites injected with NE plus ATP compared to the other groups. In some 
experiments total RNA was extracted from injected sites and quantitative reverse-transcriptase 
polymerase chain reaction performed for proteins of interest. A significant increase in the mRNA 
level of tryptase was observed in the NE plus ATP group compared to the other groups, consistent 
with enhanced mast cell content of the skin. A preliminary experiment indicates that exposure of 
murine dermal microvascular endothelial cells to ATP and NE results in enhanced IL-6 release 
compared to either ATP or NE exposure alone. If confirmed, this may be of interest as IL-6 reportedly 
enhances mast cell proliferation through a fibroblast-mediated mechanism. Exacerbation of rosacea 
by stress might be mediated by release of NE and ATP from sympathetic nerves in the skin acting 
to enhance skin mast cell content.    
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Cathelicidin is required for normal TLR9 function by dendritic cells
Y Nakagawa and RL Gallo Dermatology, University of California, San Diego, San Diego, CA
Cathelicidins were originally identified as an antimicrobial peptide (AMP), although the human 
and mouse peptides, LL-37 and CRAMP respectively, can also stimulate chemotaxis, angiogenesis, 
neutralize LPS, and enhance TLR7 and TLR9 responses in several cell types. We found that bone 
marrow-derived dendritic cells (BMDCs) express the gene for CRAMP (Camp) 170 fold greater than 
that expressed by the keratinocyte cell line Pam212. To understand the function of endogenous 
Camp expression, BMDCs from wild-type and Camp-/- mice were stimulated with a range of TLR 
ligands. Compared to controls, BMDCs from Camp-/- mice showed normal responses to TLR2, 3, 
4 or 7 ligands but impaired IL-6 and IL-12 response to the TLR9 ligand CpG(p<0.005). BM-derived 
plasmacytoid DCs also had reduced IFNα production after CpG treatment (p<0.01). Camp-/- BMDCs 
showed otherwise normal expression of MHC II, TLR9 and co-stimulatory molecules:CD40, CD80 
and CD86. Uptake of CpG-FITC was also normal as assessed by flow cytometry. Furthermore, 
enhancing CpG entry with Dotap or addition of CRAMP peptide or full length CRAMP protein to 
culture media did not resolve the defect in TLR9 response, suggesting that intracellular cathelici-
din, rather than uptake of DNA due to the presence of the peptide, is necessary for TLR9 function. 
Confirming this, Camp-/- mice showed impaired IFNα, TNFα, IL-6 and IL-12 production after 
intravenous administration of CpG (IFNα; P<0.05, TNFα; P<0.005, IL-6; P<0.005, IL-12; P<0.05, 
N=7). Ear swelling (P<0.005 N=9) and induction of IL-6 and IL-12A were also reduced by 50% 
in Camp-/- mice after CpG injection (IL-6; P<0.005, IL-12A; P<0.005, N=6). Collectively, these 
results indicate that endogenous CRAMP is crucially involved in DNA recognition and triggering 
both NFκB-proinflammatory and IRF7-IFNα pathways, important systems for immune defense and 
autoimmunity.    
